Download Curriculum Vitae - MD Anderson Cancer Center

Curriculum Vitae
Date of preparation: 10/14/10
_________________
Signature
Name:
Fazlul Hoque Sarkar
Office Address:
Telephone:
Department of Pathology
Wayne State University
School of Medicine
540E Canfield
Detroit, MI 48201
313-576-8327
Personal Data:
Date of Birth:
Marital Status:
Citizenship:
01/26/52
Married with three children
USA
Education:
Baccalaureate:
B.Sc
Graduate:
M.Sc
Ph.D
Training:
1975-78
1978-79
1979-82
1982-1984
Faculty Appointments:
1984-1987
1987-1988
1988 - 1990
1988-1990
1990- 1999
1999-Present
1990- Present
1995- Present
1990- 1997
1997-present
1999-present
Home
Address:
Telephone:
Physics, Chemistry, Math,
Calcutta University, India
Biochemistry, Aligarh Muslim
University, India
Biochemistry, Banaras Hindu
University, India
13926 Knollview Ct.
Plymouth
MI 48170
734-454-6620
1971
(Distinction)
1974
(First Class)
1978
Research Fellow, Banaras Hindu University, Varanasi, India
Associate Researcher, Department of Animal Virology, Sloan Kettering Institute for Cancer
Research, NY 10021
Postdoctoral Fellow, Interferon Laboratory, Sloan-Kettering Institute for Cancer Research,
NY 10021
Research Associate, Interferon Laboratory, Sloan-Kettering Institute for Cancer Research, NY
10021
Assistant Researcher, Equivalent to Assistant Professor, Oakland University, Rochester, MI
48309.
Director of Research, Oxford Biomedical Research, Inc., Rochester, MI 48309.
Director, Tumor Biology, Dept of Pathology, Henry Ford Hospital, Detroit, MI 48202.
Adjunct Assistant Professor, Department of Chemistry, Oakland University, Rochester, MI
48309.
Associate Professor of Pathology, Wayne State University School of Medicine, and Director
of Molecular Biology Laboratory, Harper Hospital, Detroit, MI 48201.
Professor of Pathology, Wayne State University School of Medicine, Detroit, MI 48201.
Adjunct Professor, Department of Chemistry, Oakland University, Rochester, MI 49309.
Faculty member of The National Institute of Environmental Health: Molecular and Cellular
Toxicology, Wayne State University, Detroit, MI 48202.
Director of Molecular Biology, Department of Pathology, Harper Hospital, Detroit Medical
Center, Detroit, MI 48201.
Professor, Center for Molecular Medicine and Genetics, Wayne State University School of
Medicine, Detroit, MI 48201
Professor, Department of Pathology, Karmanos Cancer Institute, Wayne State University,
Detroit, MI 48201.
1
Major Professional Societies:
Active Member: American Association for the Advancement of Science
Active Member: American Association for Cancer Research
Active Member: American Society of Biochemistry and Molecular Biology
Honors/Awards:
1975-1976:
National Merit Scholarship (Junior Research Fellowship), UGC (This award is given at the National level
for meritorious students to complete Ph.D thesis work), India.
1976-1978:
National Merit Scholarship (Senior Research Fellowship), CSIR (This award is given at the National level
for meritorious students to complete Ph.D thesis work), India.
1989:
Invited guest on "Live Channel 50 news" to speak and provide expertise on DNA Finger Printing in1989.
1994:
Local television and news paper coverage on the discovery of a new protein molecule that modulate
ERBB2 gene. This work has been published in the prestigious journal named Journal Biological Chemistry.
Based on this work a worldwide and USA patent application has been submitted and is still pending.
1997:
Invited guest on "Live Channel 50 news" to speak and provide expertise on Chemoprevention and Breast
cancer.
1998:
Invited guest on "Live Channel 50 news" to speak and provide expertise on Tamoxifen and other novel
new therapies for breast and other cancers.
1998:
Program taped and broadcasted on the topics of “chemoprevention in prostate cancer” for Fox-2 television
news.
1996:
Patent: A patent application has been issued regarding the discovery of a novel protein that interacts with
Her-2/Neu promoter in Breast cancer. Title: ERBB2 promoter binding protein in neoplastic disease.
Submitted by Fazlul H. Sarkar (WSU) and Raziuddin of NCI/NIH.
1997:
Patent: A second patent has been issued on the similar subject as stated above with monoclonal antibodies
to Her-2/neu promoter binding protein.
2009:
Senior Editor for Molecular Cancer Therapeutics
Service:
Clinical Service:
1990-1995:
Director, Molecular Biology, Dept. of Pathology, Harper Hospital with clinical responsibilities related to the
Molecular Diagnosis of T&B cell gene rearrangements, and BCR gene abnormalities (see publication list).
Responsibilities include carrying out diagnostic test and clinical signing out of test reports as a consultant to
Hematopathologist.
Other Hospital Related Activities:
1990-Present:
Member, Multidisciplinary Lung Cancer Program, Harper Hospital, comprehensive cancer center.
Member, Multidisciplinary Breast cancer Program, Harper Hospital, Comprehensive Cancer Center.
3.
Member, Prostate Cancer Working Group, Harper Hospital, Comprehensive Cancer Center.
4.
Member, Pancreatic Cancer Research Group, Karmanos Cancer Institute.
5.
Member, Oral Cancer Research Center, Karmanos Cancer Institute.
6.
Teaching: lectures and journal club presentations to the above cancer program.
2
Public Presentation:
1994: Local television and news paper coverage on the discovery of a new protein molecule that modulate ERBB2
gene. This work has been published in the prestigious journal named Journal Biological Chemistry. Based on this
work an USA patent application has been approved in 1996.
Consulting to Private Enterprises:
1990-Present:
Serves as Director of Research; Oxford Biomedical Research, Inc. as a consultant; developed and received funding
for grant proposal such as Small Business Innovative Research (SBIR), and Small Business Technology
Transfer Research (STTR) grants which are supported by NIH.
Member Editorial Board:
1994- 1996:
Elected Member of the Editorial board for the following Scientific Journals:
(1) Molecular Diagnostic Pathology
(2) The Prostate
1994- Present:
Molecular Diagnostic Pathology
1998-Present:
(1) Oncology Reports
(2) Pancreas
2009- Present:
(1) Senior Editor for Molecular Cancer Therapy
(2) Editorial Board of World Journal of Biological Chemistry (WJBC)
(3) Editorial Board of Journal of Hematology & Oncology
NIH and other Study Section:
1995 – Present:
Ad hoc member, SRC (NIH/NCI) study section on Breast cancer.
Served as special reviewer for Breast cancer conference grant.
Served as a reviewer “California breast cancer research program”
Ad hoc member, “Metabolic Pathology (MPH) Study Section” (1995-1998)
Member, CDP study section (2003 - 2005)
Ad hoc member of Program Project Review Panels
Grant Study Section: International.
1995- Present:
Ad hoc study section member, Israel Academy of Science
Department of Defense Study Section (DOD).
1995-Present: Breast Cancer
1996-Present: Prostate Cancer
University Committee:
1994-1997: Member, Medical Library Committee.
Departmental Committees:
Member, departmental salary committee, 1992-1995.
Member, departmental graduate education committee, 1993-present.
Supervisor, departmental Student Employment, 1992-present.
3
Course Director, Pathology Lecture Series (departmental lectures) and Accredited by CME, 1993-present.
Member, departmental graduate program, 1991-present.
Member, Cancer Biology Graduate Program, 1991-present.
Member, departmental promotion and tenure committee, 1998-present
Member, P&T Committee, Karmanos Cancer Institute, 2005 – present.
Member, Pathology Department Salary Committee, 2007- present
Other Professional Activies:
Editorial Duties:
1990:
Reviewer, BioTechniques
1991:
Reviewer, Diagnostic Cytopathology, BioTechniques
1991:
Reviewer, BioTechniques, Diagnostic Cytopathology
1991:
Reviewer, Clinical Biotechnology, BioTechniques, Diagnostic Cytopathology
1992:
Reviewer, The Prostate, BioTechniques, Clinical Biotechnology, and Diagnostic
Cytopathology, Clinical Cancer Research, Cancer Research
1993:
Reviewer, The Prostate, BioTechniques, Blood, Clinical Biotechnology,
Diagnostic Cytopathology, Cancer, Diagnostic Molecular Pathology, Clinical Cancer Research,
Cancer Research
1994:
Reviewer, The Prostate, BioTechniques, Blood, Clinical Biotechnology,
Diagnostic Cytopathology, Cancer, Diagnostic Molecular Pathology, Clinical Cancer Research,
Cancer Research
1995-Present:
Reviewer, The Prostate, BioTechniques, Blood, Clinical Biotechnology, Diagnostic
Cytopathology, Cancer, Diagnostic Molecular Pathology, Cell Growth &. Differentiation,
Oncogene, Cancer Research, Clinical Cancer Research, Journal of Biological Chemistry,
Molecular Cancer Therapeutics, Carcinogenesis, Cancer Letters, International Journal Cancer, etc.
Invited Speaker/Honors:
1981:
An Abstract was considered for press release as a major discovery in an Annual Meeting “Sarkar,
F. H., and Stewart, II, W. E., 1981. Biochemical Characterization of Leukocyte Derived Human
Interferon Subtypes. 81st Annual Meeting "American Society for Microbiology ".
1987:
The work on Chemical Carcinogenesis lead to obtain Federal Funding and a press release was
published " Sarkar, F. H; Radcliff, G; Callewaert, D. M; Marnett, L. J; Eling, T. E; and Caspary,
W. J. Mutagenic activation of 2-Aminofluorene and Benzidine by Purified Prostaglandin
Synthase.
1988:
Invited speaker in the department of Chemistry, Oakland University.
Lecture Topics in 1988:
a) Prostaglandin Synthase mediated mutagenesis of aromatic amines in mouse lymphoma
L5178Y cells.
b) Role of Oncogenes in the development of mammalian Carcinogenesis.
c) Studies to understand the regulation of gene expression utilizing anti-Sense RNA approach.
1989:
Invited guest on "Live ,Channel 50 news" to speak and provide expertise on DNA Finger
Printing in1989.
1989-1990:
Invited speaker in the department of Chemistry, Oakland University.
Lecture topics in 1989 and 1990:
a) Fundamentals of Genetic engineering: Two 2hr. lecture for the Chem 553 course.
1991:
Invited speaker in the department of Chemistry, Oakland University.
Lecture topics in 1991:
a) Fundamentals of Genetic engineering and Biotechnology: Two 2hr. lecture for the Chem 700
course.
4
1994:
1994:
Invited speaker at Oncor Corporation, Gaithersburg, MD. "Transcriptional regulation of erbB2
gene in breast cancer"
Invited speaker in the department of Molecular Virology, M.D. Anderson Cancer Research
Center, Houston, TX. "Molecular mechanism of Her-2/neu over-expression"
1995:
Invited speaker in the department of Molecular Medicine and Genetics, WSU.
1995:
Invited speaker in the Institute of Chemical Toxicology, WSU.
1998:
Invited guest on "Live ,Channel 50 news" to speak and provide expertise on Breast and other
cancers, and novel therapies, including chemotherapy, hormone therapy, anti-angiogenic therapy,
etc.
2003:
Invited Speaker at Ohio State University speaking on the role of genistein in prostate cancer.
2003:
Invited Speaker at the 5th international meeting on soy isoflavone (Orlando, FL) speaking on
sensitization of cancer cells to chemotherapeutic agents by soy isoflavone.
2003 – Present
Invited speaker to many universities and cancer centers
TEACHING EXPERIENCES:
Years at Wayne State University: 20
1990-1991:
1.
Taught CHEM 104 to Nursing Student (Fall Semester). Full 4 credit course.
Fifty five students.
2.
Taught CHEM 201 to Nursing Student (Winter Semester). Full 4 credit course.
Forty six students.
3.
Graduate teaching “Molecular Pathology, PTH 760" (winter semester)
Course advisor: Dr. Chua.
Lecture Topics: "Lung Cancer, Colon Cancer, AIDS and related diseases" for a total of four, one and one half hour
lecture. Six students.
4.
Graduates teaching “Microscopy, PTH734" (spring semester)
Course advisor: Dr. Giacomelli.
Lecture topic was “Molecular Biological Techniques in Light and Electron Microscopy". One, two hour lecture.
Five students.
5.
Graduate and Faculty Teaching "Multi-disciplinary Lung Cancer Clinic" Department of Hematology and Oncology,
Harper Hospital and Wayne State University School of Medicine. Two, one hour lecture. 25-30 Faculty members
and Staff.
6.
Graduate and Faculty Teaching "Multi-disciplinary Breast Cancer Clinic" Department of Surgery, Radiology and
Oncology, Harper Hospital and Wayne State University School of Medicine. Two, one hour lecture. 25-30 Faculty
members and Staff.
1991-1992:
1.
Taught CHEM 104 to Nursing Student (Fall Semester). Full 4 credit course. Fifty Three Students.
2.
Graduate and Faculty Teaching "Multi-disciplinary Lung Cancer Clinic" Department of Hematology and Oncology,
Harper Hospital and Wayne State University School of Medicine. One, one hour lecture. 25-30 Faculty members
and Staff.
3.
Graduate and Faculty Teaching "Multi-disciplinary Breast Cancer Clinic" Department of Surgery, Radiology and
Oncology, Harper Hospital and Wayne State University School of Medicine. Two, one hour lecture. 25-30 Faculty
members and Staff.
1992- 1994:
1.
Graduate teaching "Cancer Biology II, Bio Sci 565" (Winter Semester) at the department of Biological Sciences and
Radiation Oncology, Wayne State University, Course advisor: Drs. K.V.Honn, A. Porter and J. Tylor.
Lecture Topic: "Suppressor genes", one 2 hr lecture. Twenty Three Students.
5
2.
3.
4.
5.
6.
7.
Graduates teaching “Molecular Pathology, PTH 760" (winter semester) at the department of Pathology, Wayne State
University School of Medicine, Course Advisor: Dr. Chua. Lecture Topics: "Lung Cancer, Colon Cancer, AIDS and
related diseases". Four, one and one half hour lecture. Six Students.
Graduate and Faculty Teaching "Multi-disciplinary Lung Cancer Clinic" Department of Hematology and Oncology,
Harper Hospital and Wayne State University School of Medicine. One, one hour lecture. 25-30 Faculty members
and Staff.
Graduate and Faculty Teaching "Multi-disciplinary Breast Cancer Clinic” Department of Surgery, Radiology and
Oncology, Harper Hospital and Wayne State University School of Medicine. One, one hour lecture. 25-30 Faculty
members and Staff.
Graduate Teaching: PTH 708 (Spring/Summer Semester), Special Topic: Molecular Pathology Laboratory Course;
Course Designed and Taught by Dr. Sarkar. Full 3 credit course. Three Students.
Faculty, Staff and Pathology Resident Teaching: Molecular Diagnostic Pathology (Fall Semester); This course was
designed and Taught by Dr. Sarkar. Accreditation by CME; a total of sixteen, one hour lecture. 15-20 Faculty
members, Staff and Pathology Residents.
Graduate Teaching: PTH 765 (Winter Semester), Molecular Pathology Laboratory Course; Course Designed and
Taught by Dr. Sarkar. Full 4 credit course. Four Students.
1994- 1995:
1.
Graduate Teaching: PTH 765 (Winter Semester), Molecular Pathology Laboratory Course; Course Designed and
Taught by Dr. Sarkar. Full 4 credit course. Four Students.
2.
Faculty, Staff and Pathology Resident Teaching: Molecular Diagnostic Pathology (Spring Semester); This course was
designed and Taught by Dr. Sarkar. Accreditation by CME; a total of sixteen, one hour lecture. 15-20 Faculty
members, Staff and Pathology Residents.
3.
Graduates teaching “Molecular Pathology, PTH 760" (winter semester) Course advisor: Dr. Sarkar. Full Four Credit
course. Eight two hour lecture. Seven Students.
4.
Graduates teaching: Cancer Biology, CB-721 (winter semester). Thirty Two students, two one and one half hour
lecture on Stem cells and growth factors.
5.
First year Medical Student teaching (winter semester). Two, one hour lecture on Cancer Genetics. The course
name: Year I Medical Genetics.
6.
Graduate Teaching: PTH 765 (Spring/Summer Semester), Molecular Pathology Laboratory Course; Course Designed
and Taught by Dr. Sarkar. Full 4 credit course. Three Students.
7.
Graduate and Faculty Teaching "Multi-disciplinary Lung Cancer Clinic" Department of Hematology and Oncology,
Harper Hospital and Wayne State University School of Medicine. One, one hour lecture. 25-30 Faculty members
and Staff.
8.
Graduate and Faculty Teaching "Multi-disciplinary Breast Cancer Clinic” Department of Surgery, Radiology and
Oncology, Harper Hospital and Wayne State University School of Medicine. One, one hour lecture. 25-30 Faculty
members and Staff.
1995- 1996:
1.
Graduates teaching “Molecular Pathology, PTH 760" (winter semester) Course advisor: Dr. Sarkar. Full Four Credit
course. Eight two hour lecture. Five Students.
2.
Graduates teaching: Cancer Biology, CB-721 (winter semester). Twenty three students, Two one and one half hour
lecture on Stem cells and growth factors.
3.
Graduate Teaching: PTH 765 (Spring/Summer Semester), Molecular Pathology Laboratory Course; Course Designed
and Taught by Dr. Sarkar. Full 4 credit course. Four Students.
4.
Graduate and Faculty Teaching "Multi-disciplinary Lung Cancer Clinic" Department of Hematology and Oncology,
Harper Hospital and Wayne State University School of Medicine. Two, one hour lecture. 25-30 Faculty members
and Staff.
5.
Graduate and Faculty Teaching "Multi-disciplinary Breast Cancer Clinic" Department of Surgery, Radiology and
Oncology, Harper Hospital and Wayne State University School of Medicine. One, one hour lecture. 25-30 Faculty
members and Staff.
6.
Graduate and Faculty Teaching "Pancreatic Cancer” Karmanos Cancer Institute and Wayne State University School of
Medicine. Two, one hour lecture. 25-30 Faculty members and Staff.
1996- 1998:
1.
Graduates teaching “Molecular Pathology, PTH 760" (Every Fall semester) Course advisor: Dr. Sarkar. Full Three
Credit course. Eight two hour lecture. Five to Eight Students.
6
2.
3.
4.
5.
6.
Graduate Teaching: PTH 765 (Every Winter Semester), Molecular Pathology Laboratory Course; Course Designed
and Taught by Dr. Sarkar. Full 4 credit course. Four to Seven Students.
Graduate and Faculty Teaching "Multi-disciplinary Lung Cancer Clinic" Department of Hematology and Oncology,
Harper Hospital and Wayne State University School of Medicine. Two, one hour lecture. 25-30 Faculty members
and Staff.
Graduate and Faculty Teaching "Multi-disciplinary Breast Cancer Clinic" Department of Surgery, Radiology and
Oncology, Harper Hospital and Wayne State University School of Medicine. One, one hour lecture. 25-30 Faculty
members and Staff.
Graduate and Faculty Teaching "Pancreatic Cancer" Karmanos Cancer Institute and Wayne State University School of
Medicine. Two, one hour lecture. 25-30 Faculty members and Staff.
Internal Medicine “Collaborative Fellowship Conference: One hour lecture on Cancer Genetics. Eight Resident
Fellows.
1998- 2000:
1.
Graduate and Faculty Teaching "Multi-disciplinary Lung Cancer Clinic" Department of Hematology and Oncology,
Harper Hospital and Wayne State University School of Medicine. Two, one hour lecture. 25-30 Faculty members
and Staff.
2.
Graduate and Faculty Teaching "Multi-disciplinary Breast Cancer Clinic" Department of Surgery, Radiology and
Oncology, Harper Hospital and Wayne State University School of Medicine. One, one hour lecture. 25-30 Faculty
members and Staff.
3.
Graduate and Faculty Teaching "Pancreatic Cancer" Karmanos Cancer Institute and Wayne State University School of
Medicine. Two, one hour lecture. 25-30 Faculty members and Staff.
4.
Internal Medicine “Collaborative Fellowship Conference: One hour lecture on Cancer Genetics. Eight Resident
Fellows.
2000- 2003:
1.
Graduate and Faculty Teaching "Multi-disciplinary Lung Cancer Clinic" Department of Hematology and Oncology,
Harper Hospital and Wayne State University School of Medicine. Two, one hour lecture. 25-30 Faculty members
and Staff.
2.
Graduate and Faculty Teaching “Multi-disciplinary Breast Cancer Clinic” Departments of Surgery, Pathology,
Radiology, Radiation Oncology and Oncology, Karmanos Cancer Institute, Harper Hospital and Wayne State
University School of Medicine. One, one hour lecture. 25-30 Faculty members and Staff.
3.
Graduate and Faculty Teaching "Pancreatic Cancer" Karmanos Cancer Institute and Wayne State University School of
Medicine. Two, one hour lecture. 25-30 Faculty members and Staff.
4.
Internal Medicine “Collaborative Fellowship Conference: One hour lecture on Cancer Genetics. Eight Resident
Fellows.
5.
Graduate Teaching, Cancer Biology: CB 7090. One, one hour lecture; 13 students.
6.
Graduate and Faculty Teaching, Cancer Biology: CB 7210. “Fundamentals of Cancer Biology Teaching Faculty.”
One, one hour lecture, 26 students.
7.
Graduate Teaching, Cancer Biology: CB 7250, Lecture on Mechanisms of chemoprevention with soy isoflavones.
One, one hour lecture, 30 students.
8.
Graduate and Faculty Teaching “Multi-disciplinary Prostate Cancer Clinic” Departments of Surgery, Pathology,
Radiology, Radiation Oncology and Oncology, Karmanos Cancer Institute, Harper Hospital and Wayne State
University School of Medicine. Two, 45 minute lectures. 25-30 Faculty members and Staff.
9.
Graduate and Faculty Teaching “Pancreatic Cancer” Karmanos Cancer Institute and Wayne State University School of
Medicine. One, one hour lecture. 25-30 Faculty members and Staff.
10. Graduate Teaching, Cancer Biology: CB 7250, Lecture on molecular mechanism of action of chemopreventive agents.
One, one hour lecture. 2 credit course, 32 students.
11. Graduate Teaching, Cancer Biology: CB 7212, Lecture on “Molecular Pathology of Cancer.” One, one and one-half
hour lecture. 3 credits course, 28 students.
12. Graduate Teaching: PTH 7090 & CB 7090, Lecture on “Androgen Signaling.” Two, one and one-half hour lecture, 6
students.
2004 –2009:
1.
Internal Medicine “Collaborative Fellowship Conference: One hour lecture on Cancer Genetics. Eight Resident
Fellows.
2.
Graduate Teaching, Cancer Biology: CB 7090. One, one hour lecture; 13 students.
3.
Graduate and Faculty Teaching, Cancer Biology: CB 7210. “Fundamentals of Cancer Biology Teaching Faculty.”
One, one hour lecture, 26 students.
7
4.
5.
6.
7.
8.
9.
Graduate Teaching, Cancer Biology: CB 7250, Lecture on Mechanisms of chemoprevention with soy isoflavones.
One, one hour lecture, 30 students.
Graduate and Faculty Teaching “Multi-disciplinary Prostate Cancer Clinic” Departments of Surgery, Pathology,
Radiology, Radiation Oncology and Oncology, Karmanos Cancer Institute, Harper Hospital and Wayne State
University School of Medicine. Two, 45 minute lectures. 25-30 Faculty members and Staff.
Graduate and Faculty Teaching “Pancreatic Cancer” Karmanos Cancer Institute and Wayne State University School of
Medicine. One, one hour lecture. 25-30 Faculty members and Staff.
Graduate Teaching, Cancer Biology: CB 7250, Lecture on molecular mechanism of action of chemopreventive agents.
One, one hour lecture. 2 credit course, 32 students.
Graduate Teaching, Cancer Biology: CB 7212, Lecture on “Molecular Pathology of Cancer.” One, one and one-half
hour lecture. 3 credits course, 28 students.
Graduate Teaching: PTH 7090 & CB 7090, Lecture on “Androgen Signaling.” Two, one and one-half hour lecture, 6
students.
2009- Present:
1.
Graduate Taching, Cancer Biology: CB 7212, Lecture on “Molecular Pathology of Cancer. One, one and one-half hour
lecture, 3 credit course
Years at other Institution: Four years
1987-1988:
1.
Taught graduate level courses with Drs. Roy and Walia, in the Department of Biological Sciences, Oakland University
in special topics such as Oncogenes and Lymphokines. Three, two hour lecture. 12 Students.
1988-1989:
1.
Taught CHEM 201 Course to Nursing Student. This Course was jointly offered by Oakland University and Henry
Ford Hospital (Winter Semester). Full 4 credit course. 56 Students.
2.
Taught Chem 104 course to nursing student (fall semester). Full 4 credit course. 65 Students.
1989-1990:
1.
Taught CHEM 201 to Nursing Student (Winter Semester). Full 4 credit course. 54 Students.
2.
Taught a Special course (6 months duration) entitled "Concepts in Molecular Biology” to the Staff and Resident of
the department of Pathology. This course was completely designed and offered by Dr. Sarkar. Sixteen, one hour
lecture. 25-30 Faculty, Staff and Resident Students.
3.
Graduate teaching “Biochemistry, CHM 704" (Winter Semester) at Oakland University,
Course advisor: Denis
Callewaert. Lecture Topic: "Nucleic Acids". One, three hour lecture. Ten Students.
COURSE DEVELOPMENT AT WAYNE STATE:
1.
Molecular Diagnostic Pathology, PTH 765
(Four credit hours Laboratory Course for Graduate student)
2.
Molecular Diagnostic Pathology, accredited by CME
(Lecture Course for Resident and Faculty thought at Harper Hospital, 1990-1995)
3.
Molecular Pathology, PTH760
(Three credit hours Lecture Course for Graduate students)
4.
Department of Pathology lecture series (1991-Present), Accredited by CME.
GRADUATE TEACHING/ADVISOR AT WAYNE SATE:
1.
Principal Advisor (Ph.D, “Pathology” Thesis Advisor): Ms. Juliet Bailey-Penrod, 1994-1998(graduated in 1998).
2.
Secondary Advisor (Ph.D. “Pathology Thesis Committee): Ms. Deborah Kukuruga 1993-1996 (graduated).
3.
Principal Advisor (Ph.D, “Pathology” Thesis Advisor): Ms. Fangru Lian, 1996-1988 (transferred to different
institution).
4.
Principal Advisor (Ph.D, “Pathology” Thesis Advisor): Mr. Sunil Upadhyay, 1996-2000 (graduated).
5.
Principal Advisor (Ph.D, “Pathology” Thesis Advisor): Ms. Olivia Aranha, 1997-2000 (graduated).
6.
Principal Advisor (Ph.D, “Cancer Biology” Thesis Advisor): Ms. Joanne N. Davis, 1997-2000 (graduated).
7.
Principal Advisor (MS; MSBMS Thesis Advisor): Dr. Kazi Rahaman (Thesis Title: Potency of p21 in pancreatic
cancer therapy), 1996-1997 (completed).
8.
Principal Advisor (Ph.D, “Cancer Biology” Thesis Advisor): Ms. Farhana Feroze (Thesis Title: Androgen Regulation
of the Vascular Endothelial Growth Factor (VEGF) and its Receptor in Prostate Cancer), 1998-2003 (graduated).
9.
Principal Advisor (Ph.D, “Cancer Biology” Thesis Advisor): Mr. Zhiwei Wang, 2003-2007(graduated).
8
10.
Principal Adivsor (PhD, “Pathology”)Mr. Ma’in Maitah, 2009- (current)
RESIDENT ROTATION:
1992-1994:
Director: Pathology resident rotation for two weeks in Molecular Diagnostic Pathology, Harper Hospital. Three
Pathology Resident each year (1992, 1993 and 1994)
1995- 1996:
1.
One pathology resident (Dr. Kattar) to carry out Molecular Research for a period of eight weeks in a project
involving chromosome X inactivation in human cancer (particularly in Brain Tumors).
2.
One pathology resident (Dr. Hala Abdel Aziz) of Medical College of Ohio in Diagnostic Molecular Pathology for
six weeks.
1996-1997:
One pathology resident (Dr. Schinder) to carry out Molecular Research for a period of four weeks in a project
involving chromosome p53 mutation in prostate tissue specimens obtained from prostate cancer patients treated with
hormone and radiation.
1997-1998:
One Urology resident (Dr. Peter) to carry out Molecular Research for a period of eight months in a project involving
p53 mutation in bladder cancer specimens and correlation of 3-D p53 protein structure with survival and other
clinical parameters.
1999-present:
Mentor of several researchers and clinical fellows for research
Special Presentation:
Presented lecture at a special symposium “Cytokines in Pancreatic Disorders” at the Annual Meeting of the
American Pancreatic Association. Preclinical evaluation of rAd-p21 gene therapy in pancreatic cancer. November 8,
1997, Chicago, IL.
Kurzrock R, Sarkar FH, Hess KR, Abbruzzese JL, Evans DB, Chiao PJ. Targeting NF-κB Signaling for Pancreatic
Cancer Therapy. 13th SPORE Investigators’ Workshop. July 11, 2005, Washington. DC.
Sarkar FH, Wang Z, Banerjee S, Abbruzzese. A Novel Approach to Pancreatic Cancer Therapy: Inactivation of
Notch-1 Signaling. 14th SPORE Investigators’ Workshop. July 16-19, 2006, Baltimore, MD.
PAST GRANT AWARDS:
1987:
Phase I grant, NIEHS: Development of mutagenesis assays based on mammalian Peroxidase activation,
awarded to Oxford Biomedical Research.
P.I : Fazlul H. Sarkar, grant amount $50,000 for six month.
1988-1989:
Bridge funding grant: The above Phase I Project received funding (Development of mutagenesis assays
based on mammalian Peroxidase activation) from the state Research fund of Michigan department of
Commerce as an interim funding, while the above Phase II application was being reviewed by SBIR grant
system. Total amount $35,000 for 1 year awarded to Oxford Biomedical Research (1988-1989). P.I :
Fazlul H. Sarkar.
1987-1989:
Phase II Contract, NIEHS: Development of alternative exogenous metabolic systems for use in mutation
assays. Principal Investigator (P.I ): Fazlul H. Sarkar, awarded to Oxford Biomedical Research Inc.
Contract Amount $375,000 for two years (1987-1989).
1989:
Phase I grant: Isolation and Purification of mammalian Prostacyclin Synthase.P.I: Fazlul H. Sarkar,
Received total funding of $50,000 for six months from NIH, SBIR Program awarded to Oxford Biomedical
Research Inc.
9
1988-1989:
Henry Ford Hospital grant: Ultrastructural and Biochemical analysis of Tumor cell arrest. P.I : John D.
Crissman, awarded in 1988. Period of Support: July 1988- Dec 1989, $75,000. Fazlul H. Sarkar, Co -P.I
in this grant with 25% effort.
1989-1990:
Henry Ford Hospital Grant: Benign Breast Disease: Molecular Markers of Cancer Risk. P.I.: Fazlul H.
Sarkar, Period of Support: July 1989 to December1990.P.I. with 40% effort. Total amount: $188,000.
1989-1990:
Henry Ford Hospital grant: Cytogenetics and molecular study of bladder cancer, P.I : V. Ramesh Babu.
Period of support: Jan 1989-Dec 31, 1990, Grant No. A 10060. Fazlul H. Sarkar Co-P.I in this grant with
20% effort. Total Amount of funding for Co-PI was $ 75,000 for above period.
1990:
Henry Ford Hospital grant: Molecular Mechanism(s) in the Process of Tumor Cell Invasion and
Metastasis, P.I: John D. Crissman. Period of Support: January 1990-December 1990, Fazlul H. Sarkar,
Co-P.I in this grant with 40% effort. Total amount of Funding: $ 75,000.
1992-1994:
SBIR Phase II grant: Isolation, Purification and Cloning of mammalian Prostacyclin Synthase. P.I: Dr.
Sankaran; Fazlul H. Sarkar, Co-Investigator and Collaborator with 10% effort to do cloning part of
the project. Received total funding of $500,000 for two years from NIH, SBIR Program awarded to
Oxford Biomedical Research Inc. (January 1992-Dec 1994).
1993:
An amount of $3000 in total grant support was obtained from George Puschelberg Foundation to continue
breast cancer research. P.I: Fazlul H. Sarkar.
1992-1993:
An amount of $23,000 in total funds obtained from WSU developmental funds.
P.I: Fazlul H. Sarkar.
1994:
NIH/NCI R01 Supplement grant ($15,000) in Breast Cancer to purchase an automated
Immunohistochemistry instrument to conduct "Translational research to investigate lymphokine-hormone
gene expression in human breast lesion and its correlation with in vitro cell culture results". PI: Fazlul H.
Sarkar.
1994:
An amount of $2000 in total grant support was obtained from George Puschelberg Foundation to continue
breast cancer research. P.I: Fazlul H. Sarkar.
1994-1996:
NIH/NCI; PI: Fazlul H. Sarkar, Ph.D., Role: Principal investigator, Supplement to the funded R01 grant
for graduate student, Dollar: 8/01/94-4/30/96, $44,000; Total Direct Cost, Title: Novel gene in breast
cancer development and progression.
1995-1997:
Webber Fund: January 1995-December 1997. Three years with $25,000 per year. Total Funding=
$75,000. PI: Fazlul H. Sarkar with 5% effort.
1995-1996:
Milheim Foundation: 7/1/95-6/30/96. A total of $13,000 for supplies and technical support PI: Fazlul H.
Sarkar.
1995-1996:
NIH/NIEHS: Molecular and Cellular Toxicology, Wayne State University; Pilot project support on
"Molecular regulation of Her-2/neu gene. 4/1/95-3/31/96. A total of $10,000 for supplies and technical
support. PI: Fazlul H. Sarkar.
1995-1996:
NIH/NCI: Awarded to Michigan Cancer Foundation; Planning Grant for the Aging and Breast Cancer
Initiative. Title: "Definition and characterization of precursor breast lesions in African-American and
Caucasian women". 5/1/95-12/31/96. A total of $25,000. PI: Daniel W. Visscher, Co-Principal
Investigator: Fazlul H. Sarkar with 10% effort.
1995-1997:
NIH/Heart and Lung Institute; 1R01 HL 54444-01; PI: David Cherish of Scripps Research Institute.
Subcontract to Wayne State University; PI: Fazlul H. Sarkar, 10% salary support to carry out studies on
“Vascular Integrin in Angiogenesis of Breast Cancer". 7/1/95-6/30/97, a total of four years. A total of
$23,568 for first year (7/1/95-6/30/96).
10
1995-1996:
NIH/NCI-STTR Phase I grant; PI: Fazlul H. Sarkar with 20% salary support. Title: Nuclear-Matrix
associated oncogene regulator. A total of $ 99, 500 for a period of 7/1/95-12/31/95, with no cost extension
to 6/30/96.
1995-1998:
Hematology-Oncology (Hem&Onc) divisional fund for Lung Cancer Project, Harper Hospital; PI: Fazlul
H. Sarkar, 9/1/95-12/31/98. Total $45,000.
Focused Funding since 1993 -Present:
1.
NIH/NCI R01 grant in Breast Cancer; PI: Fazlul H. Sarkar, 30% effort in year one and two, 10% effort in year three
and four, Dates: 7/01/93 - 6/30/98, Total amount $395,000 direct cost, 10% salary support.
Topic: Translational research to investigate lymphokine-hormone gene expression in human breast lesion and its
correlation with in vitro cell culture results. Gene expression is initially planned to be carried out by
Immunohistochemistry and then quantitated by PCR analysis based on our preliminary results for the quantitation of
ERBB2 mRNA in microdissected breast tumor specimens. A panel of eight genes has been selected for these studies.
Many of these genes have been investigated by immunohistochemistry in our preliminary studies which produced
several publications.
2.
RGK Foundation: 1/1/95-8/31/98. A total of $45,000 for general supplies, PI: Fazlul H. Sarkar.
3.
Pushelberg Foundation: January 1995 - December 1998, $11,000 for general supplies. PI: Fazlul H. Sarkar.
4.
Marlin Pemberton Pancreatic Research Fund, Funded through Michigan Cancer Foundation. 1/1/95-12/31/97; A total
of $199,000 direct cost. No indirect cost allowed.
PI: Fazlul H. Sarkar with 10% salary support. Renewed funding up to 12/31/98 with additional amount of
$98,000.
5.
NIH/NCI- R01: PI: Wael A. Sakr, Co-Investigator: Fazlul H. Sarkar with 10% effort and salary support. Title:
Premalignant lesions of the prostate: age and race study. Period of support: 8/1/95-7/31/99. Total Direct cost for the
entire period: $919,154, Total cost for initial budget period (8/1/95-7/31/96) = $ 290,728.
6.
NIH/NCI- Development Grant: Prostate Cancer progression and metastasis; PI: Kenneth V. Honn. Project period:
9/1/95-8/31/99. Pilot project : Molecular mechanism of dietary metabolites in prostate cancer; PI: Fazlul H. Sarkar,
$80,000 for the year 1996-98. Total budget for the entire proposal $ 1,192,091.
7.
ACS; PI: Fazlul H. Sarkar, 20% salary support; Molecular regulation of Her-2/neu gene expression. Total amount
$180,000 for a period of 7/1/96-6/30/98 with potential for third year funding of $90,000.
8.
USAMRMC/DOD; PI: Fazlul H. Sarkar, 10% salary support; Period 9/30/97 8/31/01. Soy metabolites isoflavones
in cell growth and apoptosis. Total $295,108.
9.
NIH/NIEHS R01 ES 07129-01A2 (PI: David Garabrant), Fazlul H. Sarkar, Subcontract Principal Investigator;
Period 5/1/96-4/30/99. DDT and related compounds and pancreas cancer. The goal is to carry out epidemiological and
laboratory study to ascertain the role of DDT and DDE in the development and progression of human pancreas cancer.
Total $ 276,883 for the current year, Subcontract amount for a total of $75,000.
10. USAMRMC/DOD; PI: Omer Kucuk; Co-PI: Fazlul H. Sarkar, 10% salary support; Period 10/01/98-9/30/02.
Modulation of growth and differentiation in breast cancer by soy isoflavones. Total amount $740,707 direct cost.
11. VA research grant: PI: Adhip Majumdar, Co-Investigator: Fazlul H. Sarkar with 10% support and 20% support of
a research assistant and supplies budget. Period: 10/1/98-9/30/03 with a total budget of $915,000.
12. NIH/NCI Molecular mechanism of genistein in prostate cancer 1R01 CA83695-01A2 Prinicipal Investigator: Fazlul
Sarkar Period: 07/01/01-06/30/06
The purpose of this investigation is to elucidate the molecular mechanism by which genistein elicit its effects on
prostate cancer cells in vitro and to test whether genistein could function as an anti-tumor agent in two separate
animal models, such as SCID and TRAMP models of prostate cancer
13. NIH/NCI SPORE in Pancreatic Cancer 1P20CA101936-01 PI: Abbruzzese Co- Invesitgator: Fazlul Sarkar with
10% Support and supplied budget. Period 9/1/03 – 8/31/08 Total Direct: $442,615
The major goal of this project is to test the hypothesis that inhibition of NFκB and Epidermal Growth Factor Receptor
(EGFR) signaling pathways will enhance cytotoxic agent-induced apoptosis in human pancreatic cancer and will lead
to greater therapeutic effects
14. NIH/NCI 1 R01 CA101870-01A1 Targeting Akt/NF-kB pathways for pancreatic cancer therapy Sarkar (PI)
Period 5/1/03 – 5/31/09 The goal of this project is to test whether the down regulation of EGFR pathway by ERRP
and NF-kB pathway by genistein will be therapeutically superior for the treatment of pancreatic cancer, and also to
elucidate the molecular pathways by which pancreatic cancer cells could be killed.
15. NIH/NCI
1R01CA108535-01
Novel
Targets
of
Indoles
in
Prostate
Cancer.
Sarkar
(PI)
Period 8/01/04 - 05/31/09 The purpose of this investigation is to identify a comprehensive molecular target profile of
I3C/DIM in prostate cancer.
11
CURRENT ACTIVE GRANT FUNDING:
5 R01 CA83695-05A1 Sarkar (PI)
7/01/07- 6/30/12
NIH/NCI
Molecular mechanism of genistein (Isoflavone) in prostate cancer
The purpose of this investigation is to elucidate the molecular mechanism by which isoflavone elicit its effects on
prostate cancer cells in vitro and to test whether isoflavone could function as an anti-tumor agent in two separate animal
models of prostate cancer.
1 R01 CA109389-01A2 Mohammad(PI)
10/01/08-09/30/12
NIH/NCI
Specific Targets for Pancreatic Cancer Therapy
In this study we use small-molecule inhibitors of Bcl-2 family as therapeutic agents to treat pancreatic cancer.
Role: Co- Investigator
1 R01 CA 131151-01A1 Sarkar (PI)
07/07/08- 06/30/13
NIH/NCI
A novel and targeted approach to inhibit invasion and angiogenesis
The purpose of this proposal is to investigate the role of PDGF-D induce process in invasion and angiogenesis.
Moreover, the aim of this study is also focused to investigate how B-DIM could inhibit PDGF-D induced invasion and
angiogenesis in pancreatic cancer.
1 R01 CA 132794-01A1 Sarkar (PI)
01/01/09- 12/31/2014
NIH/NCI
FoxM1: A molecular target in pancreatic cancer
The purpose of the project is to elucidate the role of FoxM1 in pancreatic cancer and to test how genistein can interfere
with FoxM1 signaling.
2 R01 CA 108535-05A1 Sarkar
01/01/2010-11/30/2014
NIH/NCI
Novel Targets of Indoles in Prostate Cancer
The purpose of this investigation is to identify a comprehensive molecular target profile of I3C/DIM in prostate cancer.
Publications:
Original observation in referred journals:
1. Sarkar F. H., Hasan SS, Singh PM, Udupa KN. Effect of Whole Body Irradiation on Skin 5-hydroxytryptamine and
Its Degradating Enzyme in Albino Rats. Ind. J. Zootomy, 16 (2): 99,1975.
2. Sarkar FH, Hasan SS, Singh PM, Udupa KN. The Effect of Whole Body Irradiation on Spleen and Its 5-HT
Content. Ind. J. Zootomy, 16 (2): 103, 1975.
3. Sarkar FH, Singh RH, Udupa KN. Role of Serotonin in Health. Quart. J. Surg. Sci. 21(1): 38, 1976.
4. Sarkar FH, Hasan SS, Prasad R, Sharma TR, Verma, MD, Singh RH, Chansouria JPN, Udupa KN. Role of Certain
Biogenic amines in Gastric Ulcer and Prevention by an Indigenous Drug. Quart. J. Surg. Sci. 12(2): 108, 1976.
5. Sarkar FH, Singh RH, Udupa KN. Effect of Electric Shock on Serotonin (5-HT) content in Different Organs of Rat.
Experientia, 33: 417, 1977.
6. Sarkar FH, Nimai Singh RK, Srivastava ON, Singh RH, Udupa KN. Studies on the role of Serotonin in Certain
Stressful Mental Disorders. Proceedings of the International Seminar on Stress in Health and Disease. Quart. J. Surg.
Sci. 13(part 1): 158, 1977.
7. Hasan SS, Sarkar FH, Sharma TR, Prasad GC, Pant GC, Udupa KN. Response of Adrenal Gland to Whole Body 60Cobalt irradiation. Ind. J. Exp. Biol. 15: 513, 1977.
8. Khatri S, Prasad R, Sarkar FH, Chansouria JPN, Udupa KN. Role of Stress Factors in Malignant conditions. Quart. J.
Surg. Sci. 13 (part 1): 154, 1977.
9. Ojha SC, Sarkar FH, Khanna NN, Udupa KN Changes in blood Serotonin in Experimental Intestinal Obstruction in
Dogs. Ind. J. Exp. Biol. 15: 931, 1977.
10. Hasan SS, Sarkar FH, Singh PM, Majumdar S, Pandey SN, Pant GC, Gupta RC, Prasad GC. Effect of Betnesol on
Changes in Neuro-humors After Radiation Stress. Quart. J. Surg. Sci. 13 (part3): 126, 1977.
11. Sarkar FH, Hasan SS, Pandey SN, Udupa KN. Effect of a Chemical Radioprotector administered before Irradiation
on Thyroid,Testis and Pituitary. Ind. J. Med. Res. 67: 616, 1978.
12. Hasan SS, Sarkar FH, Singh PM, Majumdar, S, Prasad, GC, Pant GC, Udupa KN. Responses of Brain Bioamines
and Its Enzymes to Cobalt-60 irradiation. Strahlentherapie 154: 349, 1978.
13. Hasan SS, Sarkar FH, Pandey SN, Udupa KN. A Note on the Response of Adrenal Gland and Its Catecholamine to
Chemical Radioprotector. Ind. J. Animal. Sci. 48 (9): 698, 1978.
12
14. Sarkar FH, Singh RH, Udupa KN. Altered 5-HT Metabolism Under the Influence of 5,6-dihydroxytryptamine in
Rats. Ind. J. Exp. Biol. 18 (9): 1033, 1980.
15. Sarkar FH, Singh RH, Udupa KN. Pattern of blood 5-HT Changes in Gastrointestinal Resection in Dogs. Ind. J.
Exp. Biol. 18 (8): 862, 1980.
16. Singh HC, Sarkar FH, Singh RH, Udupa KN. Blood Platelet Monoamine Oxidase and Acetylcholinesterase in
Thyrotoxicosis. Ind. J. Med. Res. 71: 384, 1980.
17. Sarkar FL, Singh RH., Udupa KN. Diurnal Variations in Blood and Brain 5-HT in Animals. Ind. J. Exp. Biol. 18
(10): 1210, 1980.
18. Stewart II WE, Sarkar FH, Taira H, Halls S, Nagata S, Weissman C. Comparisons of Several Biological and
Physicochemical Porperties of Human Leukocyte Interferons Produced by Human Leukocytes and by E. coli. Gene,
11: 181-186, 1980.
19. Sarkar FH Pharamacokinetic Comparison of leukocyte and E.Coli- derived Human Interferon type alpha. Antiviral
Res., 2: 103-106, 1982.
20. Sarkar FH, Sussman Berger P, Pickering LA. Mouse Interferon mRNA: Characterization of the Xenopus laevis
oocyte Translation Product. Arch. Biochem.Biophys. 217: 273-281, 1982.
21. Sarkar FH, Gupta SL. Inhibition of Interferon Secretion in Human Fibroblast byVinblastine. Arch. Virol. 73: 343349, 1982.
22. Sarkar FH, Gupta SL. On the Inhibition of Interferon Action by Inhibitors of Fatty Acid Cyclooxygenase. Virology,
123: 448-451, 1982.
23. Joshi AR, Sarkar FH, Gupta SL. Interferon Receptors: Cross-linking of Human Leukocyte Interferon- alpha 2 to its
Receptor on Human Cells. J. Biol. Chem. 247: 13884 -13887, 1982.
24. Pickering LA, Lin LS, Sarkar FH. Characterization of Spontaneously Produced and of Virus Induced Human LuKII
Cell Interferons. Arch. Virol. 75: 201-211, 1983.
25. Sarkar FH, Gupta SL. Interferon Receptor Interaction: Internalization of Interferon -alpha2 and Modulation of Its
Receptor on Human Cells. Europ. J. Biochem. 140: 461-467, 1984.
26. Gupta SL, Raziuddin A, Sarkar FH. Receptors for Human alpha Interferon: Are Gangliosides Involved? J.
Interferon Res. 4: 305-314, 1984.
27. Sarkar FH, Gupta SL. Receptors for Human gamma Interferon: Binding and Cross-linking of 125I-labeled
ecombinant Human gamma Interferon to Receptors on WISH Cells. Proc. Natl. Acad. Sci. USA. 81: 5160-5164,
1984.
28. Raziuddin A, Sarkar FH, Dukkowski R, Shulman L, Ruddl, FH, Gupta SL. Receptors for Human alpha and beta
Interferon but not for gamma Interferon are specified by Human Chromosome 21. Proc. Natl. Acad. Sci. USA. 81:
5504-5508, 1984.
29. Sarkar FH, Mancini MA, Nag AC, Roy AK. Cellular Interactions in the Hormonal Induction of alpha-2u Globulin in
Rat Liver. J. Endocrinol. 111, 205-208, 1986.
30. Murty CVR, Sarkar FH, Mancini MA, Roy AK. Sex Independent Synthesis of alpha-2u Globulin and Its mRNA in
the Rat Preputial Gland:Biochemical and Immunocytochemical Analyses. Endocrinology 121: 1000-1005, 1987.
31. Sarkar FH, Sarkar PK, Watson S, Poulik MD, Roy AK. Cytoplasmic Androgen Binding Protein of Rat Liver:
Molecular Characterization after Photoaffinity Labeling and Functional Correlation with the Age-Dependent Synthesis
of alpha-2u Globulin. Biochemistry 26: 3965-3970, 1987.
32. Roy AK, Mancini MA, Sarkar FH, Majumdar D, Murty CVR, Demyan WF. Androgenic Regulation of Hepatic Gene
Expression. J. Steroid Biochem. 27: 1129-1134, 1987.
33. Demyan WF: Sarkar FH; Murty CVR, Roy AK. Purification and immunochemical characterization of the
cytoplasmic androgen-binding Protein of the Rat Liver. Biochemistry 28: 1732- 1736, 1988.
34. Crissman JD, Zarbo RJ, Johnson TJ, Babu VR, Sarkar FH, Miles BJ, Cerny JC. Advances in the diagnosis of
urothelial neoplasia. Med. J. 37:19- 23, 1989.
35. Sarkar FH, Crissman JD. Detection of Human Papilloma Virus DNA sequences by Polymerase Chain Reaction.
BioTechniques 9: 180-185, 1990.
36. Sarkar FH, Radclifff G; Callewaert DM, Marnett LJ, Eling TE, Caspary WJ. Mutagenic response of mouse
lymphoma cells after activation of benzidine and 2 -Aminofluorene with Purified Prostaglandin H Synthase. Mutation
Research 242: 319-328, 1990.
37. Johnson TL, Plieth DA, Crissman JD, Sarkar FH. HPV detection by polymerase chain reaction (PCR) in verrucous
lesions of the upper aerodigestive tract. Modern Pathology 4: 461-465, 1991.
38. Visscher DW, Sarkar FH, Crissman JD. Correlation of DNA ploidy with c-erbB-2 expression in pre-invasive and
invasive breast trumors. Analytical and Quantitative Cytology and Histology. 13(6): 418-424, 1991.
39. Sarkar FH, Ball DE, Li YW, Crissman JD. Analysis of mRNA expression using a single 10 µm frozen tissue section.
Clinical Biotechnology 3: 121-125,1991.
13
40. Sarkar FH, Li YW, Ball DE, Crissman JD. A comparative method for the detection of RNA-PCR amplified signals.
BioTechniques 12(1): 22-26, 1992.
41. Sarkar FH, Miles BJ, Plieth DA, Crissman JD. Detection of human papillomavirus in squamous neoplasm of the
penis. J. Urol. 147: 389-392, 1992.
42. Johnson TL, Kim WS, Plieth DA, Sarkar FH. Detection of HPV 16/18 in cervical adenocarcinoma using polymerase
chain reaction (PCR) methodology. Modern Pathology 5: 35-40, 1992.
43. Sarkar FH, Visscher DW, Kintanar EB, Zarbo RJ, Crissman JD. Sinonasal Schneiderian papillomas: Human
papilloma virus typing by polymerase chain reaction. Modern Pathology 5: 329-332, 1992.
44. Wolman SR, Pauley RM, Mohamed A, Dawson PJ, Visscher DW, Sarkar FH. Genetic markers as prognostic
indicators in breast cancer. Cancer 70: 1765-1774, 1992.
45. Sarkar FH, Radcliff, Callewaert DM. Prostaglandin Synthase mediated metabolic activation of premutagen in
Salmonella Typhimurium. Mutation Research 282: 273-281, 1992.
46. Sarkar FH, Sakr W, Li YW, Macoska J, Ball DE, Crissman JD. Analysis of retinoblastoma (RB) gene deletion in
human prostatic carcinomas. The Prostate 21: 145-152, 1992.
47. Sarkar FH, Sakr WA, Li YW, Sreepathi P, Crissman JD. Detection of human papillomavirus (HPV) DNA in human
prostatic tissues by polymerase chain reaction (PCR). The Prostate 22: 171-180, 1993.
48. Sakr WA, Sarkar FH, Sreepathi P, Drozdowicz S, Crissman JD. Measurement of cellular proliferation in human
prostate by AgNOR, PCNA and SPF. The Prostate 22: 147-154, 1993.
49. Sarkar FH, Ball DE, Tsang W, Li YW, Kuo TH. Use of the polymerase chain reaction for the detection of
alternatively spliced mRNAs of plasma membrane calcium pump. DNA and Cell Biology 12: 435-440, 1993.
50. Sarkar FH, Visscher DW. Human cancer: Molecular concepts and their influence in cytodiagnosis. Diagnostic
Cytopathology 9: 333-343, 1993.
51. Visscher DW, Sarkar FH, LoRusso P, Sakr W, Ottosen S, Wykes S, Crissman JD. Immunohistologic evaluation of
invasion-associated proteases in breast carcinoma. Modern Pathology 6: 302-306, 1993.
52. Visscher DW, Sarkar FH, Wykes S, Kothari K, Macoska J, Crissman JD. Clinicopathologic significance of p53
immunostaining in adenocarcinoma of the breast. Archives of Pathology and Laboratory Medicine 117: 973-976,
1993.
53. Sarkar FH, Li YW, Crissman JD. A method for PCR-sequencing of the p53 gene from a single 10µm frozen or
paraffin-embedded tissue section. BioTechniques 15: 36-38, 1993.
54. Sarkar FH, Ball DE, Li YW, Crissman JD. Molecular cloning and sequencing of an intron of Her-2/neu (ERBB2)
gene. DNA and Cell Biology 12: 611-615, 1993.
55. Sarkar FH, Visscher DW, Crissman JD. Quantitative analysis of Her-2/neu (ERBB2) gene expression using reverse
transcriptase polymerase chain reaction. Diag Molecular Pathol 2(3):210-218, 1993.
56. Crissman JD, Visscher DW, Sarkar FH. Premalignant lesions of the upper Aerodigestive Tract: Biomarkers of
genetic alterations, proliferation and differentiation. In:" Chemoprevention of Premalignant lesions of the upper
Aerodigestive Tract" , J. Cell. Biochem 17F: 192-198, 1993.
57. Visscher DW, Castellani R, Wykes SM, Sarkar FH, Hussain ME. Concurrent abnormal expression of ERBB2, EGFR
and p53 genes and clinical disease progression of breast carcinoma. Breast Cancer Research and Treatment 28: 261266, 1993.
58. Visscher DW, Sarkar FH, Sakr WA, Crissman JD. Immunohistologic analysis of invasive phenotype in breast
carcinoma: A clinicopathologic study. Pathology Research and Practice 189: 867-872, 1993.
59. Sarkar FH, Kupsky WJ, Li YW, Sreepathi P. Analysis of p53 gene mutations in human gliomas by polymerase chain
reaction based SSCP and DNA sequencing. Diagnostic Molecular Pathology 3(1): 2-8, 1994.
60. Castellani R, Visscher DW, Wykes S, Sarkar FH, Crissman JD. Interaction of transforming growth factor-alpha
(TGF-β) and epidermal growth factor receptor (EGFR) in breast carcinoma: An immunohistologic study. Cancer 73:
344-349, 1994.
61. Sarkar FH, Smith MR, Hoover T, Princlear G, Crissman JD, Visscher DW, Longo DL, Kung HF, Raziuddin. cerbB2 promoter specific DNA-binding protein isolated from human breast cancer tissues displays mitogenic activity.
J. Biol. Chem.269: 12285-12289, 1994.
62. Johnson TJ, Joseph CLM, Caison-Sorey TJ, Smith RE, Bedrossian C, Sarkar FH. Prevalence of HPV 16 and 18
DNA sequences in CIN III lesions of adults and adolescents. Diagnostic Cytopathology 10: 276-283, 1994.
63. Visscher DW, Sarkar FH, Wolman SR, Bedrossian CWM. Special techniques in clinical cytology: Theory and
methodology of evaluating genetic alterations. Diagnostic Cytopathology 10: 289-298, 1994.
64. Gao X, Wu N, Grignon D, Zacharek A, Liu H, Salkoski A, Li G, Sakr W, Sarkar FH, Porter A, Chen YQ, Honn KV.
High frequency of mutator phenotype in human prostatic adenocarcinoma. Oncogene 9: 2999-3003, 1994.
65. Chen YQ, Gao X, Grignon D, Sarkar FH, Sakr W, Honn KV, Borders JS, Crissman JD. Multiple mechanisms of p53
inactivation in prostatic carcinoma. Cancer Molecular Biology 1: 330-337, 1994.
14
66. Visscher DW, Hoyhtya M, Ottosen S, Liang C-M, Sarkar FH, Crissman JD, Fridman R. Enhanced expression of
tissue inhibitor of metalloproteinase-2 (TIMP-2) in the stroma of breast carcinomas correlates with tumor recurrence.
Int. J. Cancer 59: 339-344, 1994.
67. Brooks,P.C., Stromblad,S., Klemke,R., Visscher,D., Sarkar,F.H. and Cheresh,D.A. Antiintegrin alpha v beta 3 blocks
human breast cancer growth and angiogenesis in human skin, J Clin.Invest, 96: 1815-1822, 1995.
68. Mohamed,A.N., Koppitch,F., Varterasian,M., Karanes,C., Yao,K.L. and Sarkar,F.H. BCR/ABL fusion located on
chromosome 9 in chronic myeloid leukemia with a masked Ph chromosome, Genes Chromosomes.Cancer, 13: 133137, 1995.
69. Mohamed,A.N., Ebrahim,S.A., Sarkar,F.H., Uberti,J. and Wolman,S.R. Detection of M-bcr/abl fusion by
fluorescence in situ hybridization (FISH) in a case of Ph negative CML, Cancer Genet.Cytogenet., 80: 60-62, 1995.
70. Sarkar,F.H., Valdivieso,M., Borders,J., Yao,K.L., Raval,M.M., Madan,S.K., Sreepathi,P., Shimoyama,R., Steiger,Z.,
Visscher,D.W. and . A universal method for the mutational analysis of K-ras and p53 gene in non-small-cell lung
cancer using formalin-fixed paraffin-embedded tissue, Diagn.Mol.Pathol., 4: 266-273, 1995.
71. Upadhyay,S., Li,G., Liu,H., Chen,Y.Q., Sarkar,F.H. and Kim,H.R. bcl-2 suppresses expression of p21WAF1/CIP1 in
breast epithelial cells, Cancer Res., 55: 4520-4524, 1995.
72. Visscher,D.W., DeMattia,F., Ottosen,S., Sarkar,F.H. and Crissman,J.D. Biologic and clinical significance of basic
fibroblast growth factor immunostaining in breast carcinoma, Mod.Pathol., 8: 665-670, 1995.
73. Chopra,D.P., Grignon,D.J., Joiakim,A., Mathieu,P.A., Mohamed,A., Sakr,W.A., Powell,I.J. and Sarkar,F.H.
Differential growth factor responses of epithelial cell cultures derived from normal human prostate, benign prostatic
hyperplasia, and primary prostate carcinoma, J Cell Physiol, 169: 269-280, 1996.
74. Nag,A.C., Lee,M.L. and Sarkar,F.H. Remodelling of adult cardiac muscle cells in culture: dynamic process of
disorganization and reorganization of myofibrils, J Muscle Res.Cell Motil., 17: 313-334, 1996.
75. Sarkar,F.H., Sakr,W.A., Li,Y.W., Jacobs,J. and Crissman,J.D. Tumor suppressor p53 gene mutation in squamous cell
carcinoma of the larynx, Diagn.Mol.Pathol., 5: 201-205, 1996.
76. Visscher,D.W., Sarkar,F.H., Shimoyama,R.K. and Crissman,J.D. Correlation between p53 immunostaining patterns
and gene sequence mutations in breast carcinoma, Diagn.Mol.Pathol., 5: 187-193, 1996.
77. Chopra,D.P., Sarkar,F.H., Grignon,D.J., Sakr,W.A., Mohamed,A. and Waghray,A. Growth of human nondiploid
primary prostate tumor epithelial cells in vitro, Cancer Res., 57: 3688-3692, 1997.
78. Dergham,S.T., Dugan,M.C., Arlauskas,P., Du,W., Vaitkevicius,V.K., Crissman,J.D. and Sarkar,F.H. Relationship of
family cancer history to the expression of p53, p21WAF-1, HER-2/neu, and K-ras mutation in pancreatic
adenocarcinoma, Int.J Pancreatol., 21: 225-234, 1997.
79. Dergham,S.T., Dugan,M.C., Kucway,R., Du,W., Kamarauskiene,D.S., Vaitkevicius,V.K., Crissman,J.D. and
Sarkar,F.H. Prevalence and clinical significance of combined K-ras mutation and p53 aberration in pancreatic
adenocarcinoma, Int.J Pancreatol., 21: 127-143, 1997.
80. Dergham,S.T., Dugan,M.C., Joshi,U.S., Chen,Y.C., Du,W., Smith,D.W., Arlauskas,P., Crissman,J.D.,
Vaitkevicius,V.K. and Sarkar,F.H. The clinical significance of p21(WAF1/CIP-1) and p53 expression in pancreatic
adenocarcinoma, Cancer, 80: 372-381, 1997.
81. Dugan,M.C., Dergham,S.T., Kucway,R., Singh,K., Biernat,L., Du,W., Vaitkevicius,V.K., Crissman,J.D. and
Sarkar,F.H. HER-2/neu expression in pancreatic adenocarcinoma: relation to tumor differentiation and survival,
Pancreas, 14: 229-236, 1997.
82. Grignon,D.J., Caplan,R., Sarkar,F.H., Lawton,C.A., Hammond,E.H., Pilepich,M.V., Forman,J.D., Mesic,J., Fu,K.K.,
Abrams,R.A., Pajak,T.F., Shipley,W.U. and Cox,J.D. p53 status and prognosis of locally advanced prostatic
adenocarcinoma: a study based on RTOG 8610, J Natl.Cancer Inst., 89: 158-165, 1997.
83. Kattar,M.M., Kupsky,W.J., Shimoyama,R.K., Vo,T.D., Olson,M.W., Bargar,G.R. and Sarkar,F.H. Clonal analysis of
gliomas, Hum.Pathol., 28: 1166-1179, 1997.
84. Raziuddin,A., Court,D., Sarkar,F.H., Liu,Y.L., Kung,H. and Raziuddin,R. A c-erbB-2 promoter-specific nuclear
matrix protein from human breast tumor tissues mediates NF-kappaB DNA binding activity, J Biol.Chem., 272:
15715-15720, 1997.
85. Spindler,S.A., Sarkar,F.H., Sakr,W.A., Blackburn,M.L., Bull,A.W., LaGattuta,M. and Reddy,R.G. Production of 13hydroxyoctadecadienoic acid (13-HODE) by prostate tumors and cell lines, Biochem.Biophys.Res.Commun., 239:
775-781, 1997.
86. Tureaud,J., Sarkar,F.H., Fligiel,S.E., Kulkarni,S., Jaszewski,R., Reddy,K., Yu,Y. and Majumdar,A.P. Increased
expression of EGFR in gastric mucosa of aged rats, Am.J Physiol, 273: G389-G398, 1997.
87. Visscher,D.W., Yadrandji,S., Tabaczka,P., Kraut,M. and Sarkar,F.H. Clinicopathologic analysis of k-ras, p53, and
ERBB-2 gene alterations in pulmonary adenocarcinoma, Diagn.Mol.Pathol., 6: 64-69, 1997.
88. Visscher,D.W., Sarkar,F.H., Kasunic,T.C. and Reddy,K.B. Clinicopathologic analysis of amphiregulin and heregulin
immunostaining in breast neoplasia, Breast Cancer Res.Treat., 45: 75-80, 1997.
89. Visscher,D.W., Sarkar,F.H. and Crissman,J.D. Molecular genetic analysis in the pathologic evaluation of solid
tumors: theory and practice, J Clin.Lab Anal., 11: 10-16, 1997.
90. Zhou,J., Olsen,S., Moldovan,J., Fu,X., Sarkar,F.H., Moudgil,V.K. and Callewaert,D.M. Glucocorticoid regulation of
natural cytotoxicity: effects of cortisol on the phenotype and function of a cloned human natural killer cell line, Cell
Immunol., 178: 108-116, 1997.
15
91. Davis,J.N., Singh,B., Bhuiyan,M. and Sarkar,F.H. Genistein-induced upregulation of p21WAF1, downregulation of
cyclin B, and induction of apoptosis in prostate cancer cells, Nutr.Cancer, 32: 123-131, 1998.
92. Dergham,S.T., Dugan,M.C., Sarkar,F.H. and Vaitkevicius,V.K. Molecular alterations associated with improved
survival in pancreatic cancer patients treated with radiation or chemotherapy, J Hepatobiliary.Pancreat.Surg., 5: 269272, 1998.
93. Dugan,M.C. and Sarkar,F.H. Current concepts in pancreatic cancer: symposium summary, Pancreas, 17: 325-333,
1998.
94. Joshi,U.S., Dergham,S.T., Chen,Y.Q., Dugan,M.C., Crissman,J.D., Vaitkevicius,V.K. and Sarkar,F.H. Inhibition of
pancreatic tumor cell growth in culture by p21WAF1 recombinant adenovirus, Pancreas, 16: 107-113, 1998.
95. Joshi,U.S., Chen,Y.Q., Kalemkerian,G.P., Adil,M.R., Kraut,M. and Sarkar,F.H. Inhibition of tumor cell growth by
p21WAF1 adenoviral gene transfer in lung cancer, Cancer Gene Ther., 5: 183-191, 1998.
96. Keshishian,A., Sarkar,F.H., Kucyj,G. and Just-Viera,J.O. Four multiple primary malignant neoplasms of the
aerodigestive tract, Ann.Thorac.Surg., 65: 252-254, 1998.
97. Li,Y., Bhuiyan,M., Mohammad,R.M. and Sarkar,F.H. Induction of apoptosis in breast cancer cells by TPA,
Oncogene, 17: 2915-2920, 1998.
98. Li,Y., Bhuiyan,M., Vaitkevicius,V.K. and Sarkar,F.H. Molecular analysis of the p53 gene in pancreatic
adenocarcinoma, Diagn.Mol.Pathol., 7: 4-9, 1998.
99. Lian,F., Bhuiyan,M., Li,Y.W., Wall,N., Kraut,M. and Sarkar,F.H. Genistein-induced G2-M arrest, p21WAF1
upregulation, and apoptosis in a non-small-cell lung cancer cell line, Nutr.Cancer, 31: 184-191, 1998.
100. Mohammad,R.M., Dugan,M.C., Mohamed,A.N., Almatchy,V.P., Flake,T.M., Dergham,S.T., Shields,A.F., AlKatib,A.A., Vaitkevicius,V.K. and Sarkar,F.H. Establishment of a human pancreatic tumor xenograft model:
potential application for preclinical evaluation of novel therapeutic agents, Pancreas, 16: 19-25, 1998.
101. Mohammad,R.M., Al-Katib,A., Pettit,G.R., Vaitkevicius,V.K., Joshi,U., Adsay,V., Majumdar,A.P. and Sarkar,F.H.
An orthotopic model of human pancreatic cancer in severe combined immunodeficient mice: potential application for
preclinical studies, Clin.Cancer Res., 4: 887-894, 1998.
102. Nangia-Makker,P., Sarvis,R., Visscher,D.W., Bailey-Penrod,J., Raz,A. and Sarkar,F.H. Galectin-3 and L1
retrotransposons in human breast carcinomas, Breast Cancer Res.Treat., 49: 171-183, 1998.
103. Rakozy,C., Grignon,D.J., Sarkar,F.H., Sakr,W.A., Littrup,P. and Forman,J. Expression of bcl-2, p53, and p21 in
benign and malignant prostatic tissue before and after radiation therapy, Mod.Pathol., 11: 892-899, 1998.
104. Adsay,N.V., Dergham,S.T., Koppitch,F.C., Dugan,M.C., Mohamed,A.N., Vaitkevicius,V.K. and Sarkar,F.H. Utility
of fluorescence in situ hybridization in pancreatic ductal adenocarcinoma, Pancreas, 18: 111-116, 1999.
105. Alhasan,S.A., Pietrasczkiwicz,H., Alonso,M.D., Ensley,J. and Sarkar,F.H. Genistein-induced cell cycle arrest and
apoptosis in a head and neck squamous cell carcinoma cell line, Nutr.Cancer, 34: 12-19, 1999.
106. Chomchai,J.S., Du,W., Sarkar,F.H., Li,Y.W., Jacobs,J.R., Ensley,J.F., Sakr,W. and Yoo,G.H. Prognostic significance
of p53 gene mutations in laryngeal cancer, Laryngoscope, 109: 455-459, 1999.
107. Davis,J.N., Kucuk,O. and Sarkar,F.H. Genistein inhibits NF-kappa B activation in prostate cancer cells, Nutr.Cancer,
35: 167-174, 1999.
108. Gururajanna,B., Al-Katib,A.A., Li,Y.W., Aranha,O., Vaitkevicius,V.K. and Sarkar,F.H. Molecular effects of taxol
and caffeine on pancreatic cancer cells, Int.J Mol.Med, 4: 501-507, 1999.
109. Jaszewski,R., Khan,A., Sarkar,F.H., Kucuk,O., Tobi,M., Zagnoon,A., Dhar,R., Kinzie,J. and Majumdar,A.P. Folic
acid inhibition of EGFR-mediated proliferation in human colon cancer cell lines, Am.J Physiol, 277: C1142-C1148,
1999.
110. Li,Y., Bhuiyan,M., Vaitkevicius,V.K. and Sarkar,F.H. Structural alteration of p53 protein correlated to survival in
patients with pancreatic adenocarcinoma, Pancreas, 18: 104-110, 1999.
111. Li,Y., Singh,B., Ali,N. and Sarkar,F.H. Induction of growth inhibition and apoptosis in pancreatic cancer cells by
auristatin-PE and gemcitabine, Int.J Mol.Med, 3: 647-653, 1999.
112. Li,Y., Bhuiyan,M. and Sarkar,F.H. Induction of apoptosis and inhibition of c-erbB-2 in MDA-MB-435 cells by
genistein, Int.J Oncol., 15: 525-533, 1999.
113. Li,Y., Upadhyay,S., Bhuiyan,M. and Sarkar,F.H. Induction of apoptosis in breast cancer cells MDA-MB-231 by
genistein, Oncogene, 18: 3166-3172, 1999.
114. Lian,F., Li,Y., Bhuiyan,M. and Sarkar,F.H. p53-independent apoptosis induced by genistein in lung cancer cells,
Nutr.Cancer, 33: 125-131, 1999.
115. Mohammad,R.M., Li,Y., Mohamed,A.N., Pettit,G.R., Adsay,V., Vaitkevicius,V.K., Al-Katib,A.M. and Sarkar,F.H.
Clonal preservation of human pancreatic cell line derived from primary pancreatic adenocarcinoma, Pancreas, 19:
353-361, 1999.
116. Rakozy,C., Grignon,D.J., Li,Y., Gheiler,E., Gururajanna,B., Pontes,J.E., Sakr,W., Wood,D.P., Jr. and Sarkar,F.H.
p53 gene alterations in prostate cancer after radiation failure and their association with clinical outcome: a molecular
and immunohistochemical analysis, Pathol.Res.Pract., 195: 129-135, 1999.
117. Sarkar,F.H., Li,Y., Sakr,W.A., Grignon,D.J., Madan,S.S., Wood,D.P., Jr. and Adsay,V. Relationship of p21(WAF1)
expression with disease-free survival and biochemical recurrence in prostate adenocarcinomas (PCa), Prostate, 40:
256-260, 1999.
16
118. Alhasan,S.A., Ensley,J.F. and Sarkar,F.H. Genistein induced molecular changes in a squamous cell carcinoma of the
head and neck cell line, Int.J Oncol., 16: 333-338, 2000.
119. Aranha,O., Wood,D.P., Jr. and Sarkar,F.H. Ciprofloxacin mediated cell growth inhibition, S/G2-M cell cycle arrest,
and apoptosis in a human transitional cell carcinoma of the bladder cell line, Clin.Cancer Res., 6: 891-900, 2000.
120. Davis,J.N., Muqim,N., Bhuiyan,M., Kucuk,O., Pienta,K.J. and Sarkar,F.H. Inhibition of prostate specific antigen
expression by genistein in prostate cancer cells, Int.J Oncol., 16: 1091-1097, 2000.
121. He,Z., Evelhoch,J.L., Mohammad,R.M., Adsay,N.V., Pettit,G.R., Vaitkevicius,V.K. and Sarkar,F.H. Magnetic
resonance imaging to measure therapeutic response using an orthotopic model of human pancreatic cancer, Pancreas,
21: 69-76, 2000.
122. Li,Y., Bhuiyan,M., Alhasan,S., Senderowicz,A.M. and Sarkar,F.H. Induction of apoptosis and inhibition of c-erbB-2
in breast cancer cells by flavopiridol, Clin.Cancer Res., 6: 223-229, 2000.
123. Li,Y., Chinni,S.R., Senderowicz,A.M. and Sarkar,F.H. Induction of growth inhibition and apoptosis in prostate
cancer cells by flavopiridol, Int.J Oncol., 17: 755-759, 2000.
124. Rahman,K.M., Aranha,O., Glazyrin,A., Chinni,S.R. and Sarkar,F.H. Translocation of Bax to mitochondria induces
apoptotic cell death in indole-3-carbinol (I3C) treated breast cancer cells, Oncogene, 19: 5764-5771, 2000.
125. Alhasan,S.A., Aranha,O. and Sarkar,F.H. Genistein elicits pleiotropic molecular effects on head and neck cancer
cells, Clin.Cancer Res., 7: 4174-4181, 2001.
126. Chinni,S.R., Li,Y., Upadhyay,S., Koppolu,P.K. and Sarkar,F.H. Indole-3-carbinol (I3C) induced cell growth
inhibition, G1 cell cycle arrest and apoptosis in prostate cancer cells, Oncogene, 20: 2927-2936, 2001.
127. Davis,J.N., Kucuk,O., Djuric,Z. and Sarkar,F.H. Soy isoflavone supplementation in healthy men prevents NF-kappa
B activation by TNF-alpha in blood lymphocytes, Free Radic.Biol.Med, 30: 1293-1302, 2001.
128. Glazyrin,A.L., Adsay,V.N., Vaitkevicius,V.K. and Sarkar,F.H. CD95-related apoptotic machinery is functional in
pancreatic cancer cells, Pancreas, 22: 357-365, 2001.
129. Hillman,G.G., Forman,J.D., Kucuk,O., Yudelev,M., Maughan,R.L., Rubio,J., Layer,A., Tekyi-Mensah,S., Abrams,J.
and Sarkar,F.H. Genistein potentiates the radiation effect on prostate carcinoma cells, Clin.Cancer Res., 7: 382-390,
2001.
130. Kucuk,O., Sarkar,F.H., Sakr,W., Djuric,Z., Pollak,M.N., Khachik,F., Li,Y.W., Banerjee,M., Grignon,D.,
Bertram,J.S., Crissman,J.D., Pontes,E.J. and Wood,D.P., Jr. Phase II randomized clinical trial of lycopene
supplementation before radical prostatectomy, Cancer Epidemiol.Biomarkers Prev., 10: 861-868, 2001.
131. Mohammad,R.M., Adsay,N.V., Philip,P.A., Pettit,G.R., Vaitkevicius,V.K. and Sarkar,F.H. Bryostatin 1 induces
differentiation and potentiates the antitumor effect of Auristatin PE in a human pancreatic tumor (PANC-1) xenograft
model, Anticancer Drugs, 12: 735-740, 2001.
132. Pierson,C.R., Schober,M.S., Wallis,T., Sarkar,F.H., Sorensen,P.H., Eble,J.N., Srigley,J.R., Jones,E.C., Grignon,D.J.
and Adsay,V. Mixed epithelial and stromal tumor of the kidney lacks the genetic alterations of cellular congenital
mesoblastic nephroma, Hum.Pathol., 32: 513-520, 2001.
133. Prasad,A.S., Bao,B., Beck,F.W. and Sarkar,F.H. Zinc activates NF-kappaB in HUT-78 cells, J Lab Clin.Med, 138:
250-256, 2001.
134. Sarkar,F.H., Li,Y. and Vallyathan,V. Molecular analysis of p53 and K-ras in lung carcinomas of coal miners, Int.J
Mol.Med, 8: 453-459, 2001.
135. Tiguert,R., Bianco,F.J., Jr., Oskanian,P., Li,Y., Grignon,D.J., Wood,D.P., Jr., Pontes,J.E. and Sarkar,F.H. Structural
alteration of p53 protein in patients with muscle invasive bladder transitional cell carcinoma, J Urol., 166: 2155-2160,
2001.
136. Upadhyay,S., Neburi,M., Chinni,S.R., Alhasan,S., Miller,F. and Sarkar,F.H. Differential sensitivity of normal and
malignant breast epithelial cells to genistein is partly mediated by p21(WAF1), Clin.Cancer Res., 7: 1782-1789, 2001.
137. Aranha,O., Zhu,L., Alhasan,S., Wood,D.P., Jr., Kuo,T.H. and Sarkar,F.H. Role of mitochondria in ciprofloxacin
induced apoptosis in bladder cancer cells, J Urol., 167: 1288-1294, 2002.
138. Chinni,S.R. and Sarkar,F.H. Akt inactivation is a key event in indole-3-carbinol-induced apoptosis in PC-3 cells,
Clin.Cancer Res., 8: 1228-1236, 2002.
139. Davis,J.N., Kucuk,O. and Sarkar,F.H. Expression of prostate-specific antigen is transcriptionally regulated by
genistein in prostate cancer cells, Mol.Carcinog., 34: 91-101, 2002.
140. El-Rayes,B.F., Grignon,R., Aslam,N., Aranha,O. and Sarkar,F.H. Ciprofloxacin inhibits cell growth and synergises
the effect of etoposide in hormone resistant prostate cancer cells, Int.J Oncol., 21: 207-211, 2002.
141. Feng,J., Adsay,N.V., Kruger,M., Ellis,K.L., Nagothu,K., Majumdar,A.P. and Sarkar,F.H. Expression of ERRP in
normal and neoplastic pancreata and its relationship to clinicopathologic parameters in pancreatic adenocarcinoma,
Pancreas, 25: 342-349, 2002.
142. Glazyrin,A.L., Chinni,S., Alhasan,S., Adsay,V.N., Vaitkevicius,V.K. and Sarkar,F.H. Molecular mechanism(s) of
actinomycin-D induced sensitization of pancreatic cancer cells to CD95 mediated apoptosis, Int.J Oncol., 20: 201205, 2002.
143. Kucuk,O., Sarkar,F.H., Djuric,Z., Sakr,W., Pollak,M.N., Khachik,F., Banerjee,M., Bertram,J.S. and Wood,D.P., Jr.
Effects of lycopene supplementation in patients with localized prostate cancer, Exp.Biol.Med (Maywood.), 227: 881885, 2002.
17
144. Lahiri,D.K., Kotwal,G.J., Farlow,M.R., Sima,A., Kupsky,W., Sarkar,F.H. and Sambamurti,K. The role of the
carboxyl-terminal fragments of amyloid precursor protein in Alzheimer's disease, Ann.N.Y.Acad.Sci., 973: 334-339,
2002.
145. Li,Y. and Sarkar,F.H. Inhibition of nuclear factor kappaB activation in PC3 cells by genistein is mediated via Akt
signaling pathway, Clin.Cancer Res., 8: 2369-2377, 2002.
146. Li,Y. and Sarkar,F.H. Down-regulation of invasion and angiogenesis-related genes identified by cDNA microarray
analysis of PC3 prostate cancer cells treated with genistein, Cancer Lett., 186: 157-164, 2002.
147. Li,Y. and Sarkar,F.H. Gene expression profiles of genistein-treated PC3 prostate cancer cells, J Nutr., 132: 36233631, 2002.
148. Pernick,N.L., Sarkar,F.H., Tabaczka,P., Kotcher,G., Frank,J. and Adsay,N.V. Fas and Fas ligand expression in
pancreatic adenocarcinoma, Pancreas, 25: e36-e41, 2002.
149. Prasad,A.S., Bao,B., Beck,F.W. and Sarkar,F.H. Zinc enhances the expression of interleukin-2 and interleukin-2
receptors in HUT-78 cells by way of NF-kappaB activation, J Lab Clin.Med, 140: 272-289, 2002.
150. Rahman,K.M. and Sarkar,F.H. Steroid hormone mimics: molecular mechanisms of cell growth and apoptosis in
normal and malignant mammary epithelial cells, J Steroid Biochem.Mol.Biol., 80: 191-201, 2002.
151. Sarkar,F.H. and Li,Y. Mechanisms of cancer chemoprevention by soy isoflavone genistein, Cancer Metastasis Rev.,
21: 265-280, 2002.
152. Ali,S., Aranha,O., Li,Y., Pettit,G.R., Sarkar,F.H. and Philip,P.A. Sensitization of human breast cancer cells to
gemcitabine by the protein kinase C modulator bryostatin 1, Cancer Chemother.Pharmacol., 52: 235-246, 2003.
153. Aranha,O., Grignon,R., Fernandes,N., McDonnell,T.J., Wood,D.P., Jr. and Sarkar,F.H. Suppression of human
prostate cancer cell growth by ciprofloxacin is associated with cell cycle arrest and apoptosis, Int.J Oncol., 22: 787794, 2003.
154. Bismar,T.A., Bianco,F.J., Zhang,H., Li,X., Sarkar,F.H., Sakr,W.A., Grignon,D.J. and Che,M. Quantification of G250
mRNA expression in renal epithelial neoplasms by real-time reverse transcription-PCR of dissected tissue from
paraffin sections, Pathology, 35: 513-517, 2003.
155. Chinni,S.R., Alhasan,S.A., Multani,A.S., Pathak,S. and Sarkar,F.H. Pleotropic effects of genistein on MCF-7 breast
cancer cells, Int.J Mol.Med, 12: 29-34, 2003.
156. Gong,L., Li,Y., Nedeljkovic-Kurepa,A. and Sarkar,F.H. Inactivation of NF-kappaB by genistein is mediated via Akt
signaling pathway in breast cancer cells, Oncogene, 22: 4702-4709, 2003.
157. Hussain,M., Banerjee,M., Sarkar,F.H., Djuric,Z., Pollak,M.N., Doerge,D., Fontana,J., Chinni,S., Davis,J., Forman,J.,
Wood,D.P. and Kucuk,O. Soy isoflavones in the treatment of prostate cancer, Nutr.Cancer, 47: 111-117, 2003.
158. Li,Y., Ali,S., Philip,P.A. and Sarkar,F.H. Direct comparison of microarray gene expression profiles between nonamplification and a modified cDNA amplification procedure applicable for needle biopsy tissues, Cancer
Detect.Prev., 27: 405-411, 2003.
159. Li,Y., Li,X. and Sarkar,F.H. Gene expression profiles of I3C- and DIM-treated PC3 human prostate cancer cells
determined by cDNA microarray analysis, J Nutr., 133: 1011-1019, 2003.
160. Liao,D.J., Du,Q.Q., Yu,B.W., Grignon,D. and Sarkar,F.H. Novel perspective: focusing on the X chromosome in
reproductive cancers, Cancer Invest, 21: 641-658, 2003.
161. Majumdar,A.P., Du,J., Hatfield,J.S., Levi,E., Adsay,V., Schmelz,E.M., Nagothu,K.K., Jaszewski,R., Kucuk,O. and
Sarkar,F.H. Expression of EGF-receptor related protein (ERRP) decreases in gastric mucosa during aging and
carcinogenesis, Dig.Dis.Sci., 48: 856-864, 2003.
162. Marciniak,D.J., Moragoda,L., Mohammad,R.M., Yu,Y., Nagothu,K.K., Aboukameel,A., Sarkar,F.H., Adsay,V.N.,
Rishi,A.K. and Majumdar,A.P. Epidermal growth factor receptor-related protein: a potential therapeutic agent for
colorectal cancer, Gastroenterology, 124: 1337-1347, 2003.
163. Pernick,N.L., Sarkar,F.H., Philip,P.A., Arlauskas,P., Shields,A.F., Vaitkevicius,V.K., Dugan,M.C. and Adsay,N.V.
Clinicopathologic analysis of pancreatic adenocarcinoma in African Americans and Caucasians, Pancreas, 26: 28-32,
2003.
164. Rahman,K.M., Aranha,O. and Sarkar,F.H. Indole-3-carbinol (I3C) induces apoptosis in tumorigenic but not in
nontumorigenic breast epithelial cells, Nutr.Cancer, 45: 101-112, 2003.
165. Sarkar,F.H., Rahman,K.M. and Li,Y. Bax translocation to mitochondria is an important event in inducing apoptotic
cell death by indole-3-carbinol (I3C) treatment of breast cancer cells, J Nutr., 133: 2434S-2439S, 2003.
166. Sarkar,F.H. and Li,Y. Soy isoflavones and cancer prevention, Cancer Invest, 21: 744-757, 2003.
167. Adsay,N.V., Merati,K., Basturk,O., Iacobuzio-Donahue,C., Levi,E., Cheng,J.D., Sarkar,F.H., Hruban,R.H. and
Klimstra,D.S. Pathologically and biologically distinct types of epithelium in intraductal papillary mucinous neoplasms:
delineation of an "intestinal" pathway of carcinogenesis in the pancreas, Am.J Surg.Pathol., 28: 839-848, 2004.
168. Ali,S., El-Rayes,B.F., Heilbrun,L.K., Sarkar,F.H., Ensley,J.F., Kucuk,O. and Philip,P.A. Cytochrome p450 and
glutathione transferase expression in squamous cell cancer, Clin.Cancer Res., 10: 4412-4416, 2004.
169. Beck,F.W., Prasad,A.S., Butler,C.E., Sakr,W.A., Kucuk,O. and Sarkar,F.H. Differential expression of hZnT-4 in
human prostate tissues, Prostate, 58: 374-381, 2004.
170. El-Rayes,B.F., Ali,S., Sarkar,F.H. and Philip,P.A. Cyclooxygenase-2-dependent and -independent effects of
celecoxib in pancreatic cancer cell lines, Mol.Cancer Ther., 3: 1421-1426, 2004.
18
171. Hillman,G.G., Wang,Y., Kucuk,O., Che,M., Doerge,D.R., Yudelev,M., Joiner,M.C., Marples,B., Forman,J.D. and
Sarkar,F.H. Genistein potentiates inhibition of tumor growth by radiation in a prostate cancer orthotopic model,
Mol.Cancer Ther., 3: 1271-1279, 2004.
172. Hong,X., Li,Y., Hussain,M. and Sarkar,F.H. Gene expression profiling reveals novel targets of estramustine
phosphate in prostate cancer cells, Cancer Lett., 209: 187-195, 2004.
173. Levi,E., Mohammad,R., Kodali,U., Marciniak,D., Reddy,S., Aboukameel,A., Sarkar,F.H., Kucuk,O., Rishi,A.K. and
Majumdar,A.P. EGF-receptor related protein causes cell cycle arrest and induces apoptosis of colon cancer cells in
vitro and in vivo, Anticancer Res., 24: 2885-2891, 2004.
174. Li,Y., Li,X., Hussain,M. and Sarkar,F.H. Regulation of microtubule, apoptosis, and cell cycle-related genes by
taxotere in prostate cancer cells analyzed by microarray, Neoplasia., 6: 158-167, 2004.
175. Li,Y., Ellis,K.L., Ali,S., El-Rayes,B.F., Nedeljkovic-Kurepa,A., Kucuk,O., Philip,P.A. and Sarkar,F.H. Apoptosisinducing effect of chemotherapeutic agents is potentiated by soy isoflavone genistein, a natural inhibitor of NFkappaB in BxPC-3 pancreatic cancer cell line, Pancreas, 28: e90-e95, 2004.
176. Li,Y., Che,M., Bhagat,S., Ellis,K.L., Kucuk,O., Doerge,D.R., Abrams,J., Cher,M.L. and Sarkar,F.H. Regulation of
gene expression and inhibition of experimental prostate cancer bone metastasis by dietary genistein, Neoplasia., 6:
354-363, 2004.
177. Marciniak,D.J., Rishi,A.K., Sarkar,F.H. and Majumdar,A.P. Epidermal growth factor receptor-related peptide inhibits
growth of PC-3 prostate cancer cells, Mol.Cancer Ther., 3: 1615-1621, 2004.
178. Onderci,M., Sahin,K., Sahin,N., Gursu,M.F., Doerge,D., Sarkar,F.H. and Kucuk,O. The effect of genistein
supplementation on performance and antioxidant status of Japanese quail under heat stress, Arch.Anim Nutr., 58:
463-471, 2004.
179. Prasad,A.S., Bao,B., Beck,F.W., Kucuk,O. and Sarkar,F.H. Antioxidant effect of zinc in humans, Free
Radic.Biol.Med, 37: 1182-1190, 2004.
180. Rahman,K.M., Li,Y. and Sarkar,F.H. Inactivation of akt and NF-kappaB play important roles during indole-3carbinol-induced apoptosis in breast cancer cells, Nutr.Cancer, 48: 84-94, 2004.
181. Sahin,K., Ozercan,R., Onderci,M., Sahin,N., Gursu,M.F., Khachik,F., Sarkar,F.H., Munkarah,A., li-Fehmi,R.,
Kmak,D. and Kucuk,O. Lycopene supplementation prevents the development of spontaneous smooth muscle tumors
of the oviduct in Japanese quail, Nutr.Cancer, 50: 181-189, 2004.
182. Sarkar,F.H. and Li,Y. The role of isoflavones in cancer chemoprevention, Front Biosci., 9: 2714-2724, 2004.
183. Sarkar,F.H. and Li,Y. Indole-3-carbinol and prostate cancer, J Nutr., 134: 3493S-3498S, 2004.
184. Sarkar,F.H. and Li,Y. Cell signaling pathways altered by natural chemopreventive agents, Mutat.Res., 555: 53-64,
2004.
185. Siddiq,F., Sarkar,F.H., Wali,A., Pass,H.I. and Lonardo,F. Increased osteonectin expression is associated with
malignant transformation and tumor associated fibrosis in the lung, Lung Cancer, 45: 197-205, 2004.
186. Ali,S., El-Rayes,B.F., Sarkar,F.H. and Philip,P.A. Simultaneous targeting of the epidermal growth factor receptor and
cyclooxygenase-2 pathways for pancreatic cancer therapy, Mol.Cancer Ther., 4: 1943-1951, 2005.
187. Ali,S., El-Rayes,B.F., Aranha,O., Sarkar,F.H. and Philip,P.A. Sequence dependent potentiation of gemcitabine by
flavopiridol in human breast cancer cells, Breast Cancer Res.Treat., 90: 25-31, 2005.
188. Banerjee,S., Zhang,Y., Ali,S., Bhuiyan,M., Wang,Z., Chiao,P.J., Philip,P.A., Abbruzzese,J. and Sarkar,F.H.
Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an
orthotopic model of pancreatic cancer, Cancer Res., 65: 9064-9072, 2005.
189. Biliran,H., Jr., Wang,Y., Banerjee,S., Xu,H., Heng,H., Thakur,A., Bollig,A., Sarkar,F.H. and Liao,J.D.
Overexpression of cyclin D1 promotes tumor cell growth and confers resistance to cisplatin-mediated apoptosis in an
elastase-myc transgene-expressing pancreatic tumor cell line, Clin.Cancer Res., 11: 6075-6086, 2005.
190. Bollig,A., Du,Q.Q., Fan,S.T., Yu,B., Sarkar,F.H. and Liao,J. Combination of 5-deoxy-5-fluorouridine and tamoxifen
show cell-type specific antagonistic and cooperative effects on cytotoxicity in human mammary carcinoma cells,
Oncol.Rep., 14: 177-183, 2005.
191. Gupta,S.V., McGowen,R.M., Callewaert,D.M., Brown,T.R., Li,Y. and Sarkar,F.H. Quantitative chemiluminescent
immunoassay for NF-kappaB-DNA binding activity, J Immunoassay Immunochem., 26: 125-143, 2005.
192. Li,Y., Hussain,M., Sarkar,S.H., Eliason,J., Li,R. and Sarkar,F.H. Gene expression profiling revealed novel
mechanism of action of Taxotere and Furtulon in prostate cancer cells, BMC.Cancer, 5: 7, 2005.
193. Li,Y., Hong,X., Hussain,M., Sarkar,S.H., Li,R. and Sarkar,F.H. Gene expression profiling revealed novel molecular
targets of docetaxel and estramustine combination treatment in prostate cancer cells, Mol.Cancer Ther., 4: 389-398,
2005.
194. Li,Y., Ahmed,F., Ali,S., Philip,P.A., Kucuk,O. and Sarkar,F.H. Inactivation of nuclear factor kappaB by soy
isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells,
Cancer Res., 65: 6934-6942, 2005.
195. Li,Y., Chinni,S.R. and Sarkar,F.H. Selective growth regulatory and pro-apoptotic effects of DIM is mediated by AKT
and NF-kappaB pathways in prostate cancer cells, Front Biosci., 10: 236-243, 2005.
196. Mohammad,R.M., Wang,S., Banerjee,S., Wu,X., Chen,J. and Sarkar,F.H. Nonpeptidic small-molecule inhibitor of
Bcl-2 and Bcl-XL, (-)-Gossypol, enhances biological effect of genistein against BxPC-3 human pancreatic cancer cell
line, Pancreas, 31: 317-324, 2005.
19
197. Rahman,K.W. and Sarkar,F.H. Inhibition of nuclear translocation of nuclear factor-{kappa}B contributes to 3,3'diindolylmethane-induced apoptosis in breast cancer cells, Cancer Res., 65: 364-371, 2005.
198. Xu,H., Yu,Y., Marciniak,D., Rishi,A.K., Sarkar,F.H., Kucuk,O. and Majumdar,A.P. Epidermal growth factor
receptor (EGFR)-related protein inhibits multiple members of the EGFR family in colon and breast cancer cells,
Mol.Cancer Ther., 4: 435-442, 2005.
199. Zhang,Y., Banerjee,S., Wang,Z.W., Marciniak,D.J., Majumdar,A.P. and Sarkar,F.H. Epidermal growth factor
receptor-related protein inhibits cell growth and induces apoptosis of BxPC3 pancreatic cancer cells, Cancer Res., 65:
3877-3882, 2005.
200. Adsule,S., Barve,V., Chen,D., Ahmed,F., Dou,Q.P., Padhye,S. and Sarkar,F.H. Novel Schiff base copper complexes
of quinoline-2 carboxaldehyde as proteasome inhibitors in human prostate cancer cells, J Med Chem., 49: 7242-7246,
2006.
201. Altinok,G., Powell,I.J., Che,M., Hormont,K., Sarkar,F.H., Sakr,W.A., Grignon,D. and Liao,D.J. Reduction of QM
protein expression correlates with tumor grade in prostatic adenocarcinoma, Prostate Cancer Prostatic.Dis., 9: 77-82,
2006.
202. Barve,V., Ahmed,F., Adsule,S., Banerjee,S., Kulkarni,S., Katiyar,P., Anson,C.E., Powell,A.K., Padhye,S. and
Sarkar,F.H. Synthesis, molecular characterization, and biological activity of novel synthetic derivatives of chromen4-one in human cancer cells, J Med Chem., 49: 3800-3808, 2006.
203. Beck,F.W., Li,Y., Bao,B., Prasad,A.S. and Sarkar,F.H. Evidence for reprogramming global gene expression during
zinc deficiency in the HUT-78 cell line, Nutrition, 22: 1045-1056, 2006.
204. Bhuiyan,M.M., Li,Y., Banerjee,S., Ahmed,F., Wang,Z., Ali,S. and Sarkar,F.H. Down-regulation of androgen
receptor by 3,3'-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in both
hormone-sensitive LNCaP and insensitive C4-2B prostate cancer cells, Cancer Res., 66: 10064-10072, 2006.
205. Davis,D.A., Sarkar,S.H., Hussain,M., Li,Y. and Sarkar,F.H. Increased therapeutic potential of an experimental antimitotic inhibitor SB715992 by genistein in PC-3 human prostate cancer cell line, BMC.Cancer, 6: 22, 2006.
206. El-Rayes,B.F., Ali,S., Ali,I.F., Philip,P.A., Abbruzzese,J. and Sarkar,F.H. Potentiation of the effect of erlotinib by
genistein in pancreatic cancer: the role of Akt and nuclear factor-kappaB, Cancer Res., 66: 10553-10559, 2006.
207. Fryzek,J.P., Garabrant,D.H., Schenk,M., Kinnard,M., Greenson,J.K. and Sarkar,F.H. The association between
selected risk factors for pancreatic cancer and the expression of p53 and K-ras codon 12 mutations, Int.J
Gastrointest.Cancer, 37: 139-145, 2006.
208. li-Fehmi,R., Khalifeh,I., Bandyopadhyay,S., Lawrence,W.D., Silva,E., Liao,D., Sarkar,F.H. and Munkarah,A.R.
Patterns of loss of heterozygosity at 10q23.3 and microsatellite instability in endometriosis, atypical endometriosis,
and ovarian carcinoma arising in association with endometriosis, Int.J Gynecol.Pathol., 25: 223-229, 2006.
209. Li,Y., Kucuk,O., Hussain,M., Abrams,J., Cher,M.L. and Sarkar,F.H. Antitumor and antimetastatic activities of
docetaxel are enhanced by genistein through regulation of osteoprotegerin/receptor activator of nuclear factor-kappaB
(RANK)/RANK ligand/MMP-9 signaling in prostate cancer, Cancer Res., 66: 4816-4825, 2006.
210. Liao,D.J., Wang,Y., Wu,J., Adsay,N.V., Grignon,D., Khanani,F. and Sarkar,F.H. Characterization of pancreatic
lesions from MT-tgf alpha, Ela-myc and MT-tgf alpha/Ela-myc single and double transgenic mice, J Carcinog., 5: 19,
2006.
211. Mohammad,R.M., Banerjee,S., Li,Y., Aboukameel,A., Kucuk,O. and Sarkar,F.H. Cisplatin-induced antitumor
activity is potentiated by the soy isoflavone genistein in BxPC-3 pancreatic tumor xenografts, Cancer, 106: 12601268, 2006.
212. Prasad,A.S., Bao,B., Beck,F.W. and Sarkar,F.H. Correction of interleukin-2 gene expression by in vitro zinc addition
to mononuclear cells from zinc-deficient human subjects: a specific test for zinc deficiency in humans, Transl.Res.,
148: 325-333, 2006.
213. Raffoul,J.J., Wang,Y., Kucuk,O., Forman,J.D., Sarkar,F.H. and Hillman,G.G. Genistein inhibits radiation-induced
activation of NF-kappaB in prostate cancer cells promoting apoptosis and G2/M cell cycle arrest, BMC.Cancer, 6:
107, 2006.
214. Rahman,K.M., Sarkar,F.H., Banerjee,S., Wang,Z., Liao,D.J., Hong,X. and Sarkar,N.H. Therapeutic intervention of
experimental breast cancer bone metastasis by indole-3-carbinol in SCID-human mouse model, Mol.Cancer Ther., 5:
2747-2756, 2006.
215. Rahman,K.W., Li,Y., Wang,Z., Sarkar,S.H. and Sarkar,F.H. Gene expression profiling revealed survivin as a target
of 3,3'-diindolylmethane-induced cell growth inhibition and apoptosis in breast cancer cells, Cancer Res., 66: 49524960, 2006.
216. Reddy,G.P., Barrack,E.R., Dou,Q.P., Menon,M., Pelley,R., Sarkar,F.H. and Sheng,S. Regulatory processes affecting
androgen receptor expression, stability, and function: potential targets to treat hormone-refractory prostate cancer, J
Cell Biochem., 98: 1408-1423, 2006.
217. Reddy,S., Rishi,A.K., Xu,H., Levi,E., Sarkar,F.H. and Majumdar,A.P. Mechanisms of curcumin- and EGF-receptor
related protein (ERRP)-dependent growth inhibition of colon cancer cells, Nutr.Cancer, 55: 185-194, 2006.
218. Sahin,N., Sahin,K., Onderci,M., Sarkar,F.H., Doerge,D., Prasad,A. and Kucuk,O. Effects of dietary genistein on
nutrient use and mineral status in heat-stressed quails, Exp.Anim, 55: 75-82, 2006.
219. Sarkar,F.H. and Li,Y. Markers of apoptosis, Methods Mol.Med, 120: 147-160, 2006.
20
220. Sarkar,F.H. and Li,Y. Using chemopreventive agents to enhance the efficacy of cancer therapy, Cancer Res., 66:
3347-3350, 2006.
221. Sarkar,F.H., Adsule,S., Padhye,S., Kulkarni,S. and Li,Y. The role of genistein and synthetic derivatives of isoflavone
in cancer prevention and therapy, Mini.Rev.Med Chem., 6: 401-407, 2006.
222. Shen,X.J., li-Fehmi,R., Weng,C.R., Sarkar,F.H., Grignon,D. and Liao,D.J. Loss of heterozygosity and microsatellite
instability at the Xq28 and the A/G heterozygosity of the QM gene are associated with ovarian cancer, Cancer
Biol.Ther., 5: 523-528, 2006.
223. Wang,Y., Raffoul,J.J., Che,M., Doerge,D.R., Joiner,M.C., Kucuk,O., Sarkar,F.H. and Hillman,G.G. Prostate cancer
treatment is enhanced by genistein in vitro and in vivo in a syngeneic orthotopic tumor model, Radiat.Res., 166: 7380, 2006.
224. Wang,Z., Zhang,Y., Li,Y., Banerjee,S., Liao,J. and Sarkar,F.H. Down-regulation of Notch-1 contributes to cell
growth inhibition and apoptosis in pancreatic cancer cells, Mol.Cancer Ther., 5: 483-493, 2006.
225. Wang,Z., Banerjee,S., Li,Y., Rahman,K.M., Zhang,Y. and Sarkar,F.H. Down-regulation of notch-1 inhibits invasion
by inactivation of nuclear factor-kappaB, vascular endothelial growth factor, and matrix metalloproteinase-9 in
pancreatic cancer cells, Cancer Res., 66: 2778-2784, 2006.
226. Wang,Z., Zhang,Y., Banerjee,S., Li,Y. and Sarkar,F.H. Notch-1 down-regulation by curcumin is associated with the
inhibition of cell growth and the induction of apoptosis in pancreatic cancer cells, Cancer, 106: 2503-2513, 2006.
227. Wang,Z., Zhang,Y., Banerjee,S., Li,Y. and Sarkar,F.H. Inhibition of nuclear factor kappab activity by genistein is
mediated via Notch-1 signaling pathway in pancreatic cancer cells, Int.J Cancer, 118: 1930-1936, 2006.
228. Wang,Z., Sengupta,R., Banerjee,S., Li,Y., Zhang,Y., Rahman,K.M., Aboukameel,A., Mohammad,R., Majumdar,A.P.,
Abbruzzese,J.L. and Sarkar,F.H. Epidermal growth factor receptor-related protein inhibits cell growth and invasion in
pancreatic cancer, Cancer Res., 66: 7653-7660, 2006.
229. Zhang,Y., Wang,Z., Ahmed,F., Banerjee,S., Li,Y. and Sarkar,F.H. Down-regulation of Jagged-1 induces cell growth
inhibition and S phase arrest in prostate cancer cells, Int.J Cancer, 119: 2071-2077, 2006.
230. Zhang,Y., Banerjee,S., Wang,Z., Xu,H., Zhang,L., Mohammad,R., Aboukameel,A., Adsay,N.V., Che,M.,
Abbruzzese,J.L., Majumdar,A.P. and Sarkar,F.H. Antitumor activity of epidermal growth factor receptor-related
protein is mediated by inactivation of ErbB receptors and nuclear factor-kappaB in pancreatic cancer, Cancer Res.,
66: 1025-1032, 2006.
231. Ahmed,F., Adsule,S., Ali,A.S., Banerjee,S., Ali,S., Kulkarni,S., Padhye,S. and Sarkar,F.H. A novel copper complex
of 3-benzoyl-alpha methyl benzene acetic acid with antitumor activity mediated via cyclooxygenase pathway, Int.J
Cancer, 120: 734-742, 2007.
232. Banerjee,S., Zhang,Y., Wang,Z., Che,M., Chiao,P.J., Abbruzzese,J.L. and Sarkar,F.H. In vitro and in vivo molecular
evidence of genistein action in augmenting the efficacy of cisplatin in pancreatic cancer, Int.J Cancer, 120: 906-917,
2007.
233. Banerjee,S., Hussain,M., Wang,Z., Saliganan,A., Che,M., Bonfil,D., Cher,M. and Sarkar,F.H. In vitro and in vivo
molecular evidence for better therapeutic efficacy of ABT-627 and taxotere combination in prostate cancer, Cancer
Res., 67: 3818-3826, 2007.
234. Bao,B., Prasad,A.S., Beck,F.W. and Sarkar,F.H. Zinc up-regulates NF-kappaB activation via phosphorylation of
IkappaB in HUT-78 (Th0) cells, FEBS Lett., 581: 4507-4511, 2007.
235. Biliran,H., Jr., Banerjee,S., Thakur,A., Sarkar,F.H., Bollig,A., Ahmed,F., Wu,J., Sun,Y. and Liao,J.D. c-Myc-induced
chemosensitization is mediated by suppression of cyclin D1 expression and nuclear factor-kappa B activity in
pancreatic cancer cells, Clin.Cancer Res., 13: 2811-2821, 2007.
236. Chen,D., Cui,Q.C., Yang,H., Barrea,R.A., Sarkar,F.H., Sheng,S., Yan,B., Reddy,G.P. and Dou,Q.P. Clioquinol, a
therapeutic agent for Alzheimer's disease, has proteasome-inhibitory, androgen receptor-suppressing, apoptosisinducing, and antitumor activities in human prostate cancer cells and xenografts, Cancer Res., 67: 1636-1644, 2007.
237. Gadgeel,S.M., Ali,S., Philip,P.A., Ahmed,F., Wozniak,A. and Sarkar,F.H. Response to dual blockade of epidermal
growth factor receptor (EGFR) and cycloxygenase-2 in nonsmall cell lung cancer may be dependent on the EGFR
mutational status of the tumor, Cancer, 110: 2775-2784, 2007.
238. Hillman,G.G., Wang,Y., Che,M., Raffoul,J.J., Yudelev,M., Kucuk,O. and Sarkar,F.H. Progression of renal cell
carcinoma is inhibited by genistein and radiation in an orthotopic model, BMC.Cancer, 7: 4, 2007.
239. Kong,D., Li,Y., Wang,Z., Banerjee,S. and Sarkar,F.H. Inhibition of angiogenesis and invasion by 3,3'diindolylmethane is mediated by the nuclear factor-kappaB downstream target genes MMP-9 and uPA that regulated
bioavailability of vascular endothelial growth factor in prostate cancer, Cancer Res., 67: 3310-3319, 2007.
240. Li,X., Chen,D., Yin,S., Meng,Y., Yang,H., Landis-Piwowar,K.R., Li,Y., Sarkar,F.H., Reddy,G.P., Dou,Q.P. and
Sheng,S. Maspin augments proteasome inhibitor-induced apoptosis in prostate cancer cells, J Cell Physiol, 212: 298306, 2007.
241. Li,Y., Wang,Z., Kong,D., Murthy,S., Dou,Q.P., Sheng,S., Reddy,G.P. and Sarkar,F.H. Regulation of FOXO3a/betacatenin/GSK-3beta signaling by 3,3'-diindolylmethane contributes to inhibition of cell proliferation and induction of
apoptosis in prostate cancer cells, J Biol.Chem., 282: 21542-21550, 2007.
242. Liao,D.J., Thakur,A., Wu,J., Biliran,H. and Sarkar,F.H. Perspectives on c-Myc, Cyclin D1, and their interaction in
cancer formation, progression, and response to chemotherapy, Crit Rev.Oncog., 13: 93-158, 2007.
21
243. Liao,J.D., Adsay,N.V., Khannani,F., Grignon,D., Thakur,A. and Sarkar,F.H. Histological complexities of pancreatic
lesions from transgenic mouse models are consistent with biological and morphological heterogeneity of human
pancreatic cancer, Histol.Histopathol., 22: 661-676, 2007.
244. Raffoul,J.J., Banerjee,S., Singh-Gupta,V., Knoll,Z.E., Fite,A., Zhang,H., Abrams,J., Sarkar,F.H. and Hillman,G.G.
Down-regulation of apurinic/apyrimidinic endonuclease 1/redox factor-1 expression by soy isoflavones enhances
prostate cancer radiotherapy in vitro and in vivo, Cancer Res., 67: 2141-2149, 2007.
245. Raffoul,J.J., Banerjee,S., Che,M., Knoll,Z.E., Doerge,D.R., Abrams,J., Kucuk,O., Sarkar,F.H. and Hillman,G.G. Soy
isoflavones enhance radiotherapy in a metastatic prostate cancer model, Int.J Cancer, 120: 2491-2498, 2007.
246. Raffoul,J.J., Sarkar,F.H. and Hillman,G.G. Radiosensitization of prostate cancer by soy isoflavones, Curr.Cancer
Drug Targets., 7: 759-765, 2007.
247. Sarkar,F.H., Banerjee,S. and Li,Y. Pancreatic cancer: pathogenesis, prevention and treatment,
Toxicol.Appl.Pharmacol., 224: 326-336, 2007.
248. Sarkar,F.H. and Li,Y.W. Targeting multiple signal pathways by chemopreventive agents for cancer prevention and
therapy, Acta Pharmacol.Sin., 28: 1305-1315, 2007.
249. Sarkar,F.H., Adsule,S., Li,Y. and Padhye,S. Back to the future: COX-2 inhibitors for chemoprevention and cancer
therapy, Mini.Rev.Med Chem., 7: 599-608, 2007.
250. Schmelz,E.M., Xu,H., Sengupta,R., Du,J., Banerjee,S., Sarkar,F.H., Rishi,A.K. and Majumdar,A.P. Regression of
early and intermediate stages of colon cancer by targeting multiple members of the EGFR family with EGFR-related
protein, Cancer Res., 67: 5389-5396, 2007.
251. Thakur,A., Rahman,K.W., Wu,J., Bollig,A., Biliran,H., Lin,X., Nassar,H., Grignon,D.J., Sarkar,F.H. and Liao,J.D.
Aberrant expression of X-linked genes RbAp46, Rsk4, and Cldn2 in breast cancer, Mol.Cancer Res., 5: 171-181,
2007.
252. Vaishampayan,U., Hussain,M., Banerjee,M., Seren,S., Sarkar,F.H., Fontana,J., Forman,J.D., Cher,M.L., Powell,I.,
Pontes,J.E. and Kucuk,O. Lycopene and soy isoflavones in the treatment of prostate cancer, Nutr.Cancer, 59: 1-7,
2007.
253. Wang,Z., Kong,D., Banerjee,S., Li,Y., Adsay,N.V., Abbruzzese,J. and Sarkar,F.H. Down-regulation of plateletderived growth factor-D inhibits cell growth and angiogenesis through inactivation of Notch-1 and nuclear factorkappaB signaling, Cancer Res., 67: 11377-11385, 2007.
254. Wang,Z., Banerjee,S., Kong,D., Li,Y. and Sarkar,F.H. Down-regulation of Forkhead Box M1 transcription factor
leads to the inhibition of invasion and angiogenesis of pancreatic cancer cells, Cancer Res., 67: 8293-8300, 2007.
255. Ahmad,A., Banerjee,S., Wang,Z., Kong,D. and Sarkar,F.H. Plumbagin-induced apoptosis of human breast cancer
cells is mediated by inactivation of NF-kappaB and Bcl-2, J Cell Biochem., 105: 1461-1471, 2008.
256. Ali,S., Banerjee,S., Ahmad,A., El-Rayes,B.F., Philip,P.A. and Sarkar,F.H. Apoptosis-inducing effect of erlotinib is
potentiated by 3,3'-diindolylmethane in vitro and in vivo using an orthotopic model of pancreatic cancer, Mol.Cancer
Ther., 7: 1708-1719, 2008.
257. Azmi,A.S., Ahmad,A., Banerjee,S., Rangnekar,V.M., Mohammad,R.M. and Sarkar,F.H. Chemoprevention of
pancreatic cancer: characterization of Par-4 and its modulation by 3,3' diindolylmethane (DIM), Pharm.Res., 25:
2117-2124, 2008.
258. Azmi,A.S., Wang,Z., Burikhanov,R., Rangnekar,V.M., Wang,G., Chen,J., Wang,S., Sarkar,F.H. and
Mohammad,R.M. Critical role of prostate apoptosis response-4 in determining the sensitivity of pancreatic cancer cells
to small-molecule inhibitor-induced apoptosis, Mol.Cancer Ther., 7: 2884-2893, 2008.
259. Banerjee,S., Wang,Z., Mohammad,M., Sarkar,F.H. and Mohammad,R.M. Efficacy of selected natural products as
therapeutic agents against cancer, J Nat.Prod., 71: 492-496, 2008.
260. Banerjee,S., Li,Y., Wang,Z. and Sarkar,F.H. Multi-targeted therapy of cancer by genistein, Cancer Lett., 269: 226242, 2008.
261. Bao,B., Prasad,A.S., Beck,F.W., Snell,D., Suneja,A., Sarkar,F.H., Doshi,N., Fitzgerald,J.T. and Swerdlow,P. Zinc
supplementation decreases oxidative stress, incidence of infection, and generation of inflammatory cytokines in sickle
cell disease patients, Transl.Res., 152: 67-80, 2008.
262. Dass,K., Ahmad,A., Azmi,A.S., Sarkar,S.H. and Sarkar,F.H. Evolving role of uPA/uPAR system in human cancers,
Cancer Treat.Rev., 34: 122-136, 2008.
263. El-Rayes,B.F., Ali,S., Philip,P.A. and Sarkar,F.H. Protein kinase C: a target for therapy in pancreatic cancer,
Pancreas, 36: 346-352, 2008.
264. Friedman,J., Dunn,R.L., Wood,D., Vaishampayan,U., Wu,A., Bradley,D., Montie,J., Sarkar,F.H., Shah,R.B. and
Hussain,M. Neoadjuvant docetaxel and capecitabine in patients with high risk prostate cancer, J Urol., 179: 911-915,
2008.
265. Kong,D., Wang,Z., Sarkar,S.H., Li,Y., Banerjee,S., Saliganan,A., Kim,H.R., Cher,M.L. and Sarkar,F.H. Plateletderived growth factor-D overexpression contributes to epithelial-mesenchymal transition of PC3 prostate cancer cells,
Stem Cells, 26: 1425-1435, 2008.
266. Kong,D., Banerjee,S., Huang,W., Li,Y., Wang,Z., Kim,H.R. and Sarkar,F.H. Mammalian target of rapamycin
repression by 3,3'-diindolylmethane inhibits invasion and angiogenesis in platelet-derived growth factor-Doverexpressing PC3 cells, Cancer Res., 68: 1927-1934, 2008.
22
267. Li,Y., Wang,Z., Kong,D., Li,R., Sarkar,S.H. and Sarkar,F.H. Regulation of Akt/FOXO3a/GSK-3beta/AR signaling
network by isoflavone in prostate cancer cells, J Biol.Chem., 283: 27707-27716, 2008.
268. Milacic,V., Banerjee,S., Landis-Piwowar,K.R., Sarkar,F.H., Majumdar,A.P. and Dou,Q.P. Curcumin inhibits the
proteasome activity in human colon cancer cells in vitro and in vivo, Cancer Res., 68: 7283-7292, 2008.
269. Padhye,S., Banerjee,S., Ahmad,A., Mohammad,R. and Sarkar,F.H. From here to eternity - the secret of Pharaohs:
Therapeutic potential of black cumin seeds and beyond, Cancer Ther., 6: 495-510, 2008.
270. Pandya,A.K., Serhatkulu,G.K., Cao,A., Kast,R.E., Dai,H., Rabah,R., Poulik,J., Banerjee,S., Naik,R., Adsay,V.,
Auner,G.W., Klein,M.D., Thakur,J.S. and Sarkar,F.H. Evaluation of pancreatic cancer with Raman spectroscopy in a
mouse model, Pancreas, 36: e1-e8, 2008.
271. Sarkar,F.H. and Li,Y. NF-kappaB: a potential target for cancer chemoprevention and therapy, Front Biosci., 13:
2950-2959, 2008.
272. Sarkar,F.H., Li,Y., Wang,Z. and Kong,D. NF-kappaB signaling pathway and its therapeutic implications in human
diseases, Int.Rev.Immunol., 27: 293-319, 2008.
273. Solomon,L.A., Ali,S., Banerjee,S., Munkarah,A.R., Morris,R.T. and Sarkar,F.H. Sensitization of ovarian cancer cells
to cisplatin by genistein: the role of NF-kappaB, J Ovarian.Res., 1: 9, 2008.
274. Thakur,A., Sun,Y., Bollig,A., Wu,J., Biliran,H., Banerjee,S., Sarkar,F.H. and Liao,D.J. Anti-invasive and
antimetastatic activities of ribosomal protein S6 kinase 4 in breast cancer cells, Clin.Cancer Res., 14: 4427-4436,
2008.
275. Vandenboom Ii,T.G., Li,Y., Philip,P.A. and Sarkar,F.H. MicroRNA and Cancer: Tiny Molecules with Major
Implications, Curr.Genomics, 9: 97-109, 2008.
276. Wang,Z., Yu,B.W., Rahman,K.M., Ahmad,F. and Sarkar,F.H. Induction of growth arrest and apoptosis in human
breast cancer cells by 3,3-diindolylmethane is associated with induction and nuclear localization of p27kip,
Mol.Cancer Ther., 7: 341-349, 2008.
277. Wang,Z., Song,W., Aboukameel,A., Mohammad,M., Wang,G., Banerjee,S., Kong,D., Wang,S., Sarkar,F.H. and
Mohammad,R.M. TW-37, a small-molecule inhibitor of Bcl-2, inhibits cell growth and invasion in pancreatic cancer,
Int.J Cancer, 123: 958-966, 2008.
278. Wang,Z., Li,Y., Banerjee,S. and Sarkar,F.H. Exploitation of the Notch signaling pathway as a novel target for cancer
therapy, Anticancer Res., 28: 3621-3630, 2008.
279. Wang,Z., Desmoulin,S., Banerjee,S., Kong,D., Li,Y., Deraniyagala,R.L., Abbruzzese,J. and Sarkar,F.H. Synergistic
effects of multiple natural products in pancreatic cancer cells, Life Sci., 83: 293-300, 2008.
280. Yang,H., Murthy,S., Sarkar,F.H., Sheng,S., Reddy,G.P. and Dou,Q.P. Calpain-mediated androgen receptor
breakdown in apoptotic prostate cancer cells, J Cell Physiol, 217: 569-576, 2008.
281. Ahmad,A., Banerjee,S., Wang,Z., Kong,D., Majumdar,A.P. and Sarkar,F.H. Aging and inflammation: etiological
culprits of cancer, Curr.Aging Sci., 2: 174-186, 2009.
282. Ahmad,A., Kong,D., Wang,Z., Sarkar,S.H., Banerjee,S. and Sarkar,F.H. Down-regulation of uPA and uPAR by 3,3'diindolylmethane contributes to the inhibition of cell growth and migration of breast cancer cells, J Cell Biochem.,
108: 916-925, 2009.
283. Ahmad,A., Kong,D., Sarkar,S.H., Wang,Z., Banerjee,S. and Sarkar,F.H. Inactivation of uPA and its receptor uPAR
by 3,3'-diindolylmethane (DIM) leads to the inhibition of prostate cancer cell growth and migration, J Cell Biochem.,
107: 516-527, 2009.
284. Ali,A.S., Ali,S., El-Rayes,B.F., Philip,P.A. and Sarkar,F.H. Exploitation of protein kinase C: a useful target for
cancer therapy, Cancer Treat.Rev., 35: 1-8, 2009.
285. Ali,S., Al-Sukhun,S., El-Rayes,B.F., Sarkar,F.H., Heilbrun,L.K. and Philip,P.A. Protein kinases C isozymes are
differentially expressed in human breast carcinomas, Life Sci., 84: 766-771, 2009.
286. Ali,S., Varghese,L., Pereira,L., Tulunay-Ugur,O.E., Kucuk,O., Carey,T.E., Wolf,G.T. and Sarkar,F.H. Sensitization
of squamous cell carcinoma to cisplatin induced killing by natural agents, Cancer Lett., 278: 201-209, 2009.
287. Banerjee,S., Wang,Z., Kong,D. and Sarkar,F.H. 3,3'-Diindolylmethane enhances chemosensitivity of multiple
chemotherapeutic agents in pancreatic cancer, Cancer Res., 69: 5592-5600, 2009.
288. Banerjee,S., Kaseb,A.O., Wang,Z., Kong,D., Mohammad,M., Padhye,S., Sarkar,F.H. and Mohammad,R.M.
Antitumor activity of gemcitabine and oxaliplatin is augmented by thymoquinone in pancreatic cancer, Cancer Res.,
69: 5575-5583, 2009.
289. Chinnakannu,K., Chen,D., Li,Y., Wang,Z., Dou,Q.P., Reddy,G.P. and Sarkar,F.H. Cell cycle-dependent effects of
3,3'-diindolylmethane on proliferation and apoptosis of prostate cancer cells, J Cell Physiol, 219: 94-99, 2009.
290. Fan,S., Meng,Q., Saha,T., Sarkar,F.H. and Rosen,E.M. Low concentrations of diindolylmethane, a metabolite of
indole-3-carbinol, protect against oxidative stress in a BRCA1-dependent manner, Cancer Res., 69: 6083-6091, 2009.
291. Gadgeel,S.M., Ali,S., Philip,P.A., Wozniak,A. and Sarkar,F.H. Genistein enhances the effect of epidermal growth
factor receptor tyrosine kinase inhibitors and inhibits nuclear factor kappa B in nonsmall cell lung cancer cell lines,
Cancer, 115: 2165-2176, 2009.
292. Giri,B., Gomes,A., Sengupta,R., Banerjee,S., Nautiyal,J., Sarkar,F.H. and Majumdar,A.P. Curcumin synergizes the
growth inhibitory properties of Indian toad (Bufo melanostictus Schneider) skin-derived factor (BM-ANF1) in HCT116 colon cancer cells, Anticancer Res., 29: 395-401, 2009.
23
293. Jaiswal,A.S., Banerjee,S., Panda,H., Bulkin,C.D., Izumi,T., Sarkar,F.H., Ostrov,D.A. and Narayan,S. A novel
inhibitor of DNA polymerase beta enhances the ability of temozolomide to impair the growth of colon cancer cells,
Mol.Cancer Res., 7: 1973-1983, 2009.
294. Kong,D., Li,Y., Wang,Z., Banerjee,S., Ahmad,A., Kim,H.R. and Sarkar,F.H. miR-200 regulates PDGF-D-mediated
epithelial-mesenchymal transition, adhesion, and invasion of prostate cancer cells, Stem Cells, 27: 1712-1721, 2009.
295. Li,Y., Vandenboom,T.G., Kong,D., Wang,Z., Ali,S., Philip,P.A. and Sarkar,F.H. Up-regulation of miR-200 and let-7
by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic
cancer cells, Cancer Res., 69: 6704-6712, 2009.
296. Majumdar,A.P., Banerjee,S., Nautiyal,J., Patel,B.B., Patel,V., Du,J., Yu,Y., Elliott,A.A., Levi,E. and Sarkar,F.H.
Curcumin synergizes with resveratrol to inhibit colon cancer, Nutr.Cancer, 61: 544-553, 2009.
297. Padhye,S., Banerjee,S., Chavan,D., Pandye,S., Swamy,K.V., Ali,S., Li,J., Dou,Q.P. and Sarkar,F.H. Fluorocurcumins
as cyclooxygenase-2 inhibitor: molecular docking, pharmacokinetics and tissue distribution in mice, Pharm.Res., 26:
2438-2445, 2009.
298. Padhye,S., Ahmad,A., Oswal,N. and Sarkar,F.H. Emerging role of Garcinol, the antioxidant chalcone from Garcinia
indica Choisy and its synthetic analogs, J Hematol.Oncol., 2: 38, 2009.
299. Padhye,S., Yang,H., Jamadar,A., Cui,Q.C., Chavan,D., Dominiak,K., McKinney,J., Banerjee,S., Dou,Q.P. and
Sarkar,F.H. New difluoro Knoevenagel condensates of curcumin, their Schiff bases and copper complexes as
proteasome inhibitors and apoptosis inducers in cancer cells, Pharm.Res., 26: 1874-1880, 2009.
300. Patel,B.B., Yu,Y., Du,J., Rishi,A.K., Sarkar,F.H., Tarca,A.L., Wali,A. and Majumdar,A.P. Schlafen 3, a novel gene,
regulates colonic mucosal growth during aging, Am.J Physiol Gastrointest.Liver Physiol, 296: G955-G962, 2009.
301. Sarkar,F.H. and Li,Y. Harnessing the fruits of nature for the development of multi-targeted cancer therapeutics,
Cancer Treat.Rev., 35: 597-607, 2009.
302. Sarkar,F.H., Li,Y., Wang,Z. and Kong,D. Pancreatic cancer stem cells and EMT in drug resistance and metastasis,
Minerva Chir, 64: 489-500, 2009.
303. Sarkar,F.H., Li,Y., Wang,Z. and Kong,D. Cellular signaling perturbation by natural products, Cell Signal., 21: 15411547, 2009.
304. Singh-Gupta,V., Zhang,H., Banerjee,S., Kong,D., Raffoul,J.J., Sarkar,F.H. and Hillman,G.G. Radiation-induced HIF1alpha cell survival pathway is inhibited by soy isoflavones in prostate cancer cells, Int.J Cancer, 124: 1675-1684,
2009.
305. Wang,Z., Kong,D., Li,Y. and Sarkar,F.H. PDGF-D signaling: a novel target in cancer therapy, Curr.Drug Targets.,
10: 38-41, 2009.
306. Wang,Z., Azmi,A.S., Ahmad,A., Banerjee,S., Wang,S., Sarkar,F.H. and Mohammad,R.M. TW-37, a small-molecule
inhibitor of Bcl-2, inhibits cell growth and induces apoptosis in pancreatic cancer: involvement of Notch-1 signaling
pathway, Cancer Res., 69: 2757-2765, 2009.
307. Wang,Z., Li,Y., Kong,D., Banerjee,S., Ahmad,A., Azmi,A.S., Ali,S., Abbruzzese,J.L., Gallick,G.E. and Sarkar,F.H.
Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked
with activation of the notch signaling pathway, Cancer Res., 69: 2400-2407, 2009.
308. Wang,Z., Li,Y., Banerjee,S. and Sarkar,F.H. Emerging role of Notch in stem cells and cancer, Cancer Lett., 279: 812, 2009.
309. Yu,Y., Kanwar,S.S., Patel,B.B., Nautiyal,J., Sarkar,F.H. and Majumdar,A.P. Elimination of Colon Cancer Stem-Like
Cells by the Combination of Curcumin and FOLFOX, Transl.Oncol., 2: 321-328, 2009.
310. Adsule,S., Banerjee,S., Ahmed,F., Padhye,S. and Sarkar,F.H. Hybrid anticancer agents: isothiocyanate-progesterone
conjugates as chemotherapeutic agents and insights into their cytotoxicities, Bioorg.Med Chem.Lett., 20: 1247-1251,
2010.
311. Ahmad,A., Wang,Z., Ali,R., Maitah,M.Y., Kong,D., Banerjee,S., Padhye,S. and Sarkar,F.H. Apoptosis-inducing
effect of garcinol is mediated by NF-kappaB signaling in breast cancer cells, J Cell Biochem., 109: 1134-1141, 2010.
312. Ahmad,A., Wang,Z., Kong,D., Ali,R., Ali,S., Banerjee,S. and Sarkar,F.H. Platelet-derived growth factor-D
contributes to aggressiveness of breast cancer cells by up-regulating Notch and NF-kappaB signaling pathways,
Breast Cancer Res.Treat., 2010.
313. Ahmad,A., Wang,Z., Kong,D., Ali,S., Li,Y., Banerjee,S., Ali,R. and Sarkar,F.H. FoxM1 down-regulation leads to
inhibition of proliferation, migration and invasion of breast cancer cells through the modulation of extra-cellular
matrix degrading factors, Breast Cancer Res.Treat., 122: 337-346, 2010.
314. Ali,S., Banerjee,S., Schaffert,J.M., El-Rayes,B.F., Philip,P.A. and Sarkar,F.H. Concurrent inhibition of NF-kappaB,
cyclooxygenase-2, and epidermal growth factor receptor leads to greater anti-tumor activity in pancreatic cancer, J
Cell Biochem., 110: 171-181, 2010.
315. Ali,S., Ahmad,A., Banerjee,S., Padhye,S., Dominiak,K., Schaffert,J.M., Wang,Z., Philip,P.A. and Sarkar,F.H.
Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21
expression by curcumin or its analogue CDF, Cancer Res., 70: 3606-3617, 2010.
316. Azmi,A.S., Philip,P.A., Zafar,S.F., Sarkar,F.H. and Mohammad,R.M. PAR-4 as a possible new target for pancreatic
cancer therapy, Expert.Opin.Ther.Targets., 14: 611-620, 2010.
24
317. Azmi,A.S., Aboukameel,A., Banerjee,S., Wang,Z., Mohammad,M., Wu,J., Wang,S., Yang,D., Philip,P.A.,
Sarkar,F.H. and Mohammad,R.M. MDM2 inhibitor MI-319 in combination with cisplatin is an effective treatment
for pancreatic cancer independent of p53 function, Eur.J Cancer, 46: 1122-1131, 2010.
318. Azmi,A.S., Philip,P.A., Almhanna,K., Beck,F.W., Sarkar,F.H. and Mohammad,R.M. MDM2 inhibitors for pancreatic
cancer therapy, Mini.Rev.Med Chem., 10: 518-526, 2010.
319. Azmi,A.S., Philip,P.A., Aboukameel,A., Wang,Z., Banerjee,S., Zafar,S.F., Goustin,A.S., Almhanna,K., Yang,D.,
Sarkar,F.H. and Mohammad,R.M. Reactivation of p53 by novel MDM2 inhibitors: implications for pancreatic cancer
therapy, Curr.Cancer Drug Targets., 10: 319-331, 2010.
320. Banerjee,S., Choi,M., Aboukameel,A., Wang,Z., Mohammad,M., Chen,J., Yang,D., Sarkar,F.H. and
Mohammad,R.M. Preclinical studies of apogossypolone, a novel pan inhibitor of bcl-2 and mcl-1, synergistically
potentiates cytotoxic effect of gemcitabine in pancreatic cancer cells, Pancreas, 39: 323-331, 2010.
321. Banerjee,S., Azmi,A.S., Padhye,S., Singh,M.W., Baruah,J.B., Philip,P.A., Sarkar,F.H. and Mohammad,R.M.
Structure-activity studies on therapeutic potential of Thymoquinone analogs in pancreatic cancer, Pharm.Res., 27:
1146-1158, 2010.
322. Dominiak,K., McKinney,J., Heilbrun,L.K. and Sarkar,F.H. Critical need for clinical trials: an example of a pilot
human intervention trial of a mixture of natural agents protecting lymphocytes against TNF-alpha induced activation
of NF-kappaB, Pharm.Res., 27: 1061-1065, 2010.
323. El-Rayes,B.F., Philip,P.A., Sarkar,F.H., Shields,A.F., Ferris,A.M., Hess,K., Kaseb,A.O., Javle,M.M.,
Varadhachary,G.R., Wolff,R.A. and Abbruzzese,J.L. A phase II study of isoflavones, erlotinib, and gemcitabine in
advanced pancreatic cancer, Invest New Drugs, 2010.
324. Kong,L., Deng,Z., Zhao,Y., Wang,Y., Sarkar,F.H. and Zhang,Y. Down-regulation of phospho-non-receptor Src
tyrosine kinases contributes to growth inhibition of cervical cancer cells, Med Oncol., 2010.
325. Li,Y., Kong,D., Wang,Z. and Sarkar,F.H. Regulation of microRNAs by natural agents: an emerging field in
chemoprevention and chemotherapy research, Pharm.Res., 27: 1027-1041, 2010.
326. Li,Y., Vandenboom,T.G., Wang,Z., Kong,D., Ali,S., Philip,P.A. and Sarkar,F.H. miR-146a suppresses invasion of
pancreatic cancer cells, Cancer Res., 70: 1486-1495, 2010.
327. Nautiyal,J., Yu,Y., Aboukameel,A., Kanwar,S.S., Das,J.K., Du,J., Patel,B.B., Sarkar,F.H., Rishi,A.K.,
Mohammad,R.M. and Majumdar,A.P. ErbB-inhibitory protein: a modified ectodomain of epidermal growth factor
receptor synergizes with dasatinib to inhibit growth of breast cancer cells, Mol.Cancer Ther., 9: 1503-1514, 2010.
328. Nautiyal,J., Banerjee,S., Kanwar,S.S., Yu,Y., Patel,B.B., Sarkar,F.H. and Majumdar,A.P. Curcumin enhances
dasatinib-induced inhibition of growth and transformation of colon cancer cells, Int.J Cancer, 2010.
329. Padhye,S., Chavan,D., Pandey,S., Deshpande,J., Swamy,K.V. and Sarkar,F.H. Perspectives on chemopreventive and
therapeutic potential of curcumin analogs in medicinal chemistry, Mini.Rev.Med Chem., 10: 372-387, 2010.
330. Sarkar,F.H. (Part I) Recent trends in anti-cancer drug discovery, Mini.Rev.Med Chem., 10: 357-358, 2010.
331. Sarkar,F.H., Li,Y., Wang,Z., Kong,D. and Ali,S. Implication of microRNAs in drug resistance for designing novel
cancer therapy, Drug Resist.Updat., 13: 57-66, 2010.
332. Sarkar,F.H., Li,Y., Wang,Z. and Padhye,S. Lesson Learned from Nature for the Development of Novel Anti-Cancer
Agents: Implication of Isoflavone, Curcumin, and their Synthetic Analogs, Curr.Pharm.Des, 2010.
333. Sarkar,F.H. Current trends in the chemoprevention of cancer, Pharm.Res., 27: 945-949, 2010.
334. Singh-Gupta,V., Zhang,H., Yunker,C.K., Ahmad,Z., Zwier,D., Sarkar,F.H. and Hillman,G.G. Daidzein effect on
hormone refractory prostate cancer in vitro and in vivo compared to genistein and soy extract: potentiation of
radiotherapy, Pharm.Res., 27: 1115-1127, 2010.
335. Wang,Z., Li,Y., Banerjee,S., Kong,D., Ahmad,A., Nogueira,V., Hay,N. and Sarkar,F.H. Down-regulation of Notch-1
and Jagged-1 inhibits prostate cancer cell growth, migration and invasion, and induces apoptosis via inactivation of
Akt, mTOR, and NF-kappaB signaling pathways, J Cell Biochem., 109: 726-736, 2010.
336. Wang,Z., Li,Y., Kong,D. and Sarkar,F.H. The role of Notch signaling pathway in epithelial-mesenchymal transition
(EMT) during development and tumor aggressiveness, Curr.Drug Targets., 11: 745-751, 2010.
337. Wang,Z., Ahmad,A., Banerjee,S., Azmi,A., Kong,D., Li,Y. and Sarkar,F.H. FoxM1 is a novel target of a natural
agent in pancreatic cancer, Pharm.Res., 27: 1159-1168, 2010.
338. Wang,Z., Ahmad,A., Li,Y., Banerjee,S., Kong,D. and Sarkar,F.H. Forkhead box M1 transcription factor: a novel
target for cancer therapy, Cancer Treat.Rev., 36: 151-156, 2010.
339. Wang,Z., Ahmad,A., Li,Y., Kong,D., Azmi,A.S., Banerjee,S. and Sarkar,F.H. Emerging roles of PDGF-D signaling
pathway in tumor development and progression, Biochim.Biophys.Acta, 1806: 122-130, 2010.
340. Wang,Z., Li,Y. and Sarkar,F.H. Signaling mechanism(s) of reactive oxygen species in Epithelial-Mesenchymal
Transition reminiscent of cancer stem cells in tumor progression, Curr.Stem Cell Res.Ther., 5: 74-80, 2010.
341. Wang,Z., Li,Y. and Sarkar,F.H. Notch Signaling Proteins: Legitimate Targets for Cancer Therapy, Curr.Protein
Pept.Sci., 2010.
342. Wang,Z., Li,Y., Kong,D., Ahmad,A., Banerjee,S. and Sarkar,F.H. Cross-talk between miRNA and Notch signaling
pathways in tumor development and progression, Cancer Lett., 292: 141-148, 2010.
25
Books and Chapters:
1. Raziuddin, A., Sarkar, F. H., and Gupta, S. L. Interferon Receptors on Human Cells. Proceedings of the 1983
Meeting of "Biology of the "Interferon System" (E. DeMaeyer and H. Schellekens, eds.). Elsevier Science Publishers
B. V., pp.175-181, 1983.
2. Gupta, S. L., Raziuddin, A. and Sarkar, F. H. Receptors for Human Interferons. Proceedings of the 3rd International
T. N. O. Meeting (1984) on " The Biology of Interferon System". (H. Kirchner and H. Schllekens, eds.) Elsevier
Science Publishers, B. V. pp 637-644, 1985.
3. Sarkar, F. H., and Gupta, S. L. Radiolabeling of Human Leukocyte and Immune Interferons with 125I and
Lactoperoxidase. Methods in Enzymology Vol. 119, Interferon part C, volume editor Sidney Pestka, Academic Press,
Inc., pp 263-267, 1985.
4. Roy, A. K., Sarkar, F. H., Nag, A. C. and Mancini, M. A. Role of Cytodifferentiation and Cell-Cell Communication
in the Androgen Dependent Expression of alpha-2u Globulin Gene in Rat Liver. Cellular Endocrinology: Hormonal
Control of Embryonic and Cellular Differentiation. Vol. 1. (G. Serero, J. Hayashi and G. Sato, eds). Alan R. Liss, Inc.
401-415, 1986.
5. Roy, A. K., Sarkar, F. H., Murty, C. V. R., Majumdar, D. and Demyan, W. F., Intra and Inter Cellular Aspects of the
Hormonal Regulation of alpha-2u Globulin Gene Expression. In: Gene Regulation by Steroid Hormones III, A. K.
Roy and J. H. Clark (eds.), Springer Verlag, NY, Chapter 14, pp. 234-246, 1986.
6. Garg, B. D., Olson, M. J., Sarkar, F. H., and Roy, A. K. Renal Hyalin Droplet and Alpha-2u Globulin Accumulation
After Gasoline Administration to Male Rats. Research Publication of General Motors Research Laboratories, GMR
5514, 1-13, 1986.
7. Olson, M. J., Garg, B. D., Sarkar, F. H., and Roy, A. K. Hyaline Droplet and Alpha-2u Globulin Accumulation in
the Kidneys of Male Rats After Gasoline Administration. Research Publication of General Motors Research
Laboratories. GMR 5597, 1-13, 1986.
8. Sarkar, F. H., Squires, J. J. and Gupta, S. L. On the Mechanism of Anticellular Activity of Human Interferon (s).
Proceedings of The Miami Biotechnology Winter Symposia, Advances in Gene Technology: Protein Engineering and
Production. ( Brew, K; Ahmad, F; Bialy, H. et al.) Vol. 8: 197, 1988.
9. Sarkar, F.H., Squires, J.: Modulation of P53 gene expression by Interferon treatment. Proceedings of The 1991
Miami Biotechnology Winter Symposium, Advances in Gene Technology: The Molecular Biology of Human Genetic
Disease (Ahmad, F; Bialy, H; Black, S. et al, eds). Vol. 1: 82, 1991.
10. Crissman, J. D; Cerra, R; and Sarkar, F. H. The Morphology of Cancer Cell Arrest and Extravasation. In:
Microcirculation in cancer metastasis, CRC press, Boca Raton, Florida Chapter 13, 205-215,1991.
11. Visscher, D.W; Sarkar, F.H; and Crissman, J.D. Clinical Significance of pathologic, cytometric, and molecular
parameters in carcinoma of the breast. Advances in Pathology and Laboratory Medicine. 5: 123-161, 1992.
12. Sarkar, F. H; Miles, B. J; Plieth, D. A; and Crissman, J. D. Detection of human papillomavirus in squamous
neoplasm of the penis. Urology/Nephrology Digest #1, Page 19-20, 1992.
13. Sarkar, F.H; Ball, D.E. TA Cloning: Direct PCR cloning. The Digest, Published by Invitrogen Corporation. Vol 5,
Issue 4, 1992.
14. Visscher DW, Sarkar FH, Fridman R, Crissman JD. Biological and clinical significance of "invasion-associated"
proteases in epithelial neoplasia. Advances in Path and Lab Med 7: 533-564, 1994.
15. Visscher DW, Sarkar FH, Crissman JD. Molecular Genetic Analysis in the Pathologic Evaluation of Neoplasia:
Theory and Practice. Focuss issue on Molecular Diagnosis for the Journal of Clinical Laboratory Analysis. 11: 10-16,
1997.
16. Sarkar FH, Li Y-W, Crissman JD. A method for PCR sequencing of the p53 gene from a single 10µm frozen or
paraffin-embedded tissue section. Page 291-295, 1997. The PCR Technique: DNA Sequencing II. Biotechniques
Book, Eaton Publishing, MA.
17. Sarkar FH, Joshi US, Adsay V, Mohammad RM. Experimental models of human pancreatic tumors for clinical
therapy. In: Pancreatic Cancer: Advances in molecular pathology, diagnosis and clinical management. Edited By:
Fazlul H. Sarkar and Michael C. Dugan, BioTechniques Books, Eaton Publishing, PP 165-188, 1998.
18. Dugan MC, Sarkar FH. Molecular markers of in situ neoplasia in the pancreas. In: Pancreatic Cancer: Advances in
molecular pathology, diagnosis and clinical management. Edited By: Fazlul H. Sarkar and Michael C. Dugan,
BioTechniques Books, Eaton Publishing, PP 83-96, 1998.
19. Sarkar FH, Li Y. Markers of Apoptosis. In: Methods in Medicine, Vol. 120: Breast Cancer Research Protocols.
Edited by S.A. Brooks and A.L. Harris. Humana Press, Inc, Totowa, NJ. PP 147-160, 2005.
20. Sarkar FH, Li Y. Plant derived antioxidants. In: Oxidative Stress, Disease and Caner. Edited by Keshav K. Singh,
et al. 2005.
21. Sarkar FH, Li Y. Isoflavones, Soybean Phytoestrogens, and Cancer. In: Nutrition and Cancer Prevention. Edited
by: Atif B. Awad and Peter G. Bradford. Taylor & Francis Group, Boca Raton. PP 295-312, 2006.
26
22. Sarkar FH, Li Y. Turning off the Master Switch-NF-κB: A Novel Strategy for Pancreatic Cancer Therapy. In:
Pancreatic Cacner. Edited by: A.M. Lowry et al. Springer Science + Business Media, LLC. 2008
Book Editing:
Advances in molecular pathology, diagnosis and clinical management. Edited By: Fazlul H. Sarkar and Michael C.
Dugan, BioTechniques Books, Eaton Publishing, 1998.
Abstracts:
1. Platsoucas, C. D., Telerman, A., Squires, J. J., Sarkar, F. H., and Gupta, S. L.Chemical Crosslinking of the T3
Antigen with other Cell Surface Molecules. The 38th Annual Symposium on Fundamental Cancer Research. M. D.
Anderson Hospital and Tumor Institute, Houston, Texas, 1985
2. Telerman, A., Sarkar, F. H., Kunnicka, J., Gupta, S. L., and Platsoucas, C. D., Fed. Proc. Fed. Am. Soc. Exp. Biol.
44, 791 (abstr.), 1985.
3. Roy, A. K., Mamcini, M. A., and Sarkar, F. H. Cellular Specialization in the Hepatic Synthesis of alpha-2u Globulin.
1st International Congress in Cellular Endocrinology, Lake Placid, N. Y., 1985
4. Sarkar, F. H., and Roy, A. K. Molecular transition of the Cytoplasmic Androgen Binding Protein of Rat Liver and Its
Role in alpha-2u Globulin Synthesis as Determined by Photoaffinity Labeling and Cell Sorting. 86th Annual Meeting
of the Endocrine Society, Anaheim, CA, June 24-27 (presented), 1986.
5. Chatterjee, B., Ali, M., Sarkar, F. H. and Roy, A. K. Purification and Characteriazation of a Senescent Marker
Protein (SMP-2) of Rat Liver and Production of Its Monoconal Antibody. Fed. Proc. 45 (6), 1986. Abstract No. 560.
Washington, D. C., June 8-12, 1986.
6. Sarkar, F. H., Murty, C. V. R., Chatterjee, B. and Roy, A. K. Cellular Interaction of alpha-2u Globulin in the Rat
Liver. VII International Congress on Hormonal Steroids. Madrid, Spain, September 21-26. (presented), 1986.
7. Garg, B. D., Olson, M. J., Sarkar, F. H. and Roy, A. K. Renal Hyalin Droplet and alpha-2u Globulin Accumulation
After Gasoline Administration to Male Rats. Pharmacologist, 28: 210, 1986.
8. Olson, M. J., Garg, B. D., Sarkar, F. H., and Roy, A. K. Hyalin Droplet and alpha-2u Globulin Accumulation in the
Kidneys of Male Rats After Gasoline Administration. 16th Annual Conference of Toxicology, Dayton, Ohio, p.78,
1987.
9. Sarkar, F. H., Squires, J. J. and Gupta, S. L. On the Mechanism of Anticellular Activity of Human Interferon (s).
Proceedings of The Miami Biotechnology Winter Symposia, Advances in Gene Technology: Protein Engineering and
Production. ( Brew, K; Ahmad, F; Bialy, H. et al.) Vol. 8: 197, 1988.
10. Sarkar, F.H., Pleith, D.A., Wykes, S.M., Johnson, T.L., Crissman, J.D. Rapid detection of human papilloma virus
DNA sequences by polymerase chain reaction. Human Genome I. San Dieago, CA, Oct 2-4. (Presented), 1989.
11. Johnson, T.L., Sarkar, F.H., Pleith, D.A., and Crissman, J.D. HPV detection by PCR in verrucous lesions of the
upper aerodigestive tract. Annual meeting of the United States and Canadian academy of Pathology. Boston, March 39. 1989.
12. Gottlieb, C.A., Sarkar, F.H., Poffenberger, R., and Crissman, J.D. Squamous cell carcinoma of the bladder: DNA
quantitation and evaluation for HPV. Annual meeting of the United States and Canadian academy of Pathology.
Boston, March 3-9, 1989.
13. Sarkar, F.H., Zarbo, R.J., and Crissman, J.D. Sinonasal inverted papillomas: Human papilloma virus typing by
polymerase chain reaction. Annual meeting of the United States and Canadian academy of Pathology. Boston, March
3-9. (Presented), 1990.
14. Sarkar, F.H. Prostaglandin synthase mediated activation of Benzidine and 2-aminofluorene: Mutagenic to mouse
lymphoma cells. Annual meeting of the American Association for Cancer Research. Washington ,D.C, May 23-26.
(Presented), 1990.
15. Johnson, T.L., Sarkar, F.H., Plieth, D.A., Porter, D.A. and Williams,R.J. Detection of HPV 16/18 in CIN II using
PCR methodology. Fourth International Conference on Human Papilloma Viruses and Genital Carcinoma. Chicago,
September 17-19, 1990.
16. Sarkar, F.H. Johnson, T.L., Plieth, D.A. abd Kim, W.S. Detection of HPV 16/18 in cervical adenocarcinoma using
PCR methodology. Fourth International Conference on Human Papilloma Viruses and Genital Carcinoma. Chicago,
September 17-19. ( Presented), 1990.
17. Sarkar, F.H., Miles, B., Crissman, J.D.: Detection of human papilloma virus of in situ and invasive squamous
carcinoma of the penis. Annual meeting of the United States and Canadian Academy of pathology. Chicago, 1991.
18. Visscher, D.W., Wykes, S., Sarkar, F.H., Crissman, J.D.: Correlation of DNA ploidy with c-erbB2 expression in preinvasive and invasive breast tumors. Annual meeting of the United States and Canadian Academy of pathology.
Chicago, 1991.
27
19. Kintanar, E.B., Sarkar, F.H., Plieth, D.A., Crissman, J.D., Greenawald, K.A., Zarbo, R.J.: Cylindrical cell sinonasal
papillomas: HPV typing by polymerase chain reaction.Annual meeting of the United States and Canadian Academy of
pathology. Chicago, 1991.
20. Sarkar, F.H., Squires, J.: Modulation of P53 gene expression by Interferon treatment. Proceedings of The 1991
Miami Biotechnology Winter Symposium, Advances in Gene Technology: The Molecular Biology of Human Genetic
Disease (Ahmad, F; Bialy, H;
Black, S. et al, eds). Vol. 1: 82, 1991.
21. Sarkar, F.H., Ball, D.E., Li, Y-W., Visscher, D.W., Crissman, J.D.: Analysis of Her-2/neu gene expression in a single
10 µm frozen tumor tissue specimen of the human breast. Breast Cancer Research and Treatment 19 (2): 203, 1991.
22. Visscher, D.W., Wykes, S., Sarkar, F.H., Crissman, J.D.: Correlation of DNA analysis and c-erbB2 expression in
breast neoplasia. Cytometry 5: 95, 1991. XV Congress of the International Society for Analytical Cytology, The
Grieghallen, Bergen, Norway, August 1991.
23. Sarkar, F.H; Sakr, W.A; Drozdowicz, S.M; Sreepathi, P; and Crissman, J.D.: Measurment of cellular proliferation in
human prostate by AgNOR, PCNA and SPF. Modern Pathology 5(1): 59A, 1992.
24. Sakr, W.A; Li, Y-W; Sreepathi, P; Visscher, DW; and Sarkar, F.H: Detection of human papilloma virus (HPV) DNA
in human prostatic tissues by polymerase chain reaction (PCR). Modern Pathology 5(1): 59A, 1992.
25. Sarkar, F.H; Sakr, W.A; Li, Y-W; Macoska, J; Ball, D.E; and Crissman, J.D: Analysis of retinoblastoma (RB) gene
deletion in human prostatic adenocarcinomas. Modern Pathology 5(1): 1992.
26. Visscher, D.W; Sakr, W.A; Suchowski,C; Sloane, B.F; Weaver, D; Bouman, D; and Sarkar, F.H.: Cathepsin-B
immunostaining vs clinicopathologic parameters in colorectal adenocarcinoma. Modern Pathology 5(1): 1992.
27. Johnson, T.L; Sarkar, F.H; Joseph, C.L.M; Caison-Sorey, T.J; and Smith, R.E.: Comparison of HPV 16/18 infections
in adolescents and adults with CIN III using polymerase chain reaction (PCR). Modern Pathology 5(1): 1992.
28. Valdivieso, M; Smith, D; Frick, J; Sarkar, F.H; and Kraut, M.: Increased lung cancer incidence after 10 or more years
of non-smoking. Proceedings of ASCO annual meeting, May 17-19, Vol. 11: 1054,1992.
29. Sarkar, F.H; Li, Y-W; Sakr, W.A; Valdivieso, M; and Crissman, J.D.: Mutational activation of human K-RAS
oncogene in non-small cell lung carcinomas. Modern Pathology 5(1): 1992.
30. Callewaert, D.M; and Sarkar, F.H. Prostaglandin synthase-mediated activation of aromatic amines to derivatives that
are mutagenic to salmonella typhimurium. 8th International conference on Prostaglandins and related compounds.
Montreal, Canada, July 26-31, 1992.
31. Visscher DW, Shaheen C, Sarkar F, Crissman JD. Clonal DNA content heterogeneity in adenocarcinoma of the
breast. Cell Kinetics Society and International Cell Cycle Society, New Orleans, Louisiana, March 27-29, 1992.
32. Visscher, D.W; Sarkar, F.H; Bedrossian, C and Crissman, J.D.: Clinicopathologic
significance of oncogene
and tumor suppressor gene expression in adenocarcinoma of the breast. XIX international congress of the
international academy of pathology, Madrid 18-23 october, 1992.
33. Sarkar FH, Sakr WA, Li Y-W, Jacobs J, Crissman JD. Detection and analysis of p53 in squamous cell carcinoma
(SCC) of the larynx. Modern Pathology 6(1): 83A, 1993.
34. Castellani R, Visscher Dw, Wykes S, Sarkar FH, Crissman JD. Interaction of transforming growth factor- (TGF- )
and epidermal growth factor receptor (EGFR) in breast carcinoma: An immunohistologic study. Modern Pathology
6(1): 13A, 1993.
35. Sarkar FH, Kupsky WJ, Li Y-W, Sreepathi P, Crissman JD. Analysis of p53 gene mutations in human gliomas.
Modern Pathology 6(1): 121A, 1993.
36. Visscher DW, Sarkar FH, Wykes S, Macoska J, Crissman JD. Clinicopathologic study of INT-2 amplification and
expression in breast carcinoma. Modern Pathology 6(1): 21A, 1993.
37. Gregoire L, Sarkar FH, Sakr WA, Crissman JD. Identification of HPV DNA sequences by polymerase chain reaction
(PCR) in prostatic adenocarcinoma. Modern Pathology 6(1): 60A, 1993.
38. Castellani R, Visscher Dw, Sarkar FH, Crissman JD. Accumulation of genetic aberrations and disease progression in
breast carcinoma. Modern Pathology 6(1): 13A, 1993.
39. Sarkar FH, Ball D, Visscher DW, Wykes S, Crissman JD. Analysis of Her-2/neu gene expression by polymerase
chain reaction. Annual Meeting of AACR. 1993.
40. Sarkar FH, Visscher DW, Sreepathi P, and Yao K-L. Detection of human papillomavirus DNA sequences in
human breast cancer. Lab. Invest. 70: # 743, 1994.
41. Bedrossian C, Yao K-L, Sreepathi P, Galindo L, Fahey C, and Sarkar FH. Longitudinal follow-up of patients with
cervical biopsies tested for human papillomavirus
(HPV). Lab. Invest. 70: # 493, 1994.
42. Grignon DJ, Ravier V, Sakr WA, Angulo J, Sarkar FH, Shamsa F, Pontes JE, Montie J, and Crissman JD. Growth
factor expression and invasive bladder cancer: A clinicopathologic analysis of 43 cases. Lab. Invest. 70: # 429, 1994.
43. Grignon DJ, Chen YQ, Sarkar FH, Sakr WA, Gao X, Borders J, Honn KV, Crissman JD. p53 abonormalities in
prostatic adenocarcinoma. Lab. Invest. 70: # 430, 1994.
44. Grignon DJ, Sakr WA, Angulo J, Ravier V, Sarkar FH, Shamsa F, Pontes JE, Montie J, and Crissman JD.
Retinoblastoma gene expression as a prognostic indicator in invasive bladder cancer. Lab. Invest. 70: # 428, 1994.
28
45. Sakr WA, Grignon DJ, Sarkar FH, Tabaczka PM, Foster JR, Crissman JD. Immunostaining patterns of nm23 in
benign prostatic tissue, organ confined and locally metastatic prostatic adenocarcinoma (PCa). Lab. Invest. 70: # 842,
1994.
46. Visscher DW, Fridman R, Sarkar FH, Ottosen S, and Crissman JD. Clinopathological analysis of type IV
collagenase, basal lamina and metalloproteinase inhibitor distribution in breast carcinoma. Lab. Invest. 70: # 120,
1994.
47. Visscher DW, Wallis T, and Sarkar FH. Comparison of touch preparations and paraffin-embedded sections for
interphase cytogenetic analysis of breast tissue. Lab.
Invest. 70: # 985, 1994.
48. Visscher DW, Crissman JD, and Sarkar FH. Association between transforming growth factor-beta (TGF- )
expression and stromal desmoplasia in breast carcinoma. Lab. Invest. 70: # 119, 1994.
49. DeMattia F, Ottosen S, Sarkar FH, Visscher DW. Biological and clinical significance of fibroblast growth factor
immunostaining in breast carcinoma. Lab. Invest. 70: #64, 1994.
50. Moiin A, Borders JS, Hasimoto K, Sarkar FH. Detection of p53 mutation in merkel cell carcinoma. 1994.
51. Mohamed AN, Ebrahim SAD, Sarkar FH, Uberti J, Wolman SR. Ph negative myeloid leukemia with t(6;9).
Proceedings, 85th annual Meeting of AACR. 35: # 1156, 1994.
52. Ensley J, Alonso M, Naik H, Pear A, Pietraszkiewicz H, Sarkar F, Wozniak A, Kraut M, Valdivieso M. Comparative
DNA content analysis of non-small cell cancers of the lung (NSCCL), their correlation with other intermediate
markers and clinical outcome. Proceedings, 85th annual Meeting of AACR. 35: # 1411, 1994.
53. Gao X, Grignon D, Sarkar FH, Sakr W, Honn KV, Chen YQ. Multiple mechanisms of p53 inactivation in prostatic
carcinoma. Proceedings, 85th annual Meeting of AACR. 35: # 1057, 1994.
54. Gupta S, Weaver A, Grignon D, Sarkar FH. Alteration in P-53 and RB gene expression in leukemia survivor. Annual
Meeting: American Academy of Otolaryngology-Head and Neck Surgery, Sept. 18-21, San Diego, 1994.
55. Grignon G, Chen Y, Sleeman J, Sakr W, Sarkar FH and Crissman JD.Expression of CD44 and CD44 variants in
normal prostate tissue and prostatic adenocarcinoma. Lab. Invest. 72(1): 77A ,1995.
56. Grignon D, Caplan R, Sarkar FH, Forman J, Mesic J, Fu KK, Abrams R and Lawton C. P-53 suppressor gene status
as a predictor of outcome in patients with locally advanced prostatic adenocarcinoma (PCa) treated by radiation
therapy and without androgen ablation pre-treatment: A study based on RTOG protocol 8610. Lab. Invest. 72(1): 77A,
1995.
57. Kattar M, Grignon G, Sarkar FH, Sakr W, and Crissman JD. P-53 expression in sarcomatoid renal cell carcinoma
(RCC): A clinicopathologic analysis and immunohistochemical study. Lab. Invest. 72(1): 78A, 1995.
58. Sarkar FH, Visscher DW, Raval M, Madan S, Tabaczka P, Wozniak A, Kraut M, Steiger Z. Valdivieso M.
Immunohistochemical evaluation of cathepsin D and B in non-small cell lung cancer. Lab. Invest. 72(1): 153A, 1995.
59. Yu L, Tabaczka P, Sarkar FH, Visscher DW. Clinicopathologic analysis of bcl-2 immunoreactivity in breast
carcinoma. Lab. Invest. 72(1): 29A, 1995.
60. DeMattia F, Visscher DW, Tabaczka P, Sarkar FH and Crissman JD. Clinicopathologic relevance of platelet-derived
growth factor receptor (PDGFR) immunostaining patterns in breast carcinoma. Lab. Invest. 72(1): 16A, 1995.
61. Gao X, Chen YQ, Wu N, Zacharek A, Salkowski A, Grignon D, Sakr W, Sarkar FH, Porter AT, Honn KV.
Microsatellite instability in human prostatic adenocarcinoma: Association with advanced stage and poor
differentiation. Proceedings, 86th annual Meeting of AACR. 36: # 864, 1995.
62. Shekhar PVM, Welte RA, Sarkar FH, Jones R, Pauley RJ, Christman JK. Role of p53 in neoplastic progression of
MCF-10AneoT in a xenograft model for human breast cancer. Proceedings, 86th annual Meeting of AACR. 36: #
3413, 1995.
63. Dergham ST, Kucway R, Dugan MC, Singh K, Biernat L, Vaitkevicius VK, Crissman JD, Sarkar FH. Distribution of
K-RAS codon 12 substitution in 100 cases of pancreatic carcinoma. Annual Meeting of the American Pancreatic
Association. Pancreas 11: 425,
1995.
64. Dergham ST, Dugan MC, Kucway R, Singh K, Biernat L, Vaitkevicius VK, Crissman JD, Sarkar FH. Prevalence of
combined K-RAS mutation and P53 expression in pancreatic carcinoma. Annual Meeting of the American Pancreatic
Association. Pancreas 11: 425, 1995.
65. Dugan MC, Dergham ST, Kucway R, Singh K, Biernat L, Vaitkevicius VK, Crissman JD, Sarkar FH. Her-2/neu gene
expression within intraductal and invasive lesions of the pancreas. Annual Meeting of the American Pancreatic
Association. Pancreas 11: 427,
1995.
66. Kucway R, Dergham ST, Dugan MC, Singh K, Biernat L, Vaitkevicius VK, Crissman JD, Sarkar FH. The role of the
P53 gene in ductal carcinoma in situ of the pancreas. Annual Meeting of the American Pancreatic Association.
Pancreas 11: 435, 1995.
67. Rivard S, Shridhar V, Paisley C, Dugan MC, Sarkar FH, Beirnat L, Vaitkevicius VK, Smith DI. Annual Meeting of
the American Pancreatic Association. Pancreas 11: 445, 1995.
68. Court D, Sarkar FH, Kung H-F, Raziuddin. A role for heterogeneous nuclear ribonucleoproteins (hnRNPs) in HER2/neu/c-erbB2 gene regulation and the pathogenesis of prostate cancer. The Molecular Basis of Gene Transcription.
An AACR Special Conference, San Diego, CA, December 2-6, 1995.
29
69. Sameni M, Rozhin J, Ziegler G, Sarkar FH, Sloane BF. Cathepsin B: A marker of
invasiveness in human
breast carcinoma?. An AACR special conference on " Proteases and Protease Inhibitors". March 1-5, Panama City
Beach, Florida. B45: 1996.
70. Sarkar FH, Grignon DJ, Sakr WA, Tabaczka P, Crissman JD. Over-expression of erbb2 gene in the prostate of
african american (aa) and caucasian (c) men. Modern Pathology 9: 82A, 1996.
71. Yadrandji S, Visscher DW, Madan SK, Valdivieso M, Sarkar FH. Mutation of k-ras and p53 in pulmonary
adenocarcinoma - histologic correlations. Modern Pathology 9: 164A, 1996.
72. Kattar MM, Kupsky WJ, Shimoyama RK, Vo TD, Sarkar FH. Clonal analysis of malignant gliomas in postmortem
brains. Modern Pathology 9: 140A, 1996.
73. Madan S, Grignon DJ, Sarkar FH, Kattar MM, Sakr WA, Haas G, Crissman JD. Significance of p21WAF1 (p21) and
p53 expression in renal cell carcinoma (RCC). Modern Pathology 9: 78A, 1996.
74. Minhas F, Grignon DJ, Sarkar FH, Sakr WA, Haas G, Crissman JD. Expression of growth factors (egf and tgfa) and
their receptors (egfr and erbb2) in renal cell carcinoma: a clinicopathologic study. Modern Pathology 9: 78A, 1996.
75. Madan SK, Lee PJ, Valdivieso M, Sarkar FH. Significance of p53, bcl-2 and p21waf-1 (p21) expression in lung
carcinoma. Modern Pathology 9: 160A, 1996.
76. Dugan MC, Dergham ST, Kucway R, Vaitkevicius VK, Crissman JD, Sarkar FH. Molecular clues to a new
interpretation of in situ neoplasia in pancreas. Modern Pathology 9: 134A, 1996.
77. Chopra DP, Grignon DJ, Joiakim A, Mathieu PA, Mohamed A, Sakr WA, Sarkar FH. Differential growth factor
responses of epithelial cell cultures derived from normal human prostate, benign prostatic hyperplasia and primary
prostate carcinoma. Proceedings 87th annual meeting, AACR. 37: 1666, 1996.
78. Shridhar V, Rivard S, Shridhar R, Mullins C, Wang X, Grignon D, Sakr W, Sarkar FH, Dugan M, Heppner G,
Vaitkevicius V, Smith DI. Genes containing cryptic trinucleotide repeats are mutated in many different solid tumors.
Proceedings 87th annual meeting, AACR. 37: 3710, 1996.
79. Chen YQ, Cipriano SC, Sarkar FH, Ware JL, Arenkiel JM. p53-independent expression of p21WAF1 in tumor cells.
Proceedings 87th annual meeting, AACR. 37: 3975, 1996.
80. Dergham ST, Dugan MC, Vaitkevicius, Crissman JD, Sarkar FH. Association of p53 and WAF1 (p21) expression in
pancreatic carcinoma. Proceedings 87th annual meeting, AACR. 37: 3987, 1996.
81. Kukuruga DL, Eisenbrey AB, Sarkar F, Kithier K, Smith DI. Isolation and molecular characterization of a non-HLA
transplantation antigen expressed by human epidermal keratinocytes. 15th Annual Meeting, American Society of
Transplant Physicians, May 2630, 1996.
82. Dergham ST, Dugan MC, Arlauskas P, Vaitkevicius VK, Crissman JD, Sarkar FH. Relationship of family cancer
history to the expression of p53 and p21WAF1 in pancreatic carcinoma. First combined meeting of the European
Pancreatic Club and the International Association of Pancreatology, Mannheim, Germany, June 12-15, 1996.
83. Dugan MC, Dergham ST, Singh B, Vaitkevicius VK, Crissman JD, Sarkar FH. Islet cell staining of cyclin D1 in
normal and neoplastic pancreas. Annual Meeting of the American Pancreatic Association. Pancreas 1996.
84. Sarkar FH, Dergham ST, Koppitch FC, Dugan MC, Mohamed A, Crissman JD, Vaitkevicius VK. Analysis of c-myc
and multiple chromosome copy number in pancreatic adenocarcinoma using fluorescence insitu hybridization (FISH).
Annual Meeting of the American Pancreatic Association. Pancreas 1996.
85. Dergham ST, Dugan MC, singh B, Crissman JD, Vaitkevicius VK, Sarkar FH. Cyclin D1 expression in pancreatic
adenocarcinomas. Annual Meeting of the American Pancreatic Association. Pancreas 1996.
86. Joshi US, Chen YQ, Miller FR, Dergham ST, Dugan MC, Crissman JD, Vaitkevicius VK, Sarkar FH. Inhibition of
pancreatic tumor cell growth in culture by p21WAF-1 (p21)-recombinant adenovirus. Annual Meeting of the
American Pancreatic Association. Pancreas 1996.
87. Spindler SA, Sarkar FH, Sakr WA, Callewaert DM, Reddy RG. What is the role of 13-hydroperoxyoctadecadienoic
acid in prostate cancer?. Annual metting of the 6th International Congress on Cell Biology and 36th American Society
for Cell Biology, 1996.
88. Shridhar V, Shridhar R, Sarkar F, Dugan M, Wilke C, Glover TW, Vaitkevicius V, Smith DI. FRA3B is a hot-spot
for chromosomal breakage in pancreatic cancer. Annual Meeting of The American Society of Human Genetics, 1996.
89. Adsay V, Sakr W, Grignon D, Frank J, Crissman J, Sarkar F. Distribution of WAF-1 (p21) in normal and neoplastic
prostate tissue. Modern Pathology 10 (1): 68A, 1997.
90. Minhas F, Grignon D, Sakr W, Sarkar F, Wood Jr D, Pontes E, Crissman J. BCL-2 expression in renal cell cercinoma
(RCC): A clinicopathologic study. Modern Pathology 10 (1): 82A, 1997.
91. Schneider C, Grignon D, Sakr W, Sarkar F, Littrup P, Long D, Meetze K, Porter A, Crissman J, Forman J. Pathologic
and biologic features of positive post radiation therapy biopsies as predictors of treatment failure in prostate cancer.
Modern Pathology 10 (1): 89A, 1997.
92. Schneider C, Grignon D, Sakr W, Sarkar F, Littrup P, Tabaczka P, Porter A, Crissman J, Forman J. Apoptosis related
markers in prostate carcinoma: A comparison of pre- and post-radiation therapy. Modern Pathology 10 (1): 89A, 1997.
30
93. Trent V, Grignon D, Sakr W, Sarkar F, Wood Jr D, Pontes E, Crissman J. p21WAF1 (p21) overexpression in invasive
bladder cancer: A clinicopathologic study and correlation with p53, BCL-2 and cellular proliferation. Modern
Pathology 10 (1): 92A, 1997.
94. Sakr WA, Crissman JD, Sarkar FH, Tabaczka P, Kucuk O, Bertrram J. Connexin 43 (Cx43): A marker for early
neoplastic transformation in squamous neoplasia of the upper aerodigestive tract (UADT). Modern Pathology 10 (1):
117A, 1997.
95. Dergham SD, Dugan MD, Du W, Smith DW, Arlauskas P, Vaitkevicuis VK, Crissman JD, Sarkar FH. p21WAF1
(p21) expression is related to early stage and increased survival with conventional therapies in pancreatic
adenocarcinoma. Modern Pathology 10 (1): 144A, 1997.
96. Yadranji S, Visscher D, Wallis T, Sarkar F. Analysis of ERBB-2 immunostaining and gene copy number in
pulmonary adenocarcinoma. Modern Pathology 10 (1): 174A, 1997.
97. Sarkar FH, Odenwaller R, Singh B, Davis JN, Li Y-W. Up-regulation of p21WAF1 (p21) by isoflavone genistein in
prostate cancer (PCa) cells. Annual Meeting of the American Urological Association. J. Urol. 157: 21, 1997.
98. Sarkar FH, Sakr WA, Grignon DJ, Frank JJ, Crissman JD, Adsay VN. Increased expression of p21 WAF-1 in
prostate cancer progression. Annual Meeting of the American Urological Association. J. Urol. 157: 443, 1997.
99. Chopra DP, Sarkar FH, Grignon DJ, Mohamed A, Sakr WA. Propagation of diploid and aneuploid epithelial cells
derived from human prostate tumors. Proceedings of 88th annual meeting, AACR. 38: Abstract 2256, page-426, 1997.
100. Mohammad RM, Dugan M, Mohamed AM, Almatchy VP, Pettit GR, Vaitkevicius VK, Sarkar FH. Establishment of
a human pancreatic tumor xenograft model: Potential application for preclinical evaluation of novel therapeutic agents.
Proceedings of 88th annual meeting, AACR. 38: Abstract 3282, page-490, 1997.
101. Tobi M, Prabhu S, Zenilman M, Peleman R, Dugan M, Sarkar F, Evans D, Abbruzzesse J. Pancreatic cancer:
Identification of surgical candidates using molecular markers. Proceedings of 88th annual meeting, AACR. 38:
Abstract 3498, page-521, 1997.
102. Majumdar APN, Tureaud J, Reddy KB, Sarkar FH. Increased expression of EGF-receptor (EGF-R) and c-erbB2 in
the gastric mucosa of aged rats. Annual Meeting of the Society for Experimental Biology, 1997.
103. Bianco FJ, Grignon DJ, Wood Jr DP, Trent V, Sakr WA, Sarkar FH, Crissman JD. Expression of apoptosis related
markers (p53, Bcl-2 and p21WAF1) in invasive bladder cancer: A clinicopathologic study of 45 cases. Annual
Meeting of the American Urological Association. J. Urol. 157: 1997.
104. Mohammad R, Al-Katib A, Pettit G, Vaitkevicius V, Joshi U, Adsay V, Majumdar APN, Sarkar FH. An orthotopic
model of human pancreas cancer in SCID-Xenograft: Potential application for preclinical studies. Annual Meeting of
the American Pancreatic Association, 1997. Pancreas 15 (4): 446, 1997.
105. Singh B, Dergham ST, Sarkar FH. Molecular mechanism of cell growth inhibition and apoptosis induced by
isoflavone–genistein in a pancreatic tumor cell line. Annual Meeting of the American Pancreatic Association, 1997.
Pancreas 15 (4): 446, 1997.
106. Schneider C, Grignon DJ, Sarkar FH, Gheiler E, Li Y-W, Sakr WA, Pontes J and Forman J. p53 gene alteration in
prostate cancer after radiation failure and their association with clinical outcome: A molecular and
immunohistochemical analysis. Modern Pathology 11: 95A, 1998.
107. Davila J, Sarkar FH, Du W, Arlauskas P, Shields A, Zalupski M, Vaitkevicius V, Crissman J and Adsay V. Multidrug
resistance proteins (glutathiones-S transferase- and
and p-glycoproteins) and response to chemotherapy in
pancreas cancer. Modern Pathology 11: 151A, 1998.
108. Upadhyay S, Sarkar FH. Genistein induced growth inhibition but not apoptosis in untransformed MCF10A breast
epithelial cells. Proceedings of 89th annual meeting, AACR. 39: Abstract 376, page-55, 1998.
109. Tobi M, Hatfield J, Adsay V, Begum D, Arlauskus P, Vaitkevicius V, Sarkar F, Hruban RH, Abbruzzese J, Evans
DB, Fligiel S. Adnab-9 monoclonal antibody may identify long-term pancreatic cancer survivors. Proceedings of 89th
annual meeting, AACR. 39: Abstract 1561, page-228, 1998.
110. Davis J, Singh B, Sarkar FH. Molecular mechanism of cell growth inhibition and apoptosis induced by isoflavonegenistein in prostate cancer cell lines. Proceedings of 89th annual meeting, AACR. 39: Abstract 2637, page-388, 1998.
111. Alhasan S, Alonso MD, Ensley J, Sarkar FH. Genistein induced growth inhibition and apoptosis in squamous cell
carcinoma cell line of the head and neck. Proceedings of 89th annual meeting, AACR. 39: Abstract 3983, page-585,
1998.
112. Davis JN, Piscitelli RO, Singh B, Li Y-W, Dergham ST, Bhuiyan M, Alhasan S, Sarkar FH. Molecular mechanism of
cell growth inhibition and apoptosis induced by isoflavone genistein in prostate cancer cell line. Proceedings,
Innovative approaches to the prevention, diagnosis and therapy of cancer. The Fourth joint conference of the AACR
and JCA, Maui, Hawaii, February 16-21, 1998.
31
113. Mohammad RM, Li Y-W, Mohamed AN, Pettit GR, Adsay NV, Vaitkevicius VK, Al-Katib AA, Sarkar FH. Clonal
preservation of human pancreatic cell line derived from primary pancreatic adenocarcinoma. Annual Meeting of the
American Pancreatic Association, 1998. Pancreas 17 (4): pp 448, 1998.
114. Singh B, Martini S, Mohammad RM, Vatkevicius VK, Sarkar FH. Molecular mechanism of cell growth inhibition
and apoptosis induced by gemcitabine and auristatin-pe in human pancreatic cancer cell lines. Annual Meeting of the
American Pancreatic Association, 1998. Pancreas 17 (4): pp 456, 1998.
115. Martini S, Singh B, Mohammad RM, Vatkevicius VK, Sarkar FH. Growth inhibitory effects of novel
chemothreapeutic agents in pancreatic cancer cell lines. Annual Meeting of the American Pancreatic Association,
1998. Pancreas 17 (4): pp 447, 1998.
116. He Z, Mohammad RM, Evelhoch JL, Adsay NV, Vaitkevicius VK, Sarkar FH. Magnetic resonance imaging of
therapeutic response in an orthotopic model of human pancreatic cancer. Annual Meeting of the American Pancreatic
Association, 1998. Pancreas 17 (4): pp 461, 1998.
117. Davis JN, Sarkar FH. Molecular Mechanisms of Genistein-Induced Cell Growth Inhibition and Apoptosis in Prostate
Cancer Cells. IBC conference on Prostate Cancer, Amelia Iland, Florida, Nov 19-20, 1998.
118. Davis JN, Sarkar FH. Molecular Mechanisms of Genistein-Induced Cell Growth Inhibition and Apoptosis in Prostate
Cancer Cells. AACR Special Conference on Prostate, Indian Wells, California, December 2-5, 1998.
119. Sakr W, Land SJ, Akroush AM, Sarkar FH, Haas GP, Heilbrun L, Kanluen S, Everson R. Determination of steroid
hormone receptor polymorphisms in prostate tissue from autopsy specimens. Modern Pathology 12: 193A, 1999.
120. Adsay V, Logani S, Crissman J, Vaitkevicius V, Sarkar FH. Foam cell pattern of invasive ductal carcinoma of the
pancreas: A distinctive and deceptively benign-appearing variant. Modern Pathology 12: 159A, 1999.
121. Adsay V, Kabbani W, Sarkar FH, Visscher D. Infiltrating “lobular-type” carcinoma of the pancreas: A
morphologically distinctive variant of ductal adenocarcinoma of the pancreas mimiking lobular carcinoma of the
breast. Modern Pathology 12: 159A, 1999.
122. Kabbani W, Ioachim H, Sarkar FH, Adsay V. How much of a sarcoma is kaposi sarcoma?: Expression of cell cycle
proteins and proliferation markers in KS. Modern Pathology 12: 140A, 1999.
123. Visscher D, Reddy R, Sarkar FH, Long D. Immunohistologic detection of cyclooxygenase-2 (Cox-2) in breast
carcinoma. Modern Pathology 12: 32A, 1999.
124. Sarkar FH, Sakr W, Grignon D, Bianco F, Powell I, Wood D, Adsay V. Relationship of p21 (WAF1) expression with
disease free survival and biochemical recurrence in prostatic adenocarcinoma. Modern Pathology 12: 106A, 1999.
125. Adsay V, Pierson C, Sarkar FH, Klimstra D. Invasive mucinous colloid-type adenocarcinoma of the pancreas: A
distinct clinicopathologic entity. Modern Pathology 12: 159A, 1999.
126. Rakozy C, Gheiler E, Sarkar FH, Sakr W, Tiguert R, Tabasczka P, Pontes JE, Grignon D. Apoptosis-related markers
in recurrent prostatic carcinoma after radiation failure and their significance for clinical outcome. Modern Pathology
12: 105A, 1999.
127. Feng J, Nassar H, Li Y, Sarkar FH, Adsay V. p27 expression in pancreatic adenocarcinoma and its correlation with
clinical and biological parameters. Modern Pathology 12: 162A, 1999.
128. Nassar H, Sarkar FH, Das S, Crissman J, Adsay V. Secondary tumors of the pancreas. Modern Pathology 12: 165A,
1999.
129. Jimenez RE, Oskanian P, Tiguert R, Sakr WA, Li Y, Wood D Jr., Sarkar FH, Grignon DJ. Comparative analysis of
p53, p21 and Bcl-2 expression in muscle invasive urothelial carcinoma of the bladder: Correlation with progressionfree survival. Modern Pathology 12: 98A, 1999.
130. Glazyrin A, Vaitkevicius VK, Sarkar FH. Human pancreatic adenocarcinoma cells are resistant to drug-stimulated
CD95 (FAS)-mediated apoptosis. Annual Meeting of the American Pancreatic Association. Pancreas 19: 421, 1999.
131. Davis JN, Kucuk O, Sarkar FH. Molecular effects of soy-isoflavone genistein in prostate cancer cells. Third
International Symposium on the Role of Soy in Preventing and Treating Chronic Disease. Oct 31-Nov 3, 1999,
Washington, DC.
132. Chinni SR, Li YW, Sarkar FH. Molecular effects of indole-3-carbinol on PC3 prostate cancer cells. Proceedings of
9th annual research conference of American Institute for Cancer Research, Sept 2-3, 1999, Washington, DC.
133. Philip PA, Li Y, Alonso M, Manji H, Sarkar FH, Ensley J, Ali-Sadat S. Sensitization of human breast cancer cells to
gemcitabine by bryostatin 1. Proceedings of 90th annual meeting, AACR. 40: Abstract 33, page-5, 1999.
134. Chopra DP, Waghrey A, Sarkar FH. TNF- and Fas in prostate cancer growth and apoptosis in vitro. Proceedings of
90th annual meeting, AACR. 40: Abstract 1131, page-170, 1999.
135. Alhasan SA, Alonso MD, Ensley J, Sarkar FH. Genistein induced molecular changes in a head and neck cancer cell
line. Proceedings of 90th annual meeting, AACR. 40: Abstract 1710, page-258, 1999.
136. Kucuk O, Sakr W, Sarkar FH, Djuric Z, Li YW, Valazquez F, Banerjee M, Bertram JS, Crissman JD, Wood DP.
Lycopene supplementation in men with localized prostate cancer (PCa) modulates grade and volume of prostatic
intraepithelial neoplasia (PIN) and tumor, level of serum PSA and biomarkers of cell growth, differentiation and
apoptosis. Proceedings of 90th annual meeting, AACR. 40: Abstract 2706, page-409, 1999.
32
137. Davis JN, Kucuk O, Sarkar FH. Genistein down regulates prostate specific antigen (PSA) in LNCaP cells.
Proceedings of 90th annual meeting, AACR. 40: Abstract 4283, page-650, 1999.
138. Sarkar FH. Molecular mechanism(s) of selected therapeutic agents on cancer cells. Proceedings of the 4th World
Congress on Advances in Oncology and 2nd International Symposium on Molecular Medicine, October 7-9, 1999,
Athens, Greece.
139. Adsay V, Hasteh F, Sarkar FH, Vaitkevicius VK, Cheng J, Klimstra D. Squamous cell and adenosquamous
carcinomas of the pancreas: A clinicopathologic analysis of 11 cases. Modern Pathology 13: 1052A, 2000.
140. Andea A, Philip P, Shields A, Vaitkevicius VK, Sarkar FH, Adsay V. Is “Tail Carcinoma” a different entity? A
comparative analysis of resected adenocarcinomas from the head and tail of the pancreas. Modern Pathology 1054A,
2000.
141. Tranchida P, Hasteh F, Sarkar FH, Tobi M, Fligiel S, Sochacki P, Pietruk T, Adsay V. Poorly differentiated
neuroendocrine (small cell) carcinomas of the pancreas: An analysis of 8 examples of a debated entity. Modern
Pathology 1120A, 2000.
142. Davis JN, Sarkar FH. A novel effect of genistein on androgen receptor and PSA expression in prostate cancer cells.
Proceedings of 91st annual meeting, AACR 41: A5410, page 852, 2000.
143. Rahman KMW, Sarkar FH. Molecular mechanism(s) of indole-3-carbinol in breast cancer cells. Proceedings of 91st
annual meeting, AACR 41: A4198, page 660, 2000.
144. Alhasan SA, Ensley JF, Sarkar FH. Inhibition of tumor cell invasion is accompanied by down regulation of c-erbB-2
expression and MMP secretion in a head and neck squamous cell carcinoma cell line (MNSCC). Proceedings of 91st
annual meeting, AACR 41: A4388, page 690, 2000.
145. Chinni SR, Koppolu PK, Sarkar FH. Molecular mechanism(s) of indole-3-carbinol induced G1 arrest in prostate
cancer cells. Proceedings of 91st annual meeting, AACR 41: A1591, page 250, 2000.
146. Upadhyay S, Neburi M, Sarkar FH. Role of P21WAF1 in differential response to genistein in MCF10A derived cells.
Proceedings of 91st annual meeting, AACR 41: A5365, page 845, 2000.
147. Aranha O, Alhasan SA, Wood DP Jr., Sarkar FH. Ciprofloxacin induces Bax translocation and mitochondrial
depolarization during apoptosis in a bladder tumor cell line. Proceedings of 91st annual meeting, AACR 41: A5417,
page 853, 2000.
148. Sarkar FH, Upadhyay S. Induction of apoptosis in breast cancer cells by genistein. Proceedings of the Department of
Defense Breast Cancer Research Program Meeting “Era of Hope” Vol. II, page 463, 2000.
149. Kucuk O, Sarkar FH, Djuric Z, Visscher D, Bouwman D, Kosir MA, White M, Banerjee M, Hryniuk L, Hryniuk W.
Effects of soy isoflavones on biomarkers of oxidative stress and cell growth in patients with breast cancer. Proceedings
of the Department of Defense Breast Cancer Research Program Meeting “Era of Hope” Vol. I, page 332, 2000.
150. Trevedi C, Fontana J, Forman J, Banerjee M, Kucuk O, Sarkar FH, Dood D, Hussain M. PSA modulation in prostate
cancer (PCa) patients by soy isoflavones. Proceedings of 36th annual meeting of the American Society of Clinical
Oncology, 2000.
151. Adsay V, Pierson C, Sarkar FH, Zee S, Klimstra D. Immunophenotypic features of intraductal papillary mucinous
neoplasms (IPMN) of the pancreas: comparative immuno-histochemical analysis of oncoprotein expression in various
components of IPMNs. Annual combined meeting of the American Pancreatic Association and International
Association of Pancreatology. Pancreas 21: 430, 2000.
152. Pernick NL, Sarkar FH, Arlauskas P, Philip PA, Shields A, Vaitkevicius VK, Adsay NV. Fas and Fas ligand
expression in pancreatic adenocarcinoma. Annual combined meeting of the American Pancreatic Association and
International Association of Pancreatology. Pancreas 21: 470, 2000.
153. Adsay V, Siadaty MS, Sarkar FH, Frank J, Tabacska P, Koptcher G, Merati K. The significance of MUC1 and
MUC2 expression and their relationship to clinical and pathologic parameters in pancreatic ductal adenocarcinoma.
Modern Pathology, 2001 (In press).
154. Merati K, Siadati MS, Aleodor A, Sarkar FH, Mohammad R, Philip P, Shields A, Vaitkevicius V, Adsay V.
Expression of inflamatory modulator Cox-2 in pancreatic ductal adenocarcinoma and its relationship to pathologic and
clinical parameters. Modern Pathology, 2001 (In press).
155. Adsay V, Merati K, Sarkar FH, Abrams J, Wilentz RE, Hruban RH, Longnecker D, Klimstra DS. The dichotomy in
the dysplasia-CIS-invasive carcinoma sequence in the pancreas: Immunophenotypic evidence for two separate
pathways of carcinogenesis. Modern Pathology, 2001 (In press).
156. Andea A, Munn T, Sarkar FH, Cheng J, Klimstra DS, Adsay V. Pancreatic intraepithelial neoplasia (PANIN,
dysplasia) in pancreata with no primary neoplasms. Modern Pathology, 2001 (In press).
157. Merati K, Klimstra DS, Abrams J, Hruban RH, Iacobuzio-Donahue CD, Sarkar FH, Adsay V. Intraductal papillary
mucinous neoplasms (IPMNS) of the pancreas exhibit three morphologically and immunophenotypically distinct types
of epithelium. Modern Pathology, 2001 (In press).
158. Balani J, Shields A, Vaitkevicius V, Ben-Josef E, Levin K, Sarkar FH, Cheng J, Adsay V. Pathologic findings in
post-adjuvant pancreatectomy specimens. Modern Pathology, 2001 (In press).
159. Nassar H, Sarkar F, Visscher D, Adsay V. Muc2: A Marker of a Clinically and Biologically Distinct Pathway in
Mammary Carcinogenesis. Modern Pathology, 2002.
160. Nassar H, Sarkar F, Visscher D, Adsay V. The Differential Expression of Surface Glycoprotein MUC1 in Preinvasive
and Invasive Mammary Neoplasia. Modern Pathology, 2002.
33
161. Ingber M, Bentley G, Grignon D, Tabaczka P, Majumdar A, Sarkar F. Expression of a Novel Epidermal Growth
Factor Receptor-Related Protein in Muscle Invasive Urothelial Carcinoma. Modern Pathology, 2002.
162. Andea AA, Sarkar F, Cheng J, Adsay V. A Comparitive Analysis of Pancreatic Intraepithelial Neoplasis (PanIN) in
Pancreata with Ductal Adenocardinoma Versus Those without Primary Tumors. Modern Pathology, 2002.
163. Fathallah L, Vyas P, Klimstra D, Hruban R, Sarkar F, Adsay V. MUC1 and MUC2 Expression in Carcinomas of
Ampullary Region and Their Diagnostic and Clinical Significance. Modern Pathology, 2002.
164. Feng J, Pernick NL, Majumdar A, Sarkar FH, Adsay NV. Expression of ERRP in Normal and Neoplastic Pancreata
and Its Relationship to Clinicopathological Parameters in Pancreatic Adenocarcinoma. Modern Pathology, 2002.
165. Merati K, Nassar H, Sarkar F, Visscher D, Klimstra D, Adsay V. Pathogenesis of Colloid Carcinomas of the Exocrine
Organs Pancreas and Breast: Coupling of Gel-Formation Mucin (MUC2) Production with Aleration in Cell Polarity
May Be the Key Factor for the Distinctive Characteristics of Colloid Carcinomas. Modern Pathology, 2002.
166. Rahman KMW, Aranha O, Sarkar FH. Indole-3-Carbinol (IC3) induces apoptosis in breast cancer cells, but not in
normal breat epithelial cells. Proceedings from the 93rd Annual AACR: Abstract 2548, page-513, 2002.
167. Philip PA, Ali S, Hryniuk W, Newman L, Carolin K, Bouwman D, Abrams J, Heppner G, Sarkar FH. Gene
expression profile by cDNA microarrays in patients with breast cancer receiving pre-operative chemotherapy. AACR,
2002.
168. Hussain M, Sarkar FH, Djuric Z, Pollak MN, Banerjee M, Doerge D, Fontana J, Chinni S, Davis J, Forman J, Wood
DP, Kucuk O. Soy isoflavones in the treatment of prostate cancer. J Nutrition 132 (3): 575S-576S, 2002.
169. Sarkar FH, Adsay NV, Ellis KL, Majumdar APN. Expression of ERRP in normal and neoplastic pancreata and its
relationship to clinicopathological parameters in pancreatic adenocarcinoma. Annual Meeting of American Pancreatic
Association. Pancreas 25: 448, 2002.
170. Sarkar FH, Rahman KMW, Li Y. Translocation of Bax to mitochondria induces apoptotic cell death in Indole-3Carbinol (I3C) treated breast cancer cells. Nutritional Genomics and Proteomics in cancer prevention conference at
NIH, September 5-6, 2002.
171. McGowen R, Callewaert D, Sarkar FH, Gupta S. Quantitative measurement of NF-κB-DNA binding activity by
chemiluminescent immunoassay. 9th Annual Meeting of the Oxygen Society. Free Radical Biology and Medicine 33
(S2):S351, 2002.
172. Li Y, Sarkar FH. Analysis of gene expression profiles of PC3 prostate cancer cells treated with genistein.
Proceedings of the Frontiers in Chemoprevention Research (AACR meeting). October 14-18, Boston, 2002.
173. Butler C, Andea A, Pansare V, Hong X, Sarkar F, Grignon D, Sakr W. Comparitive Molecular & Morphologic
Analysis of Autopsy Discovered and Clinically Evident Prostatic Carcinoma: Loss of Heterozygosity. Modern
Pathology. 16:1, 144A, 2003.
174. Shen R, Zhang H, Bismar T, Bhan R, Vernick J, Madan S, Sarkar F, Sakr W, Grignon D, Che M. Applications of a
Reliable Quantitative Gene Analysis Approach in Urological Tumors. Modern Pathology. 16:1, 170A, 2003.
175. Zhang H, Li X, Sarkar F, Sakr W, Grignin D, Che M. HIF and COX-2 Are Potential Early Modulators of Tumor
Angiogenesis in Human Prostate Cancer. Modern Pathology. 16:1, 177A, 2003.
176. Fathallah L, Kolizeras K, Butler C, Andea D, Lonardo F, Sarkar F, Sakr W. Early Neopastic Transformation of
Squamous Epithelium and Underlying Stroma of the Upper Aerodigestive Tract (UADT): A Laser Microdissection
(LCM); Molecular, Immunohistochemical and Morphological Analysis. Modern Pathology. 16:1, 218A, 2003.
177. Vyas P, Andea A, Sarkar F, Leach S, Cheng J, Adsay NV. In Search of a Stem Cell Pancreatic Ducts: The Nature of
Round, Non-Ductal Appearing Cells in Human Pancreatic Ducts. Modern Pathology. 16:1, 287A, 2003.
178. Nassar H, Pansare V, Zhang H, Kotcher G, Che M, Sakr W, Ali-Fehmi R, Grignon D, Sarkar F, Cheng J, Adsay NV.
Reverse Polarization of Cells with Expression of MUC1 in the Stroma-Facing Surfaces May Be a Key Factor in the
Pathogenesis and Morphogenesis of Invasive Micropapillary Carcinoma. Modern Pathology. 16:1, 298A, 2003.
179. Londaro F, Siddiq F, Sarkar F, Wali A, Pass H. Experimental and Morphological Evidence Reveals That Osteonectin
Expression is Common in Lung Cancer and May Be Related to Tissue Remodeling. Modern Pathology. 16:1, 310A,
2003.
180. Lonardo F, Siddiq F, Sarkar F, Wali A, Pass H. Increased osteonectin expression is associated with cell
transformation and tissue remodeling in lung cancer. Proceedings of the 94th Annual Meeting AACR: Abstract 528,
page-121, 2003.
181. Mohammad R, Kucuk O, Aboukameel A, Ellis K, Ibrahim D, Sarkar F, Al-Katib A. Sensitization of lymphoma
tumors to CHOP chemotherapy by genistein in diffuse large cell lymphoma (DLCL) xenograft model. Proceeding of
the 94th Annual Meeting AACR: Abstract 2539, page-578, 2003.
182. Majumdar A, Mohammad R, Marciniak D, Moragoda L, Yu Y, Aboukameel A, Adsay V, Rishi AK, Sarkar F. EGFreceptor related protein (ERRP): A potential therapeutic agent for colorectal and prostate cancers. Proceeding of the 9th
Annual AACR: Abstract 4009, page-917, 2003.
183. Majumdar APN, Du J, Nagothu KK, Hatfield J, Levi E, Adsay V, Schmelz EM, Rishi AK, Jaszewski R, Sarkar FH,
Kucuk O. Regulation of EGF-receptor (EGFR) in the gastric mucosa during aging and carcinogenesis by ERRP, a
novel negative regulator of EGFR. Proceedings of the 94th Annual AACR: Abstract 4980, page-1142, 2003.
184. Yu BW, Ahmad F, Liao DJ, Sarkar F. Induction and nuclear localization of p27kip in human breast cancer cells by
diindolylmethane (DIM). Proceedings of the 94th Annual AACR: Abstract 5676, page-1301, 2003.
34
185. Li Y, Li X, Sarkar FH. Gene expression profille of I3C and DIM treated PC3 prostate cancer cells by cDNA
microarray analysis. Proceedings of the 94th Annual AACR: Abstract 6551, page-1501, 2003.
186. Rahman KMW, Li Y, Sarkar FH. Inactivation of Akt and NF-κB plays important roles during I3C-induced apoptosis
in breast cancer cells. Proceedings of the 94th Annual AACR: Abstract 5685, page-1303, 2003.
187. Hillman GG, Kucuk O, Yang Y, Che M, Wright J, Joiner MC, Marples B, Yudelev M, Forman JD, Sarkar FH.
Radiosensitization by Genistein in an Orthotopic Mouse Model of Prostate Cancer. 5th International Symposium on
the Role of Soy in Preventing and Treating Chronic Disease, 2003, Orlando, Florida.
188. Li Y, Ellis KL, Nedeljkovic A, Kucuk O, Sarkar FH. Soy Isoflavone Genistein Inhibits NF-κB and Sensitizes
Human Cancer Cells to Apoptosis Induced by Chemopreventive Agents. 5th International Symposium on the Role of
Soy in Preventing and Treating Chronic Disease, 2003, Orlando, Florida.
189. Kucuk O, Sarkar F, Sakr W, Wood D, Cher M, Abrams J, Doerge DD, Pollak MM, Djuric Z, Majumdar A. Clinical
Trial of Soy Isoflavone Supplementation Before Radical Prostatectomy in Patients with Localized Prostate Cancer. 5th
International Symposium on the Role of Soy in Preventing and Treating Chronic Disease, 2003, Orlando, Florida.
190. Vaishampayan UVA, Forman JJ, Hussain M, Cher M, Pontes E, Fontana J, Alluri KC, Doerge D, Sarkar F, Kucuk O.
Soy Isoflavones and Lycopene in the Treatment of Hormone-Sensitive and Hormone-Refractory Prostate Cancer. 5th
International Symposium on the Role of Soy in Preventing and Treating Chronic Disease, 2003, Orlando, Florida.
191. Hillman GG, Kucuk O, Joiner MC, Marples B, Wang Y, Wright JL, Ellis KL, Yudelev M, Forman JD, Sarkar FH.
Potentiation of Radiation-Induced Cell Killing by Genistein in Prostate Cancer Cells In vitro. 5th International
Symposium on the Role of Soy in Preventing and Treating Chronic Disease, 2003, Orlando, Florida.
192. Miller FR, Tait LR, Doerge D, Sarkar F, Kucuk O. Genistein and Tamoxifen Interaction in MCF10DCIS.com
Xenograph Model for Chemoprevention. 5th International Symposium on the Role of Soy in Preventing and Treating
Chronic Disease, 2003, Orlando, Florida.
193. Kucuk O, Sarkar F, Adsay V, Newman L, Bouwman D, Djuric Z, Doerge D, Parchment R, Banerjee M, Majumdar A.
Clinical Trial of Soy Isoflavones Prior to Breast Cancer Surgery. 5th International Symposium on the Role of Soy in
Preventing and Treating Chronic Disease, 2003, Orlando, Florida.
194. Kodali U, Kucuk O, Jaszewski R, Levi R, Doerge D, Sarkar F, Majumdar APN. Genistein and EGFR Related Protein
(ERRP) Potentiate Each Other in Gastric, Colon and Prostate Cancer Cells. 5th International Symposium on the Role of
Soy in Preventing and Treating Chronic Disease, 2003, Orlando, Florida.
195. Parchment RE, Sarkar F, Kassab J, Ellis KL, Doerge D, Kucuk O. Genistein Does Not Sensitize Human Bone
Marrow to XK469 Toxicity at Concentrations That Sensitize BxPC3 Pancreatic Cancer to XK469 Chemotherapy. 5th
International Symposium on the Role of Soy in Preventing and Treating Chronic Disease, 2003, Orlando, Florida.
196. Mohammad R, Al-Katib A, Aboukameel A, Ibrahim D, Doerge D, Sarkar F, Kucuk O. Genistein Sensitizes Resistant
Diffuse Large Cell Lymphoma (DLCL) Cells to Chemotherapy. 5th International Symposium on the Role of Soy in
Preventing and Treating Chronic Disease, 2003, Orlando, Florida.
197. Li Y, Ellis K, Nedeljkovic-Kurepa A, Kucuk O, Sarkar F. Soy Isoflavone Genistein Inhibits NF-B and Sensitizes
Human Cancer Cells to Apoptosis Induced by Chemotherapeutic Agents. 5th International Symposium on the Role of
Soy in Preventing and Treating Chronic Disease, 2003, Orlando, Florida.
198. Sahin K, Onderci M, Gursu MF, Sahin N, Doerge D, Sarkar F, Kucuk O. Genistein Supplementation Alleviates the
Deterioration in Performance and Anti-Oxidant Status of Japanese Quail Associated with Heat Stress. 5th International
Symposium on the Role of Soy in Preventing and Treating Chronic Disease, 2003, Orlando, Florida.
199. Sahin K, Sahin N, Onderci M, Sarkar F, Prasad A, Doerge D, Kucuk O. Effects of Dietary Genestein on Nutrient
Use and Mineral Status in Heat-Stressed Quail. 5th International Symposium on the Role of Soy in Preventing and
Treating Chronic Disease, 2003, Orlando, Florida.
200. Li Y, Ellis K-L, Nedeljkovic-Kurepa A, Kucuk O, Sarkar FH. Chemotherapeutic Agent-Induced Apoptosis is
Potentiated by Soy Isoflavone Genistein, a Natural Inhibitor of NF-κB in BXPC-3 Pancreatic Cancer Cells. American
Pancreatic Association, 2003, Chicago, Illinois.
201. El-Rayes BF, Ali S, Sarkar FH, Philip PA. Cyclooxygenase 2 (COX-2) as a Target in Pancreatic Cancer. American
Pancreatic Association, 2003, Chicago, Illinois.
202. Andea A, Kolizeras K, Butler C, Hong X, Sarkar F, Sakr W. Differences in Genetic Profile of Prostatic Carcinoma in
African-American Versus Caucasians Using Lase Micro Dissection and Loss of Heterozyggosity Analysis. Modern
Pathology. 17:1, 570A, 2004.
203. Grignon DJ, Bismar TA, Bianco F, Sakr WA, Pontes JE, Sarkar F, Che M. VHL Gene Mutation in Multilocular
Cystic Renal Cell Carcinoma: Evidence in Support of its Classification as a Type of Clear Cell Renal Cell Carcinoma.
Modern Pathology. 17:1, 645A, 2004.
204. Ali-Fehmi R, Nassar H, Pansare, Bandyopadhyay, Sarkar F, Munkarah AR, Liao J. QM Gene Expression in Normal
Ovary and in Serous Ovarian Carcinoma. Modern Pathology. 17:1, 791A, 2004.
205. Adsay NV, Levi E, Basturk O, Frank J, Altinok G, Sarkar F, Hruban R, Klimstra DS. CDX2 Expression in
Intraductal Papillary Mucinous Neoplasms and Colloid Carcinomas of the Pancreas: Further Avidence for a Distinct
Pathway of Carcinogenesis with Intestinal Lineage. Modern Pathology. 17:1, 1238A, 2004.
206. Andea AA, Basturk O, Klimstra D, Hruban R, Sarkar F, Adsay VN. Colloid Carcinoma of the Pancreas Lacks the
Mollecular Alterations Characteristic of Ordinary Ductal Adenocarcinoma. Modern Pathology. 17:1, 1240A, 2004.
35
207. Khanani F, Basturk O, Sarkar F, Levi E, Cheng JD, Adsay NV. P63 Expression in Pancreas and Pancreatic
Neoplasia: A Reliable Marker for Distinguishing Squamous/Transitional Metaplasia from Pancreatic Intraepithlial
Neoplasia. Modern Pathology. 17:1, 1279A, 2004.
208. Khanani F, Liao J, Sarkar F, Basturk O, Levi E, Adsay NV. Pancreatic Intraepithelial and Mucinous Cystic
Neoplasia Type Ductal Lesions in TGFA Transgenic Mice: An Animal Model with Potential Applications in
Understanding Carcinogenesis and Developing Preventive and Therapeutic Strategies. Modern Pathology. 17:1,
1280A, 2004.
209. Pryor E, Levi E, Sarkar F, Cheng JD, Basturk O, Adsay NV. Association of Her2/neu Overexpression with Akt
activation in Pancreatic Ductal Carcinoma. Modern Pathology. 17:1, 1303A, 2004.
210. Ellis KL, Mohammad R, Wang S, Wu X, Chen J, Min J, Sarkar FH. Potentiation of apoptosis inducing activity of
BL-193, an inhibitor of Bcl-XL protein, by genistein in pancreatic cancer cells. 40th Annual Meeting of the American
Society of Clinical Oncology. 23: Abstract 3133, page 228, 2004
211. Sarkar FH. Indole-3-carbinol and Prostate Cancer. International Research Conference on Food, Nutrition, and
Cancer, 2004, Washington, DC.
212. Rahman KMW, Sarkar FH. Apoptosis inducing effect of DIM is mediated by inhibition of nuclear translocation of
NF-kappaB in breast cancer cells. 95th Annual Meeting of the American Association for Cancer Research. Abstract
3144, page 728, 2004, Orlando, Florida.
213. Li Y, Ahmad F, Ellis KL, Kucuk O, Philip P, Sarkar FH. Chemosensitization of cancer cells by soy isoflavone
genistein, a chemopreventive agent, is mediated by inactivation of NF-κB activity. 3rd Annual AACR International
Conference: Frontiers in Cancer Prevention Research. Abstract #A24, page 75, 2004, Seattle, Washington.
214. Banerjee S, Zhang Y, Chiao P, Sarkar FH. Cisplatin-Induced Cytotoxicity is Enhanced by Genistein in Pancreatic
Cancer Cells with Varied Metastatic Potential. Pancreas. 29: 4, November 2004.
215. Mohammad R, Aboukameel A, Kucuk O, Sarkar FH. Anti-Tumor Activity of Cisplatin is Potentiated by Soy
Isoflavone Genistein in BXPC-3 Pancreatic Tumor Xenograft. Pancreas. 29: 4, November 2004.
216. Mohammad R, Wang S, Wu X, Chen J, Min J, Sarkar FH. Potentiation of Apoptosis Inducing Activity og BL-193, a
Nonpeptidic Small-Molecule Inhibitor of BCL-2/BCL-XL Proteins, by Genistein in Pancreatic Cancer Cells. Pancreas.
29: 4, November 2004.
217. Banerjee S, Zhang Y, Sarkar FH. Genistein Potentiated Cisplatin-Induced Cytotoxicity in Human Pancreatic Cancer
Cells. Pancreas. 29: 4, November 2004.
218. Wang Z, Zhang Y, Liao D, Sarkar FH. Notch-1 Down Regulation Contributes to Genistein Induced Growth
Inhibition and Apoptosis in BXPC-3 Pancreatic Cancer Cells. Pancreas. 29: 4, November 2004.
219. Zhang Y, Banerjee S, Majumdar AP, Sarkar FH. Inhibition of Pancreatic Cancer Cell Growth by an Epidermal
Growth Factor Receptor-Related Protein (ERRP). Pancreas. 29: 4, November 2004.
220. Kucuk O, Sarkar F, Sakr W, Wood D, Cher M, Abrams J, Doerge DD, Pollak MM, Djuric Z, Majumdar A. Clinical
trial of soy isoflavone supplementation before radical prostatectomy in patients with localized prostate cancer. Journal
of Nutrition. 134: 1258S-1258S, 2004.
221. Kucuk O, Sarkar F, Adsay V, Newman L, Bouwman D, Djuric Z, Doerge D, Parchment R, Banerjee M, Majumdar A.
Clinical trial of soy isoflavones before breast cancer surgery. Journal of Nutrition. 134: 1262S-1262S, 2004.
222. Miller FR, Tait LR, Doerge D, Sarkar F, Kucuk O. Genistein and tamoxifen interaction in MCF10DCIS.corn
xenograft model for chemoprevention. Journal of Nutrition. 134: 1261S-1261S, 2004.
223. Mohammad R, Al Katib A, Aboukameel A, Ibrahim D, Doerge D, Sarkar F, Kucuk O. Genistein sensitizes resistant
diffuse large cell lymphoma cells to chemotherapy. Journal of Nutrition. 134: 1264S-1264S, 2004.
224. Parchment RE, Sarkar F, Kassab J, Ellis KL, Doerge D, Kucuk O. Genistein does not sensitize human bone marrow
to XK469 toxicity at concentrations that sensitize BxPC3 pancreatic cancer to XK469 chemotherapy. Journal of
Nutrition. 134: 1264S-1264S, 2004.
225. Vaishampayan UV, Forman JJ, Hussain M, Cher M, Pontes E, Fontana J, Alluri KC, Doerge D, Sarkar F, Kucuk O.
Soy isoflavones and lycopene in the treatment of hormone-sensitive and hormone-refractory prostate cancer. Journal
of Nutrition. 134: 1258S-1258S, 2004.
226. Kodali U, Kucuk O, Jaszewski R, Levi E, Doerge D, Sarkar F, Majumdar APN. Genistein and EGFR related protein
(ERRP) potentiate each other in gastric, colon and prostate cancer cells. Journal of Nutrition. 134: 1263S-1264S,
2004.
227. Li Y, Ellis K, Ali S, El-Rayes BF, Nedeljkovic-Kurepa A, Kucuk O, Sarkar F. Soy isoflavone genistein inhibits
nuclear factor-kappa B and sensitizes human cancer cells to apoptosis induced by chemotherapeutic agents. Journal of
Nutrition. 134: 1265S-1265S, 2004.
228. Sahin K, Onderci M, Gursu MF, Sahin N, Doerge D, Sarkar F, Kucuk O. Genistein supplementation alleviates the
deterioration in performance and antioxidant status of Japanese quail associated with heat stress. Journal of Nutrition.
134: 1266S-1267S, 2004.
229. Sarkar,F.H. and Li,Y. Indole-3-carbinol and prostate cancer, J.Nutr., 134: 3493S-3498S, 2004. Review.
230. Banerjee S, Zhang Y, Wang Z, Chiao PJ, Sarkar FH. Anti-tumor Activity of Gemcitabine is Enhanced by Genistein
in Pancreatic Cancer. 95th Annual Meeting of the American Association for Cancer Research.. Abstract 2244, April
2005, Anaheim/Orange County, CA.
36
231. Kurzrock R, Sarkar FH, Hess KR, Abbruzzese JL, Evans DB, Chiao PJ. Targeting NF-κB Signaling Pathways for
Pancreatic Cancer Therapy. 13th SPORE Investigators’ Workshop, 2005, Washington, DC.
232. Basturk O, Adsay NV, Banerjee M, Newman L, Bouwman D, Doerge D, Djuric D, Parchment R, Majumdar A, Miller
F, Sarkar F, Kucuk O. The Value of Soy Isoflavones in Modulatin Biomarkers of Grwoth and Differentiation in
Breast Cancer. Modern Pathology. 19:1, 21A, 2006.
233. Singh R, Basturk O, Sarkar F, Frankel W, Adsay NV. The Role of GLUt-1 in “Clear-Cell” Ductal Tumors of the
Pancreas. Modern Pathology. 19:1, 280A, 2006.
234. Chen D, Cui, QC, Yang H, Sarkar FH, Reddy GPV, Sheng S, Barrea RA, Dou QP. Cliquinol, a Therapeutic Agent
for Alzheimer’s Disease, has Proteasome-Inhibitory, Apoptosis-Inducing and Anti-Tumor Activities in Prostate
Cancer Cells and Xenografts. 6th Annual Symposium Michigan Prostate Research Colloquium Basic and Clinical
Advances in Prostate Cancer Research. Ann Arbor, MI, May 6, 2006.
235. Rahman KMW, Li Y, Wang Z, Sarkar S, Sarkar F. Gene expression profiling survivin as a target of DIM-induced
cell growth inhibition and apoptosis in breast cancer cells. 97th Annual Meeting of the American Association for
Cancer Research. April 2006, Washington DC.
236. Rahman, KMW, Sarkar FH, Liao DJ, Banerjee S, Wang Z, Hong X. 97th Annual Meeting of the American
Association for Cancer Research. April 2006, Washington DC.
237. Adsule SA, Ahmed F, Wang Z, Banerjee S, Skafar D, Kulkarni S, Katiyar P, Padhye S, Sarkar F. Synthesis,
characterization, molecular modeling and biological studies of novel steroidal Schiff base metal conjugates against
breast cancer. 97th Annual Meeting of the American Association for Cancer Research. April 2006, Washington DC.
238. Schmelz EM, Xu H, Rishi AK, Sarkar FH, Majumdar AP. Reversal of early stages of colorectal cancer with EGFreceptor related protein (ERRP). 97th Annual Meeting of the American Association for Cancer Research. April 2006,
Washington DC.
239. Gadgeel S, Ali S, Philip P, Wozniak A, Sarkar F. Dual blockade of Epidermal Growth Factor Receptor (EGFR) and
Cyclooxygenase 2 (COX 2) may be dependent upon the EGFR mutational status in Non-small cell lung cancer
(NSCLC) cell lines. 97th Annual Meeting of the American Association for Cancer Research. April 2006, Washington
DC.
240. Raffoul JJ, Banerjee S, Knoll ZE, Che M, Kucuk O, Sarkar FH, Hillman GG. Soy is a safe and potent radiosensitizer
for prostate cancer in vitro and in vivo compared to pure genistein. 97th Annual Meeting of the American Association
for Cancer Research. April 2006, Washington DC.
241. Banerjee S, Wang Z, Chiao PJ, Sarkar FH. Experimental and molecular therapeutics 42: Circumventing drug
resistance. 97th Annual Meeting of the American Association for Cancer Research. April 2006, Washington DC.
242. Thoutreddy S, Ali S, Mohammad R, Sarkar FH. Sensitization of pancreatic cancer cells to ApoG2 induced killing by
Curcumin. American Society of Clinical Oncology Annual Meeting. Abstract 13152. June 2006, Atlanta, GA.
243. Gadgeel S, Ali S, Philip P, Wozniak A, Sarkar F. Dual blockade of Epidermal Growth Factor Receptor (EGFR) and
Cyclooxygenase 2 (COX 2) may be dependent upon the EGFR mutational status in Non-small cell lung cancer
(NSCLC) cell lines. American Society of Clinical Oncology Annual Meeting. Abstract 7170. June 2006, Atlanta,
GA.
244. Sarkar FH, Wang Z, Banerjee S, Abbruzzese. A Novel Approach to Pancreatic Cancer Therapy: Inactivation of
Notch-1 Signaling. 14th SPORE Investigators’ Workshop. Abstract 205. July 16-19, 2006, Baltimore, MD.
245. Serhatkulu GK, Dai H, Weber R, Cao A, Pandya A, Thakur J, Freeman C, Naik R, Naik VM, Auner G, Rabah R,
Poulik J, Liao J, Banerjee S, Sarkar FH, Klein M. Raman spectroscopic studies of normal and cancerous tissues in
human and mice. 20th International Conference on Raman Spectroscopy. Yokohama, Japan. August 20-25, 2006.
246. Wang Zhiwei, Banerjee S, Kong D, Li Y, Rahman W, Sarkar FH. Down-regulation of Forkhead Box M1
transcription factor leads to inhibition of cell growth and invasion of pancreatic cancer cells. 2007 American
Association for Cancer Research Annual Meeting. Los Angeles, California. April 14-18, 2007.
247. Dejuan Kong, Yiwei Li, Zhiwei Wang, Sanjeev Banerjee, Fazlul H. Sarkar. Inhibition of angiogenesis and invasion
by 3, 3’-diindolylmethane is mediated by MMP-9 and uPA regulated bioavailability of VEGF in prostate cancer.
American Association for Cancer Research 98th Annual Meeting Abstract Number 3805. April 14-18, 2007 Los
Angeles.
248. Yiwei Li, Zhiwei Wang, Fazlul H. Sarkar. 3370 Regulation of FOXO3a/Catenin/GSK signaling by DIM contributes
to inhibition of cell proliferation and induction of apoptosis in prostate cancer cells. American Association for Cancer
Research 98th Annual Meeting Abstract Number 3370. April 14-18, 2007 Los Angeles.
249. Fazlul Sarkar, Sanjeev Banerjee, Zhiwei Wang, Yiwei Li, James Abbruzzese. A novel non-toxic multi-targeted
approach for pancreatic cancer therapy. 2007 SPORE meeting. July Washington DC
250. Zhiwei Wang, Wen Song, Amro Aboukameel, Guoping Wang, Shaomeng Wang, Fazlul H Sarkar, Ramzi M
Mohammad. TW-37, a nonpeptidic small-molecule inhibitor of Bcl-2, inhibits invasion and angiogenesis in pancreatic
cancer. American Pancreatic Association, 2007, Chicago, Illinois. Nov. 1-3.
251. Fazlul Sarkar, Sanjeev Banerjee, Zhiwei Wang. A novel non-toxic multi-targeted approach for pancreatic cancer
therapy. American Pancreatic Association, 2007, Chicago, Illinois. Nov. 1-3.
252. Zhiwei Wang, Dejuan Kong, Sanjeev Banerjee, Yiwei Li and Fazlul H Sarkar. Down-regulation of PDGF-D inhibits
cell growth and angiogenesis through inactivation of Notch-1 and NF-kB signaling. American Pancreatic Association,
2007, Chicago, Illinois. Nov. 1-3.
37
253. Sanjeev Banerjee, Zhiwei Wang, Fazlul H Sarkar. In vivo molecular evidence of chemosensitization by 3,3’diindolymethane against pancreatic tumor. American Pancreatic Association, 2007, Chicago, Illinois. Nov. 1-3.
254. Banerjee S, Kaseb A, Wang Z, Sarkar FH, Mohammad R. Enhances chemosensitivity to Gemcitabine and Oxaliplatin
by cancer chemopreventive agent Thymoquinone in pancreatic cancer. American Association for Cancer Research 99th
Annual Meeting Abstract Number 712. April 12-16, 2008 San Diego.
255. Wang Z, Song W, Banerjee S, Aboukameel A, Wang G, Wang S, Sarkar FH, Mohammad R. TW-37, a non-peptidic
small-molecule inhibitor of Bcl-2, inhibts cell invasion and angiogenesis in pancreatic cancer. American Association
for Cancer Research 99th Annual Meeting Abstract Number 2264. April 12-16, 2008 San Diego.
256. Li X, Yin S, Sakr W, Sarkar FH, Heath E, Sheng S. Maspin inhibts HDAC1-mediated Hsp90 deacetylation.
American Association for Cancer Research 99th Annual Meeting Abstract Number 327. April 12-16, 2008 San Diego.
257. Singh-Gupta V, Zhang H, Banerjee S, Raffoul J, Sarkar FH, Hillman G. Targeting Src/Stat-3/HIF1α by soy
isoflavones for radiosensitization of prostate cancer. American Association for Cancer Research 99th Annual Meeting
Abstract Number 418. April 12-16, 2008 San Diego.
258. Varghese L, Tulunay O, Pereira L, Ali S, Kucuk O, Sarkar FH. Sensitization of head and neck cancer cells to
cisplatin is potentiated by B-DIM. American Association for Cancer Research 99th Annual Meeting Abstract Number
4050. April 12-16, 2008 San Diego.
259. Wang Z, Yu B, Ahmad F, Rahman KM, Sarkar FH. The induction of growth arrest and apoptosis in human breast
cancer cells by 3’3’-diindolylmethane (DIM) is associated with induction and nuclear localization of p27kip. American
Association for Cancer Research 99th Annual Meeting Abstract Number 1243. April 12-16, 2008 San Diego.
260. Banerjee S, Kaseb A, Wang Z, Kong D, Padhye S, Mohammad R, Sarkar FH. In vivo molecular evidence for
enhanced chemosensitivity of pancreatic cancer cells to gemcitabine and oxaliplatin by thymoquinone. American
Pancreatic Association 39th Annual Meeting, November 7-8, 2008 Chicago, Illinios.
261. Wang Z, Azmi A, Banerjee S, Aboukameel A, Wang S, Sarkar FH, Mohammad R. TW-37 Inhibits cell growth and
induces apoptosis in pancreatic cancer: involvement of Notch-1 signaling pathway. . American Pancreatic Association
39th Annual Meeting, November 7-8, 2008 Chicago, Illinios.
262. Banerjee S, Wang Z, Ahmad A, Kong D, Sarkar FH. In vivo and in vitro molecular evidence for better therapeutic
efficacy of combination of B-DIM and cytotoxic chemotherapeutic agents in pancreatic cancer. American Association
for Cancer Research 100th Annual meeting, 2009
263. Azmi AS, Philip PA, Wang Z, Ahmad A, Wu J , Aboukameel A, Yang D, Wang S, Sarkar FH, Mohammad RM.
Reactivation of p53 by novel MDM2 inhibitors for pancreatic cancer therapy. American Association for Cancer
Research 100th Annual meeting, 2009
264. Hillman G, Singh-Gupta V, Zhang H, Yunker C, Haacke ME, Sarkar FH. Barbara Ann Karmanos Cancer Inst.,
Detroit, MI, Wayne State University, Detroit, MI Anti-tumor activity of sunitinib and radiation is enhanced by soy
isoflavones in murine renal cell carcinoma. American Association for Cancer Research 100th Annual meeting, 2009
265. Wang Z, Li Y, Kong D, Banerjee S, Ahmad A, Azmi AS, Ali S, Abbruzzese J, Gallick GE, Sarkar FH. Acquisition of
epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation
of notch signaling pathway. American Association for Cancer Research 100th Annual meeting, 2009
266. Ahmad A, Kong D, Sarkar SH, Wang Z, Banerjee S, Sarkar FH. Inactivation of uPA and its receptor uPAR by 3, 3’Diindolylmethane (DIM) leads to the inhibition of prostate cancer cell growth and migration. American Association
for Cancer Research 100th Annual meeting, 2009
267. Ahmad A, Kong D, Wang Z, Ali R, Banerjee S, Sarkar FH. Platelet-derived growth factor-D contributes to
aggressiveness of breast cancer cells by up-regulation of Notch and NF-kB signaling pathways. American Association
for Cancer Research 101th Annual meeting, 2010
268. Ali S, Sarkar FH, Multi-targeted approach for inhibiting pancreatic tumor growth in vivo consistent with in vitro
results. American Association for Cancer Research 101th Annual meeting, 2010
269. Banerjee S, Sarkar FH. Genistein restored chemosensitivity to oxaliplatin in gemcitabine resistant pancreatic cancer
cells in vitro and in orthotopic xenograft mouse mode. American Association for Cancer Research 101th Annual
meeting, 2010
270. Li Y, VandenBoom T, Sarkar FH, Up-regulation of miR-146a contributes to the inhibition of invasion of pancreatic
cells. American Association for Cancer Research 101th Annual meeting, 2010
38